<html>
<head>
<title>Cytokines</title>
</head>
<body>
<h1>Cytokines</h1>

<h2>CCL11</h2><p><span style='mso-bidi-font-size:9.0pt; mso-bidi-font-family:"Times New Roman";color:black'>[<a href="cope.cgi?key=CC%20chemokine%20ligand%2011">CC chemokine ligand 11</a>, <a href="cope.cgi?key=chemokine%20%28C%2dC%20motif%29%20ligand%2011">chemokine (C-C motif) ligand 11</a>] This is the approved gene symbol for a member of a group of <a href="cope.cgi?key=cytokines">cytokines</a> generally known as <a href="cope.cgi?key=Chemokines">chemokines</a> (Zlotnik and Yoshie, 2000). Members of this group of so-called <a href="cope.cgi?key=CC%2dChemokines">CC-Chemokines</a> belong to the <a href="cope.cgi?key=SCY%20family%20of%20cytokines">SCY family of cytokines</a> and are <a href="cope.cgi?key=nomenclature">designated</a> CCL (L for ligand) followed by a number.</span> </p><p><span style='mso-bidi-font-size:9.0pt; mso-bidi-font-family:"Times New Roman";color:black'>CCL11 is the new designation of <a href="cope.cgi?key=Eotaxin">Eotaxin</a>. An older designation is <a href="cope.cgi?key=SCYA11">SCYA11</a> [<a href="cope.cgi?key=Small%20inducible%20cytokine%20A11">small inducible cytokine A11</a>].</span> </p><p><span style='mso-bidi-font-size:9.0pt; mso-bidi-font-family:"Times New Roman";color:black'>Yang et al (2003) have shown that CCL11 is active against Gram-negative (<a href="cope.cgi?key=Escherichia%20coli">Escherichia coli</a>) and Gram-positive (Staphyllococcus aureus) bacteria.</span> </p><p><span style='mso-bidi-font-size:9.0pt; mso-bidi-font-family:"Times New Roman";color:red'><br/> </span><b style="mso-bidi-font-weight:normal"><span style="color:red"><a href="cope.cgi?key=Copyright">Copyright</a> &#169; 2012 by H IBELGAUFTS. All rights reserved.</span></b><b style="mso-bidi-font-weight: normal"><span style='font-size:10.0pt;font-family:Times;mso-fareast-font-family: "Times New Roman"'><br/> </span></b><span style='mso-bidi-font-size:9.0pt;mso-bidi-font-family:"Times New Roman"; color:red'>ENTRY LAST MODIFIED: March 2002</span> </p><p><br/></p>

<h2>CCL2</h2><p><span style='mso-bidi-font-size:9.0pt; mso-bidi-font-family:"Times New Roman";color:black'>[<a href="cope.cgi?key=CC%20chemokine%20ligand%202">CC chemokine ligand 2</a>, <a href="cope.cgi?key=chemokine%20%28C%2dC%20motif%29%20ligand%202">chemokine (C-C motif) ligand 2</a>] This is the approved gene symbol for a member of a group of <a href="cope.cgi?key=cytokines">cytokines</a> generally known as <a href="cope.cgi?key=Chemokines">chemokines</a> (Zlotnik and Yoshie, 2000). Members of this particular group of so-called <a href="cope.cgi?key=CC%2dChemokines">CC-Chemokines</a> belong to the <a href="cope.cgi?key=SCY%20family%20of%20cytokines">SCY family of cytokines</a> and are <a href="cope.cgi?key=nomenclature">designated</a> CCL (L for ligand) followed by a number.</span> </p><p><span style='mso-bidi-font-size:9.0pt; mso-bidi-font-family:"Times New Roman";color:black'>This factor is the same as <a href="cope.cgi?key=GDCF">GDCF</a>, <a href="cope.cgi?key=HC11">HC11</a>, <a href="cope.cgi?key=LDCF">LDCF</a>, <a href="cope.cgi?key=MCAF">MCAF</a>, <a href="cope.cgi?key=MCP">MCP</a>, <a href="cope.cgi?key=MCP%2d1">MCP-1</a>, <a href="cope.cgi?key=SMC%2dCF">SMC-CF</a>, <a href="cope.cgi?key=TDCF">TDCF</a>, <a href="cope.cgi?key=TSG%2d8">TSG-8</a>. A previous designation is <a href="cope.cgi?key=SCYA2">SCYA2</a> [<a href="cope.cgi?key=Small%20inducible%20cytokine%20A2">small inducible cytokine A2</a>].</span> </p><p><span style='mso-bidi-font-size:9.0pt; mso-bidi-font-family:"Times New Roman";color:black'>CCL2 has been shown to be cleaved by the <a href="cope.cgi?key=Metalloproteinases">metalloproteinase</a> <a href="cope.cgi?key=MMP%2d12">MMP-12</a>. Cleavage produces a receptor antagonist (Dean et al, 2008).</span> </p><p><span style='mso-bidi-font-size:9.0pt; mso-bidi-font-family:"Times New Roman";color:red'><br/> </span><b style="mso-bidi-font-weight:normal"><span style="color:red"><a href="cope.cgi?key=Copyright">Copyright</a> &#169; 2012 by H IBELGAUFTS. All rights reserved.</span></b><b style="mso-bidi-font-weight: normal"><span style='font-size:10.0pt;font-family:Times;mso-fareast-font-family: "Times New Roman"'><br/> </span></b><span style='mso-bidi-font-size:9.0pt;mso-bidi-font-family:"Times New Roman"; color:red'>ENTRY LAST MODIFIED: March 2002</span> </p><p><br/></p>

<h2>CCL27</h2><p><span style='mso-bidi-font-size:9.0pt; mso-bidi-font-family:"Times New Roman";color:black'>[<a href="cope.cgi?key=CC%20chemokine%20ligand%2027">CC chemokine ligand 27</a>, <a href="cope.cgi?key=chemokine%20%28C%2dC%20motif%29%20ligand%2027">chemokine (C-C motif) ligand 27</a>] This is the approved gene symbol for a member of a group of <a href="cope.cgi?key=cytokines">cytokines</a> generally known as <a href="cope.cgi?key=Chemokines">chemokines</a> (Zlotnik and Yoshie, 2000). Members of this group of so-called <a href="cope.cgi?key=CC%2dChemokines">CC-Chemokines</a> belong to the <a href="cope.cgi?key=SCY%20family%20of%20cytokines">SCY family of cytokines</a> and are <a href="cope.cgi?key=nomenclature">designated</a> CCL (L for ligand) followed by a number.</span> </p><p><span style='mso-bidi-font-size:9.0pt; mso-bidi-font-family:"Times New Roman";color:black'>CCL27 is the new designation of <a href="cope.cgi?key=ALP">ALP</a>, <a href="cope.cgi?key=CTACK">CTACK</a> [<a href="cope.cgi?key=cutaneous%20T%2dcell%20attracting%20chemokine">cutaneous T-cell attracting chemokine</a>], <a href="cope.cgi?key=ESkine">ESkine</a>, <a href="cope.cgi?key=ILC">ILC</a> [<a href="cope.cgi?key=interleukin%2d11%20receptor%20alpha%2dlocus%20chemokine">interleukin-11 receptor alpha-locus chemokine</a>; <a href="cope.cgi?key=IL11Ralpha%2dlocus%20chemokine">IL11Ralpha-locus chemokine</a>], <a href="cope.cgi?key=PESKY">PESKY</a>, <a href="cope.cgi?key=skinkine">skinkine</a>. An older designation is <a href="cope.cgi?key=SCYA27">SCYA27</a> [<a href="cope.cgi?key=Small%20inducible%20cytokine%20A27">small inducible cytokine A27</a>].</span> </p><p><span style='mso-bidi-font-size:9.0pt; mso-bidi-font-family:"Times New Roman";color:red'><br/> </span><b style="mso-bidi-font-weight:normal"><span style="color:red"><a href="cope.cgi?key=Copyright">Copyright</a> &#169; 2012 by H IBELGAUFTS. All rights reserved.</span></b><b style="mso-bidi-font-weight: normal"><span style='font-size:10.0pt;font-family:Times;mso-fareast-font-family: "Times New Roman"'><br/> </span></b><span style='mso-bidi-font-size:9.0pt;mso-bidi-font-family:"Times New Roman"; color:red'>ENTRY LAST MODIFIED: March 2002</span> </p><p><br/></p>

<h2>CCL4</h2><p><span style='mso-bidi-font-size:9.0pt; mso-bidi-font-family:"Times New Roman";color:black'>[<a href="cope.cgi?key=CC%20chemokine%20ligand%204">CC chemokine ligand 4</a>, <a href="cope.cgi?key=chemokine%20%28C%2dC%20motif%29%20ligand%204">chemokine (C-C motif) ligand 4</a>] This is the approved gene symbol for a member of a group of <a href="cope.cgi?key=cytokines">cytokines</a> generally known as <a href="cope.cgi?key=Chemokines">chemokines</a> (Zlotnik and Yoshie, 2000). Members of this group of so-called <a href="cope.cgi?key=CC%2dChemokines">CC-Chemokines</a> belong to the <a href="cope.cgi?key=SCY%20family%20of%20cytokines">SCY family of cytokines</a> and are <a href="cope.cgi?key=nomenclature">designated</a> CCL (L for ligand) followed by a number.</span> </p><p><span style='mso-bidi-font-size:9.0pt; mso-bidi-font-family:"Times New Roman";color:black'>CCL4 is the new designation of <a href="cope.cgi?key=ACT%2d2">ACT-2</a>. This factor is identical with <a href="cope.cgi?key=744%2e1">744.1</a>, <a href="cope.cgi?key=G26">G26</a>, <a href="cope.cgi?key=H400">H400</a>, <a href="cope.cgi?key=HC21">HC21</a>, <a href="cope.cgi?key=LAG%2d1">LAG-1</a>, <a href="cope.cgi?key=MIP%2d1%2dbeta">MIP-1-beta</a>, and <a href="cope.cgi?key=SIS%2dgamma">SIS-gamma</a>. A previous designation is <a href="cope.cgi?key=SCYA4">SCYA4</a> [<a href="cope.cgi?key=Small%20inducible%20cytokine%20A4">small inducible cytokine A4</a>].</span> </p><p><span style='mso-bidi-font-size:9.0pt; mso-bidi-font-family:"Times New Roman";color:black'>The <a href="cope.cgi?key=Cytokine%20Inter%2dspecies%20Reactivities">human</a> genome contains two <a href="cope.cgi?key=paralog">paralogous</a> genes for the CCL4 <a href="cope.cgi?key=Chemokines">chemokine</a>, represented by <a href="cope.cgi?key=ACT%2d2">ACT-2</a> and <a href="cope.cgi?key=LAG%2d1">LAG-1</a>. These genes are highly <a href="cope.cgi?key=homolog">homologous</a>, but encode slightly different proteins and also are regulated and expressed differentially. This also suggests that the two genes may not have identical activities. <a href="cope.cgi?key=monocytes">Monocytes</a> express predominantly <a href="cope.cgi?key=ACT%2d2">ACT-2</a>. Peripheral blood <a href="cope.cgi?key=B%2dlymphocytes">B-lymphocytes</a> express a mixture of <a href="cope.cgi?key=ACT%2d2">ACT-2</a> and <a href="cope.cgi?key=LAG%2d1">LAG-1</a> (<a href="cope.cgi?key=Lu">Lu</a> et al, 2004).</span> </p><p><span style='mso-bidi-font-size:9.0pt; mso-bidi-font-family:"Times New Roman";color:black'>The protein is known mainly for its activity as a <a href="cope.cgi?key=chemotactic%20cytokines">chemotactic cytokine</a> but may have a potential role in host defense as a direct antiviral agent. CCL4 has been reported to show a significant direct antiviral activity against HSV-1. It binds to HSV-1 virions via envelope glycoprotein gB and is capable of generating pores in the envelope of HSV-1 (Nakayama et al, 2006).</span> </p><p><span style='mso-bidi-font-size:9.0pt; mso-bidi-font-family:"Times New Roman";color:red'><br/> </span><b style="mso-bidi-font-weight:normal"><span style="color:red"><a href="cope.cgi?key=Copyright">Copyright</a> &#169; 2012 by H IBELGAUFTS. All rights reserved.</span></b><b style="mso-bidi-font-weight: normal"><span style='font-size:10.0pt;font-family:Times;mso-fareast-font-family: "Times New Roman"'><br/> </span></b><span style='mso-bidi-font-size:9.0pt;mso-bidi-font-family:"Times New Roman"; color:red'>ENTRY LAST MODIFIED: March 2006</span> </p><p><br/></p>

<h2>CCL5</h2><p><span style='mso-bidi-font-size:9.0pt; mso-bidi-font-family:"Times New Roman";color:black'>[<a href="cope.cgi?key=CC%20chemokine%20ligand%205">CC chemokine ligand 5</a>, <a href="cope.cgi?key=chemokine%20%28C%2dC%20motif%29%20ligand%205">chemokine (C-C motif) ligand 5</a>] This is the approved gene symbol for a member of a group of <a href="cope.cgi?key=cytokines">cytokines</a> generally known as <a href="cope.cgi?key=Chemokines">chemokines</a> (Zlotnik and Yoshie, 2000). Members of this group of so-called <a href="cope.cgi?key=CC%2dChemokines">CC-Chemokines</a> belong to the <a href="cope.cgi?key=SCY%20family%20of%20cytokines">SCY family of cytokines</a> and are <a href="cope.cgi?key=nomenclature">designated</a> CCL (L for ligand) followed by a number.</span> </p><p><span style='mso-bidi-font-size:9.0pt; mso-bidi-font-family:"Times New Roman";color:black'>CCL5 has been described as <a href="cope.cgi?key=RANTES">RANTES</a>, <a href="cope.cgi?key=EoCP%2d1">EoCP-1</a> [<a href="cope.cgi?key=Eosinophil%20chemotactic%20polypeptide%2d1">Eosinophil chemotactic polypeptide-1</a>], and <a href="cope.cgi?key=SIS%2ddelta">SIS-delta</a>. The protein has been referred to also as <a href="cope.cgi?key=TCP228">TCP228</a> [<a href="cope.cgi?key=T%2dcell%2dspecific%20protein%20p228">T-cell-specific protein p228</a>]. An older designation is <a href="cope.cgi?key=SCYA5">SCYA5</a> [<a href="cope.cgi?key=Small%20inducible%20cytokine%20A5">small inducible cytokine A5</a>].</span> </p><p><span style='mso-bidi-font-size:9.0pt; mso-bidi-font-family:"Times New Roman";color:black'>The protein is known mainly for its activity as a <a href="cope.cgi?key=chemotactic%20cytokines">chemotactic cytokine</a> but may have a potential role in host defense as a direct antiviral agent. CCL5 has been reported to show a significant direct antiviral activity against HSV-1. It binds to HSV-1 virions via envelope glycoprotein gB and is capable of generating pores in the envelope of HSV-1 (Nakayama et al, 2006). Yang et al (2003) have shown that CCL5 is active against Gram-negative <a href="cope.cgi?key=Escherichia%20coli">Escherichia coli</a>.</span> </p><p><span style='mso-bidi-font-size:9.0pt; mso-bidi-font-family:"Times New Roman";color:red'><br/> </span><b style="mso-bidi-font-weight:normal"><span style="color:red"><a href="cope.cgi?key=Copyright">Copyright</a> &#169; 2012 by H IBELGAUFTS. All rights reserved.</span></b><b style="mso-bidi-font-weight: normal"><span style='font-size:10.0pt;font-family:Times;mso-fareast-font-family: "Times New Roman"'><br/> </span></b><span style='mso-bidi-font-size:9.0pt;mso-bidi-font-family:"Times New Roman"; color:red'>ENTRY LAST MODIFIED: July 2008</span> </p><p><br/></p>

<h2>CCL7</h2><p><span style='mso-bidi-font-size:9.0pt; mso-bidi-font-family:"Times New Roman";color:black'>[<a href="cope.cgi?key=CC%20chemokine%20ligand%207">CC chemokine ligand 7</a>, <a href="cope.cgi?key=chemokine%20%28C%2dC%20motif%29%20ligand%207">chemokine (C-C motif) ligand 7</a>] This is the approved gene symbol for a member of a group of <a href="cope.cgi?key=cytokines">cytokines</a> generally known as <a href="cope.cgi?key=Chemokines">chemokines</a> (Zlotnik and Yoshie, 2000). Members of this group of so-called <a href="cope.cgi?key=CC%2dChemokines">CC-Chemokines</a> belong to the <a href="cope.cgi?key=SCY%20family%20of%20cytokines">SCY family of cytokines</a> and are <a href="cope.cgi?key=nomenclature">designated</a> CCL (L for ligand) followed by a number.</span> </p><p><span style='mso-bidi-font-size:9.0pt; mso-bidi-font-family:"Times New Roman";color:black'>CCL7 is the new designation of <a href="cope.cgi?key=MCP%2d3">MCP-3</a> [<a href="cope.cgi?key=Monocyte%20chemoattractant%20protein%2d3">monocyte chemoattractant protein-3</a>], which is the same as <a href="cope.cgi?key=FIC">FIC</a>, <a href="cope.cgi?key=NC28">NC28</a>, or <a href="cope.cgi?key=MARC">MARC</a>. An older designation is <a href="cope.cgi?key=SCYA7">SCYA7</a> [<a href="cope.cgi?key=Small%20inducible%20cytokine%20A7">small inducible cytokine A7</a>].</span> </p><p><span style='mso-bidi-font-size:9.0pt; mso-bidi-font-family:"Times New Roman";color:black'>CCL7 has been shown to be cleaved by the <a href="cope.cgi?key=Metalloproteinases">metalloproteinase</a> <a href="cope.cgi?key=MMP%2d12">MMP-12</a>. Cleavage produces a receptor antagonist (Dean et al, 2008).</span> </p><p><span style='mso-bidi-font-size:9.0pt; mso-bidi-font-family:"Times New Roman";color:red'><br/> </span><b style="mso-bidi-font-weight:normal"><span style="color:red"><a href="cope.cgi?key=Copyright">Copyright</a> &#169; 2012 by H IBELGAUFTS. All rights reserved.</span></b><b style="mso-bidi-font-weight: normal"><span style='font-size:10.0pt;font-family:Times;mso-fareast-font-family: "Times New Roman"'><br/> </span></b><span style='mso-bidi-font-size:9.0pt;mso-bidi-font-family:"Times New Roman"; color:red'>ENTRY LAST MODIFIED: March 2002</span> </p><p><br/></p>

<h2>CLEC11A</h2><p><span style='mso-bidi-font-size:9.0pt; mso-bidi-font-family:"Times New Roman";color:black'>[<a href="cope.cgi?key=C%2dtype%20lectin%20domain%20family%20member%2011A">C-type lectin domain family member 11A</a>] This is the approved gene symbol for <a href="cope.cgi?key=Stem%20cell%20growth%20factor">stem cell growth factor</a>. A previous designation is <a href="cope.cgi?key=CLECSF3">CLECSF3</a><b style="mso-bidi-font-weight:normal"> </b>[<a href="cope.cgi?key=C%2dtype%20lectin%20domain%20superfamily%20member%203">C-type lectin domain superfamily member 3</a>]</span> </p><p><br/> <span style="color:red"><a href="cope.cgi?key=Copyright">Copyright</a> &#169; 2012 by H IBELGAUFTS. All rights reserved.</span><span style='font-size:10.0pt;font-family:Times;mso-fareast-font-family:"Times New Roman"; mso-bidi-font-family:"Times New Roman"'><br/> </span><span style="color:red">ENTRY COMPLETED.</span></p><p><br/></p>

<h2>CSF-1</h2><p><span style='mso-bidi-font-size:9.0pt; mso-bidi-font-family:"Times New Roman";color:black'>[<a href="cope.cgi?key=Colony%20stimulating%20factor%2d1">Colony stimulating factor-1</a>] This factor was described initially as a <a href="cope.cgi?key=Growth%20factors">growth factor</a> that promotes the development of colonies containing <a href="cope.cgi?key=macrophages">macrophages</a> in a <a href="cope.cgi?key=Colony%20formation%20assay">colony formation assay</a> (see also: <a href="cope.cgi?key=CSF">CSF</a> for general information about <a href="cope.cgi?key=Colony%20stimulating%20factors">colony stimulating factors</a>).</span> </p><p><span style='mso-bidi-font-size:9.0pt; mso-bidi-font-family:"Times New Roman";color:black'>It is identical with <a href="cope.cgi?key=M%2dCSF">M-CSF</a>. A splice variant of CSF-1 has been named <b style="mso-bidi-font-weight:normal"><a href="cope.cgi?key=CSF%2d4">CSF-4</a></b>. A binding factor for <a href="cope.cgi?key=M%2dCSF">M-CSF</a> has been found in the <a href="cope.cgi?key=Cytokine%20Concentrations%20in%20Biological%20Fluids">serum</a> from a patient in remission from <a href="cope.cgi?key=Lymphoma">lymphoma</a> (see: <a href="cope.cgi?key=CSF%2d1%20binding%20factor">CSF-1 binding factor</a>).</span> </p><p><br/> <span style="color:red"><a href="cope.cgi?key=Copyright">Copyright</a> &#169; 2012 by H IBELGAUFTS. All rights reserved.</span><span style='font-size:10.0pt;font-family:Times;mso-fareast-font-family:"Times New Roman"; mso-bidi-font-family:"Times New Roman"'><br/> </span><span style="color:red">ENTRY COMPLETED.</span> </p><p><br/></p>

<h2>CSF3</h2>

<h2>CXCL1</h2><p><span style='mso-bidi-font-size:9.0pt; mso-bidi-font-family:"Times New Roman";color:black'>approved gene symbol for a member of a group of <a href="cope.cgi?key=cytokines">cytokines</a> generally known as <a href="cope.cgi?key=Chemokines">chemokines</a>. Members of this group of so-called <a href="cope.cgi?key=CXC%2dChemokines">CXC-Chemokines</a> belong to the <a href="cope.cgi?key=SCY%20family%20of%20cytokines">SCY family of cytokines</a> and are <a href="cope.cgi?key=nomenclature">designated</a> CXCL (L for ligand) followed by a number (Zlotnik and Yoshie, 2000).</span> </p><p><span style='mso-bidi-font-size:9.0pt; mso-bidi-font-family:"Times New Roman";color:black'>CXCL1 has been identified independently as <a href="cope.cgi?key=CINC%2d2%2dbeta">CINC-2-beta</a>, <a href="cope.cgi?key=GRO1">GRO1</a>, <a href="cope.cgi?key=GRO%2dalpha">GRO-alpha</a>, <a href="cope.cgi?key=KC">KC</a>, <a href="cope.cgi?key=MGSA%2dalpha">MGSA-alpha</a>, <a href="cope.cgi?key=MIP%2d2">MIP-2</a>, <a href="cope.cgi?key=NAP%2d3">NAP-3</a>, <a href="cope.cgi?key=N51">N51</a>, which are <a href="cope.cgi?key=CXC%2dChemokines">CXC-Chemokines</a>. An older designation is <a href="cope.cgi?key=SCYB1">SCYB1</a> [<a href="cope.cgi?key=Small%20inducible%20cytokine%20subfamily%20B%20member%201">small inducible cytokine subfamily B member 1</a>]. In <a href="cope.cgi?key=Zzzz%20%2e%2e%2e%20zzzz%20%2e%2e%2e%20zzzz">databanks</a> the gene encoding <a href="cope.cgi?key=Cytokine%20Inter%2dspecies%20Reactivities">rat</a> <a href="cope.cgi?key=CINC%2d2%2dbeta">CINC-2-beta</a> is listed as <a href="cope.cgi?key=SCYB1">SCYB1</a> and <a href="cope.cgi?key=SCYB3">SCYB3</a> (see also: <a href="cope.cgi?key=SCY%20family%20of%20cytokines">SCY family of cytokines</a>).</span> </p><p><span style='mso-bidi-font-size:9.0pt; mso-bidi-font-family:"Times New Roman";color:black'>M&#159;ller et al (2001) have described the development of multi-probe RNase protection assay (RPA) template sets for the simultaneous analysis of several <a href="cope.cgi?key=Chemokines">chemokines</a>, including CXCL1.</span> </p><p><span style='mso-bidi-font-size:9.0pt; mso-bidi-font-family:"Times New Roman";color:black'>Yang et al (2003) have shown that CXCL1 is active against Gram-negative (<a href="cope.cgi?key=Escherichia%20coli">Escherichia coli</a>) and Gram-positive (Staphyllococcus aureus) bacteria.</span> </p><p><span style='mso-bidi-font-size:9.0pt; mso-bidi-font-family:"Times New Roman";color:black'>CXCL1 has been shown to be cleaved by the <a href="cope.cgi?key=Metalloproteinases">metalloproteinase</a> <a href="cope.cgi?key=MMP%2d12">MMP-12</a> at the <a href="cope.cgi?key=ELR">ELR</a> <a href="cope.cgi?key=sequence%20motif">sequence motif</a>, which is known to be the critical receptor binding <a href="cope.cgi?key=motif">motif</a> (Dean et al, 2008).</span> </p><p><span style='mso-bidi-font-size:9.0pt; mso-bidi-font-family:"Times New Roman";color:red'><br/> </span><b style="mso-bidi-font-weight:normal"><span style="color:red"><a href="cope.cgi?key=Copyright">Copyright</a> &#169; 2012 by H IBELGAUFTS. All rights reserved.</span></b><b style="mso-bidi-font-weight: normal"><span style='font-size:10.0pt;font-family:Times;mso-fareast-font-family: "Times New Roman"'><br/> </span></b><span style='mso-bidi-font-size:9.0pt;mso-bidi-font-family:"Times New Roman"; color:red'>ENTRY LAST MODIFIED: March 2002</span> </p><p><br/></p>

<h2>CXCL10</h2><p><span style='mso-bidi-font-size:9.0pt; mso-bidi-font-family:"Times New Roman";color:black'>approved gene symbol for a member of a group of <a href="cope.cgi?key=cytokines">cytokines</a> generally known as <a href="cope.cgi?key=Chemokines">chemokines</a>. Members of this group of so-called <a href="cope.cgi?key=CXC%2dChemokines">CXC-Chemokines</a> belong to the <a href="cope.cgi?key=SCY%20family%20of%20cytokines">SCY family of cytokines</a> and are <a href="cope.cgi?key=nomenclature">designated</a> CXCL (L for ligand) followed by a number (Zlotnik and Yoshie, 2000).</span> </p><p><span style='mso-bidi-font-size:9.0pt; mso-bidi-font-family:"Times New Roman";color:black'>CXCL10 has been identified independently as <a href="cope.cgi?key=IP%2d10">IP-10</a> [<a href="cope.cgi?key=Interferon%2dinducible%20protein%2d10">Interferon-inducible protein-10</a>], known also as <a href="cope.cgi?key=INP%2d10">INP-10</a>. The factor is identical with <a href="cope.cgi?key=CRG%2d2">CRG-2</a>, <a href="cope.cgi?key=C7">C7</a>, <a href="cope.cgi?key=Ifi10">Ifi10</a>, <a href="cope.cgi?key=mob%2d1">mob-1</a>. An older designation is <a href="cope.cgi?key=SCYB10">SCYB10</a> [<a href="cope.cgi?key=Small%20inducible%20cytokine%20subfamily%20B%20member%2010">small inducible cytokine subfamily B member 10</a>].</span> </p><p><span style='mso-bidi-font-size:9.0pt; mso-bidi-font-family:"Times New Roman";color:black'><br/> Yang et al (2003) have shown that CXCL10 is active against Gram-negative (<a href="cope.cgi?key=Escherichia%20coli">Escherichia coli</a>) and Gram-positive (Staphyllococcus aureus) bacteria. Cole et al (2001) have reported that CXCL10 possesses antimicrobial activity against <a href="cope.cgi?key=Escherichia%20coli">Escherichia coli</a> and Listeria monocytogenes. Proost et al (2003) have shown that CXCL10 produced by connective tissue <a href="cope.cgi?key=fibroblasts">fibroblasts</a> attracts activated <a href="cope.cgi?key=Th1%20cells">Th1 cells</a> and <a href="cope.cgi?key=natural%20killer%20cells">natural killer cells</a> expressing the CXCL10 receptor <a href="cope.cgi?key=CXCR3">CXCR3</a> to sites of infection, can also antagonize the <a href="cope.cgi?key=CCR3">CCR3</a> dependent attraction of Th2 <a href="cope.cgi?key=lymphocytes">lymphocytes</a>, and exerts CXCR3-independent, defensin-like antibacterial activity.</span> </p><p><span style='mso-bidi-font-size:9.0pt; mso-bidi-font-family:"Times New Roman";color:black'>Hensbergen et al (2004) have reported that native <a href="cope.cgi?key=Chemokines">chemokine</a> CXCL10 is processed in primary <a href="cope.cgi?key=keratinocytes">keratinocytes</a> by furin to a shorter form that lacks four amino acids at the C-terminus. The truncated CXCL10 variant is a potent ligand for <a href="cope.cgi?key=CXCR3">CXCR3</a> and retains its direct antibacterial activity.</span> </p><p><span style='mso-bidi-font-size:9.0pt; mso-bidi-font-family:"Times New Roman";color:black'>Egesten et al (2007) have reported that CXCL10 possesses antimicrobial activity against Streptococcus pyogenes, a common agent causing streptococcal pharyngitis. This activity is neutralized by a bacterial virulence factor, <a href="cope.cgi?key=SIC">SIC</a></span> </p><p><span style='mso-bidi-font-size:9.0pt; mso-bidi-font-family:"Times New Roman";color:black'>Loos et al (2008) have shown that protein citrullination by peptidylarginine deiminase of CXCL10 is a naturally occurring posttranslational modification. Citrullination reduces the chemoattracting and signaling capacity of CXCL10 for <a href="cope.cgi?key=CXC%2dChemokines">CXC-Chemokine</a> receptor <a href="cope.cgi?key=CXCR3">CXCR3</a> but does not affect receptor binding. The citrullinated <a href="cope.cgi?key=Chemokines">chemokine</a> remains active on <a href="cope.cgi?key=T%2dcells">T-cells</a> but is weaker than authentic CXCL10. Deimination decreases heparin binding properties of CXCL10.</span> </p><p>For other proteins/peptides with functions in <a href="cope.cgi?key=innate%20immunity">innate immunity</a> and/or antimicrobial activities see also: <a href="cope.cgi?key=Innate%20immunity%20defense%20peptides%20MiniCOPE%20Dictionary">Innate immunity defense peptides Dictionary</a>.  </p><p><span style='mso-bidi-font-size:9.0pt; mso-bidi-font-family:"Times New Roman";color:red'><br/> </span><b style="mso-bidi-font-weight:normal"><span style="color:red"><a href="cope.cgi?key=Copyright">Copyright</a> &#169; 2012 by H IBELGAUFTS. All rights reserved.</span></b><b style="mso-bidi-font-weight: normal"><span style='font-size:10.0pt;font-family:Times;mso-fareast-font-family: "Times New Roman"'><br/> </span></b><span style='mso-bidi-font-size:9.0pt;mso-bidi-font-family:"Times New Roman"; color:red'>ENTRY LAST MODIFIED: August 2008</span> </p><p><br/></p>

<h2>CXCL12</h2><p><span style='mso-bidi-font-size:9.0pt; mso-bidi-font-family:"Times New Roman";color:black'>approved gene symbol for a member of a group of <a href="cope.cgi?key=cytokines">cytokines</a> generally known as <a href="cope.cgi?key=Chemokines">chemokines</a>. Members of this group of so-called <a href="cope.cgi?key=CXC%2dChemokines">CXC-Chemokines</a> belong to the <a href="cope.cgi?key=SCY%20family%20of%20cytokines">SCY family of cytokines</a> and are <a href="cope.cgi?key=nomenclature">designated</a> CXCL (L for ligand) followed by a number (Zlotnik and Yoshie, 2000).</span> </p><p><span style='mso-bidi-font-size:9.0pt; mso-bidi-font-family:"Times New Roman";color:black'>CXCL12 has been identified independently as <a href="cope.cgi?key=SDF">SDF</a> [<a href="cope.cgi?key=Stromal%20cell%2dderived%20factor">Stromal cell-derived factor</a>]. The protein is identical with <a href="cope.cgi?key=IRH">IRH</a>, <a href="cope.cgi?key=SDF%2d1%2dalpha">SDF-1-alpha</a> (<a href="cope.cgi?key=CXCL12%2dalpha">CXCL12-alpha</a>), <a href="cope.cgi?key=SDF%2d1%2dbeta">SDF-1-beta</a> (<a href="cope.cgi?key=CXCL12%2dbeta">CXCL12-beta</a>), <a href="cope.cgi?key=PBSF">PBSF</a>, <a href="cope.cgi?key=TLSF%2dalpha">TLSF-alpha</a>, <a href="cope.cgi?key=TLSF%2dbeta">TLSF-beta</a>, <a href="cope.cgi?key=TPAR%2d1">TPAR-1</a>. An older designation is <a href="cope.cgi?key=SCYB12">SCYB12</a> [<a href="cope.cgi?key=Small%20inducible%20cytokine%20subfamily%20B%20member%2012">small inducible cytokine subfamily B member 12</a>].</span> </p><p><span style='mso-bidi-font-size:9.0pt; mso-bidi-font-family:"Times New Roman";color:black'>M&#159;ller et al (2001) have described the development of multi-probe RNase protection assay (RPA) template sets for the simultaneous analysis of several <a href="cope.cgi?key=Chemokines">chemokines</a>, including CXCL12.</span> </p><p><span style='mso-bidi-font-size:9.0pt; mso-bidi-font-family:"Times New Roman";color:black'>Campana et al (2009) have shown that CXCL12 in the fluid phase binds to <a href="cope.cgi?key=HMG%2d1">HMG-1</a> secreted from <a href="cope.cgi?key=dendritic%20cells">dendritic cells</a> and <a href="cope.cgi?key=macrophages">macrophages</a>. This binding protects CXCL12 conformation and function in a reducing environment and thus <a href="cope.cgi?key=HMG%2d1">HMG-1</a> may contribute to the regulation of <a href="cope.cgi?key=leukocytes">leukocyte</a> recruitment and motility.</span> </p><p><span style='mso-bidi-font-size:9.0pt; mso-bidi-font-family:"Times New Roman";color:black'>Nie et al (2008) have reported that the ligand of <a href="cope.cgi?key=CXCR4">CXCR4</a>, CXCL12, produced by <a href="cope.cgi?key=bone%20marrow%20stromal%20cells">bone marrow stromal cells</a> is not only the major <a href="cope.cgi?key=chemoattractants">chemoattractant</a> for <a href="cope.cgi?key=hematopoietic%20stem%20cells">hematopoietic stem cells</a> but also a regulatory factor that controls the quiescence of primitive <a href="cope.cgi?key=hematopoietic%20cells">hematopoietic cells</a>. CXCL12 inhibits entry of primitive <a href="cope.cgi?key=hematopoietic%20cells">hematopoietic cells</a> into the <a href="cope.cgi?key=Cell%20cycle">cell cycle</a>, and inactivation of its receptor, <a href="cope.cgi?key=CXCR4">CXCR4</a>, in <a href="cope.cgi?key=hematopoietic%20stem%20cells">hematopoietic stem cells</a> causes excessive <a href="cope.cgi?key=hematopoietic%20stem%20cells">hematopoietic stem cells</a> proliferation. The hyperproliferative <a href="cope.cgi?key=hematopoietic%20stem%20cells">hematopoietic stem cells</a> are able to maintain a stable <a href="cope.cgi?key=stem%20cells">stem cell</a> compartment and sustain <a href="cope.cgi?key=Hematopoiesis">hematopoiesis</a>.</span> </p><p><span style='mso-bidi-font-size:9.0pt; mso-bidi-font-family:"Times New Roman";color:black'>Yang et al (2003) have shown that CXCL12 is active against Gram-negative (<a href="cope.cgi?key=Escherichia%20coli">Escherichia coli</a>) and Gram-positive (Staphyllococcus aureus) bacteria.</span> </p><p><span style='mso-bidi-font-size:9.0pt; mso-bidi-font-family:"Times New Roman";color:red'><br/> </span><b style="mso-bidi-font-weight:normal"><span style="color:red"><a href="cope.cgi?key=Copyright">Copyright</a> &#169; 2012 by H IBELGAUFTS. All rights reserved.</span></b><b style="mso-bidi-font-weight: normal"><span style='font-size:10.0pt;font-family:Times;mso-fareast-font-family: "Times New Roman"'><br/> </span></b><span style='mso-bidi-font-size:9.0pt;mso-bidi-font-family:"Times New Roman"; color:red'>ENTRY LAST MODIFIED: March 2009</span> </p><p><br/></p>

<h2>CXCL9</h2><p><span style='mso-bidi-font-size:9.0pt; mso-bidi-font-family:"Times New Roman";color:black'>approved gene symbol for a member of a group of <a href="cope.cgi?key=cytokines">cytokines</a> generally known as <a href="cope.cgi?key=Chemokines">chemokines</a>. Members of this group of so-called <a href="cope.cgi?key=CXC%2dChemokines">CXC-Chemokines</a> belong to the <a href="cope.cgi?key=SCY%20family%20of%20cytokines">SCY family of cytokines</a> and are <a href="cope.cgi?key=nomenclature">designated</a> CXCL (L for ligand) followed by a number (Zlotnik and Yoshie, 2000).</span> </p><p><span style='mso-bidi-font-size:9.0pt; mso-bidi-font-family:"Times New Roman";color:black'>CXCL9 has been identified independently as <a href="cope.cgi?key=mig">mig</a> [<a href="cope.cgi?key=Monokine%20induced%20by%20gamma%2dInterferon">monokine induced by gamma-Interferon</a>] and is known also as <a href="cope.cgi?key=CRG%2d10">CRG-10</a>. An older designation is <a href="cope.cgi?key=SCYB9">SCYB9</a> [<a href="cope.cgi?key=Small%20inducible%20cytokine%20subfamily%20B%20member%209">small inducible cytokine subfamily B member 9</a>].</span> </p><p><span style='mso-bidi-font-size:9.0pt; mso-bidi-font-family:"Times New Roman";color:black'>M&#159;ller et al (2001) have described the development of multi-probe RNase protection assay (RPA) template sets for the simultaneous analysis of several <a href="cope.cgi?key=Chemokines">chemokines</a>, including CXCL9.</span> </p><p><span style='mso-bidi-font-size:9.0pt; mso-bidi-font-family:"Times New Roman";color:black'><br/> Yang et al (2003) have shown that CXCL9 is active against Gram-negative (<a href="cope.cgi?key=Escherichia%20coli">Escherichia coli</a>) and Gram-positive (Staphylococcus aureus) bacteria. Cole et al (2001) have reported that CXCL9 possesses antimicrobial activity against <a href="cope.cgi?key=Escherichia%20coli">Escherichia coli</a> and Listeria monocytogenes. Egesten et al (2007) have reported that CXCL9 possesses antimicrobial activity against Streptococcus pyogenes, which is neutralized by a bacterial virulence factor, <a href="cope.cgi?key=SIC">SIC</a>. Tonsil fluid from patients with streptococcal pharyngitis contains high amounts of this <a href="cope.cgi?key=Chemokines">chemokine</a>. In vitro, inflamed pharyngeal <a href="cope.cgi?key=epithelial%20cells">epithelium</a> produce large amounts of CXCL9 in the presence of bacteria. CXCL9 is degraded by <a href="cope.cgi?key=speB">speB</a> of Streptococcus pyogenes but, unlike other <a href="cope.cgi?key=Chemokines">chemokines</a>, retains its antibacterial activity and thus appears to be a major antibacterial factor in inflammed <a href="cope.cgi?key=epithelial%20cells">epithelium</a> (Egesten et al, 2009).</span> </p><p><span style='mso-bidi-font-size:9.0pt; mso-bidi-font-family:"Times New Roman";color:black'>The <a href="cope.cgi?key=Chemokines">chemokine</a> is detected also in seminal <a href="cope.cgi?key=Cytokine%20Concentrations%20in%20Biological%20Fluids">plasma</a> of fertile donors. Significantly lower levels of CXCL9 are found in in vasectomized donors (Linge et al, 2008). CXCL9 from seminal <a href="cope.cgi?key=Cytokine%20Concentrations%20in%20Biological%20Fluids">plasma</a> possesses antibacterial activity against the urogenital pathogen Neisseria gonorrhoeae.</span> </p><p>For other proteins/peptides with functions in <a href="cope.cgi?key=innate%20immunity">innate immunity</a> and/or antimicrobial activities see also: <a href="cope.cgi?key=Innate%20immunity%20defense%20peptides%20MiniCOPE%20Dictionary">Innate immunity defense peptides Dictionary</a>.  </p><p><span style='mso-bidi-font-size:9.0pt; mso-bidi-font-family:"Times New Roman";color:red'><br/> </span><b style="mso-bidi-font-weight:normal"><span style="color:red"><a href="cope.cgi?key=Copyright">Copyright</a> &#169; 2012 by H IBELGAUFTS. All rights reserved.</span></b><b style="mso-bidi-font-weight: normal"><span style='font-size:10.0pt;font-family:Times;mso-fareast-font-family: "Times New Roman"'><br/> </span></b><span style='mso-bidi-font-size:9.0pt;mso-bidi-font-family:"Times New Roman"; color:red'>ENTRY LAST MODIFIED: January 2009</span> </p><p><br/></p>

<h2>FGF2</h2>

<h2>HGF</h2><p><span style='mso-bidi-font-size:9.0pt; mso-bidi-font-family:"Times New Roman";color:black'>This term has multiple meanings:</span> </p><p><span style='mso-bidi-font-size:9.0pt; mso-bidi-font-family:"Times New Roman";color:black'><br/> </span><b style="mso-bidi-font-weight:normal"><span style='mso-bidi-font-size: 9.0pt;mso-bidi-font-family:"Times New Roman";color:#993300'>_____________________________________________________________________________</span></b><span style='mso-bidi-font-size:9.0pt;mso-bidi-font-family:"Times New Roman"; color:black'><br/> <br/> <b style="mso-bidi-font-weight:normal">(-1-) <a href="cope.cgi?key=Hematopoietic%20growth%20factors">hematopoietic growth factors</a></b>. See: <a href="cope.cgi?key=Hematopoietins">Hematopoietins</a>.</span> </p><p><span style='mso-bidi-font-size:9.0pt; mso-bidi-font-family:"Times New Roman";color:red'><br/> </span><b style="mso-bidi-font-weight:normal"><span style="color:red"><a href="cope.cgi?key=Copyright">Copyright</a> &#169; 2012 by H IBELGAUFTS. All rights reserved.</span></b><b style="mso-bidi-font-weight: normal"><span style='font-size:10.0pt;font-family:Times;mso-fareast-font-family: "Times New Roman"'><br/> </span><span style="color:red">ENTRY COMPLETED.</span></b> </p><p><span style='mso-bidi-font-size:9.0pt; mso-bidi-font-family:"Times New Roman";color:black'><br/> </span><b style="mso-bidi-font-weight:normal"><span style='mso-bidi-font-size: 9.0pt;mso-bidi-font-family:"Times New Roman";color:#993300'>_____________________________________________________________________________</span></b><span style='mso-bidi-font-size:9.0pt;mso-bidi-font-family:"Times New Roman"; color:black'><br/> <br/> <b style="mso-bidi-font-weight:normal">(-2-) <a href="cope.cgi?key=Hepatocyte%20growth%20factor">hepatocyte growth factor</a></b></span> </p><p><span style='mso-bidi-font-size:9.0pt; mso-bidi-font-family:"Times New Roman";color:black'>This factor is isolated from <a href="cope.cgi?key=Cytokine%20Inter%2dspecies%20Reactivities">bovine</a> liver (Ueono et al, 1986). It is <a href="cope.cgi?key=Cell%20cycle">mitogenic</a> for <a href="cope.cgi?key=hepatocytes">hepatocytes</a>. This factor is identical with <a href="cope.cgi?key=bFGF">bFGF</a> and is not identical with HGF = <a href="cope.cgi?key=Scatter%20factor">scatter factor</a> (entry -3-).</span> </p><p><span style='mso-bidi-font-size:9.0pt; mso-bidi-font-family:"Times New Roman";color:red'><br/> </span><b style="mso-bidi-font-weight:normal"><span style="color:red"><a href="cope.cgi?key=Copyright">Copyright</a> &#169; 2012 by H IBELGAUFTS. All rights reserved.</span></b><b style="mso-bidi-font-weight: normal"><span style='font-size:10.0pt;font-family:Times;mso-fareast-font-family: "Times New Roman"'><br/> </span><span style="color:red">ENTRY COMPLETED.</span></b> </p><p><span style='mso-bidi-font-size:9.0pt; mso-bidi-font-family:"Times New Roman";color:black'><br/> </span><b style="mso-bidi-font-weight:normal"><span style='mso-bidi-font-size: 9.0pt;mso-bidi-font-family:"Times New Roman";color:#993300'>_____________________________________________________________________________</span></b><span style='mso-bidi-font-size:9.0pt;mso-bidi-font-family:"Times New Roman"; color:black'><br/> <br/> <b style="mso-bidi-font-weight:normal">(-3-) <a href="cope.cgi?key=Hepatocyte%20growth%20factor">hepatocyte growth factor</a></b></span> </p><p><b style="mso-bidi-font-weight:normal"><span style='mso-bidi-font-size:9.0pt;mso-bidi-font-family:"Times New Roman"; color:black'>ALTERNATIVE NAMES</span></b> </p><p><b style="mso-bidi-font-weight:normal"><span style='mso-bidi-font-size:9.0pt;mso-bidi-font-family:"Times New Roman"; color:black'><a href="cope.cgi?key=F%2dTCF">F-TCF</a></span></b><span style='mso-bidi-font-size:9.0pt;mso-bidi-font-family: "Times New Roman";color:black'> (<a href="cope.cgi?key=Fibroblast%20tumor%20cytotoxic%20factor">fibroblast tumor cytotoxic factor</a>);<br/> <b style="mso-bidi-font-weight:normal"><a href="cope.cgi?key=HL%2d60%2dHGF">HL-60-HGF</a></b>;<br/> <b style="mso-bidi-font-weight:normal"><a href="cope.cgi?key=HPTA">HPTA</a></b> (<a href="cope.cgi?key=Hepatopoietin%20A">Hepatopoietin A</a>);<br/> <b style="mso-bidi-font-weight:normal"><a href="cope.cgi?key=SF">SF</a></b> (<a href="cope.cgi?key=Scatter%20factor">scatter factor</a>);<br/> <b style="mso-bidi-font-weight:normal"><a href="cope.cgi?key=TCF">TCF</a></b> (<a href="cope.cgi?key=Tumor%20cytotoxic%20factor">tumor cytotoxic factor</a>).<br/> The factor is referred to now frequently as <a href="cope.cgi?key=HGF%2fSF">HGF/SF</a> (for <a href="cope.cgi?key=Hepatocyte%20growth%20factor%2dscatter%20factor">Hepatocyte growth factor-scatter factor</a>). See also: individual entries for further information.</span> </p><p><b style="mso-bidi-font-weight:normal"><span style='mso-bidi-font-size:9.0pt;mso-bidi-font-family:"Times New Roman"; color:black'>SOURCES</span></b> </p><p><span style='mso-bidi-font-size:9.0pt; mso-bidi-font-family:"Times New Roman";color:black'>HGF was isolated initially from the <a href="cope.cgi?key=Cytokine%20Concentrations%20in%20Biological%20Fluids">serum</a> of partially hepatectomised <a href="cope.cgi?key=Cytokine%20Inter%2dspecies%20Reactivities">rats</a>. It is produced predominantly in the liver and the pancreas. The liver <a href="cope.cgi?key=cell%20types">cells</a> mainly responsible for the synthesis of HGF are <a href="cope.cgi?key=Kupffer%20cells">Kupffer cells</a> and sinusoidal <a href="cope.cgi?key=endothelial%20cells">endothelial cells</a>.</span> </p><p><span style='mso-bidi-font-size:9.0pt; mso-bidi-font-family:"Times New Roman";color:black'>The synthesis of HGF is stimulated in particular by injuries affecting liver tissues (hepatitis, ischemia, hepatectomy) (see also: <a href="cope.cgi?key=inflammation">inflammation</a>, <a href="cope.cgi?key=Wound%20healing">wound healing</a>). In liver <a href="cope.cgi?key=cell%20types">cells</a> the expression of the HGF gene can be repressed strongly by <a href="cope.cgi?key=TGF%2dbeta">TGF-beta</a>. In <a href="cope.cgi?key=Cytokine%20Inter%2dspecies%20Reactivities">human</a> skin <a href="cope.cgi?key=fibroblasts">fibroblasts</a> the synthesis of HGF is induced by both molecular forms of <a href="cope.cgi?key=IL1">IL1</a>.</span> </p><p><span style='mso-bidi-font-size:9.0pt; mso-bidi-font-family:"Times New Roman";color:black'>HGF can be isolated also from <a href="cope.cgi?key=platelets">platelets</a>, kidney, and <a href="cope.cgi?key=Cytokine%20Inter%2dspecies%20Reactivities">human</a> <a href="cope.cgi?key=Cytokine%20Concentrations%20in%20Biological%20Fluids">serum</a>. HGF is expressed also in <a href="cope.cgi?key=Cytokine%20Inter%2dspecies%20Reactivities">human</a> placenta and is found predominantly in <a href="cope.cgi?key=trophoblasts">trophoblastic</a> tumors. HGF is synthesized also by the <a href="cope.cgi?key=HL%2d60">HL-60</a> <a href="cope.cgi?key=Cell%20lines%20in%20Cytokine%20Research">cell line</a>.</span> </p><p><b style="mso-bidi-font-weight:normal"><span style='mso-bidi-font-size:9.0pt;mso-bidi-font-family:"Times New Roman"; color:black'>PROTEIN CHARACTERISTICS</span></b> </p><p><span style='mso-bidi-font-size:9.0pt; mso-bidi-font-family:"Times New Roman";color:black'>HGF consists of two subunits held by a disulfide bond. The alpha subunit (69 kDa) has a length of 440 amino acids. The beta subunit (34 kDa) has a length of 234 amino acids. The beta chain of the factor shows approximately 38 % homology at the protein level to the serine protease <a href="cope.cgi?key=domain">domain</a> of plasminogen. A variant of the beta chain has been shown to function as a subunit of a <a href="cope.cgi?key=hybrid%20cytokine">hybrid cytokine</a> known as <a href="cope.cgi?key=PPBSF">PPBSF</a> [<a href="cope.cgi?key=pre%2dpro%2dB%2dcell%20growth%20stimulating%20factor">pre-pro-B-cell growth stimulating factor</a>].</span> </p><p><span style='mso-bidi-font-size:9.0pt; mso-bidi-font-family:"Times New Roman";color:black'>HGF is a glycoprotein; the non-glycosylated factor is also bioactive. The beta-chain of the <a href="cope.cgi?key=Cytokine%20Inter%2dspecies%20Reactivities">murine</a> and <a href="cope.cgi?key=Cytokine%20Inter%2dspecies%20Reactivities">rat</a> factor display approximately 95 % sequence identity. The <a href="cope.cgi?key=Cytokine%20Inter%2dspecies%20Reactivities">murine</a> beta-chain also shows approximately 70 % sequence identity with <a href="cope.cgi?key=Cytokine%20Inter%2dspecies%20Reactivities">rabbit</a> <a href="cope.cgi?key=HPTA">HPTA</a> (<a href="cope.cgi?key=Hepatopoietin%20A">hepatopoietin A</a>).</span> </p><p><span style='mso-bidi-font-size:9.0pt; mso-bidi-font-family:"Times New Roman";color:black'>Miau et al (1996) have reported the identification and characterization of a novel variant HGF lacking the beta chain from the <a href="cope.cgi?key=conditioned%20medium">conditioned medium</a> of <a href="cope.cgi?key=stromal%20cells">stromal cells</a> derived from <a href="cope.cgi?key=Cytokine%20Inter%2dspecies%20Reactivities">mouse</a> spleen. Compared to <a href="cope.cgi?key=Cytokine%20Inter%2dspecies%20Reactivities">human</a> HGF, it has much lower heparin binding activity.</span> </p><p><b style="mso-bidi-font-weight:normal"><span style='mso-bidi-font-size:9.0pt;mso-bidi-font-family:"Times New Roman"; color:black'><a href="cope.cgi?key=Lung%20fibroblast%2dderived%20mitogen">Lung fibroblast-derived mitogen</a></span></b><span style='mso-bidi-font-size: 9.0pt;mso-bidi-font-family:"Times New Roman";color:black'> is a variant of HGF that is <a href="cope.cgi?key=Cell%20cycle">mitogenic</a> for <a href="cope.cgi?key=epithelial%20cells">epithelial cells</a>, <a href="cope.cgi?key=endothelial%20cells">endothelial cells</a>, and <a href="cope.cgi?key=melanocytes">melanocytes</a>.</span> </p><p><span style='mso-bidi-font-size:9.0pt; mso-bidi-font-family:"Times New Roman";color:black'>A variant of HGF is obtained by alternative splicing. This variant, <a href="cope.cgi?key=nomenclature">designated</a> <b style="mso-bidi-font-weight: normal"><a href="cope.cgi?key=HGF%2fNK2">HGF/NK2</a></b>, is no longer <a href="cope.cgi?key=Cell%20cycle">mitogenic</a> and inhibits the HGF induced proliferation of <a href="cope.cgi?key=cell%20types">cells</a>. This demonstrates that one and the same gene encodes a <a href="cope.cgi?key=Growth%20factors">growth factor</a> and a natural specific antagonist. The <b style="mso-bidi-font-weight: normal"><a href="cope.cgi?key=HGF%2fNK1">HGF/NK1</a></b> isoform, which is shorter than <a href="cope.cgi?key=HGF%2fNK2">HGF/NK2</a>, possesses modest <a href="cope.cgi?key=Cell%20cycle">mitogenic</a> and scattering activity. It possesses partial agonist/antagonist properties. For another truncated form that acts as a specific inhibitor of HGF actions see: <a href="cope.cgi?key=HGF%2fNK4">HGF/NK4</a>.</span> </p><p><b style="mso-bidi-font-weight:normal"><span style='mso-bidi-font-size:9.0pt;mso-bidi-font-family:"Times New Roman"; color:black'><a href="cope.cgi?key=dHGF">dHGF</a></span></b><span style='mso-bidi-font-size:9.0pt;mso-bidi-font-family: "Times New Roman";color:black'> is a naturally occurring splice variant of HGF that lacks a sequence of 5 amino acids in the first <a href="cope.cgi?key=kringle">kringle</a> <a href="cope.cgi?key=domain">domain</a>. The deletion significantly alters the biological activities, solubility, and immunological property of HGF. HGF is more potent than <a href="cope.cgi?key=dHGF">dHGF</a> in stimulating DNA synthesis in <a href="cope.cgi?key=HUVEC">human umbilical vein endothelial cells</a>, <a href="cope.cgi?key=Cytokine%20Inter%2dspecies%20Reactivities">human</a> aorta <a href="cope.cgi?key=smooth%20muscle%20cells">smooth muscle cells</a>, and the <a href="cope.cgi?key=Cytokine%20Inter%2dspecies%20Reactivities">murine</a> <a href="cope.cgi?key=myeloblasts">myeloblastic</a> <a href="cope.cgi?key=Cell%20lines%20in%20Cytokine%20Research">cell line</a> NSF-60. <a href="cope.cgi?key=dHGF">dHGF</a> is more potent than HGF in stimulating DNA synthesis in LLC-PK1 (<a href="cope.cgi?key=Cytokine%20Inter%2dspecies%20Reactivities">pig</a> kidney <a href="cope.cgi?key=epithelial%20cells">epithelial cells</a>), OK (American opossum kidney <a href="cope.cgi?key=epithelial%20cells">epithelial cells</a>), and <a href="cope.cgi?key=Cytokine%20Inter%2dspecies%20Reactivities">rat</a> <a href="cope.cgi?key=hepatocytes">hepatocytes</a> (Shima et al, 1994).</span> </p><p><span style='mso-bidi-font-size:9.0pt; mso-bidi-font-family:"Times New Roman";color:black'>Bell et al (1999) have generated <a href="cope.cgi?key=transgenic">transgenic</a> <a href="cope.cgi?key=Cytokine%20Inter%2dspecies%20Reactivities">mice</a> expressing <a href="cope.cgi?key=dHGF">dHGF</a> in the liver under control of the <a href="cope.cgi?key=albumin">albumin</a> promoter. These <a href="cope.cgi?key=Cytokine%20Inter%2dspecies%20Reactivities">mice</a> develop normally, have an enhanced rate of liver regeneration after partial hepatectomy, and exhibit a threefold higher incidence of <a href="cope.cgi?key=hepatocellular%20carcinoma">hepatocellular carcinoma</a> beyond 17 months of age. Overexpression of <a href="cope.cgi?key=dHGF">dHGF</a> dramatically accelerates diethyl-nitrosamine induced <a href="cope.cgi?key=hepatocellular%20carcinoma">hepatocellular carcinoma</a> tumorigenesis. These tumors arise faster, are significantly larger, more numerous and more invasive than those appearing in non-transgenic littermates. Liver tumors and cultured tumor <a href="cope.cgi?key=Cell%20lines%20in%20Cytokine%20Research">cell lines</a> from <a href="cope.cgi?key=dHGF">dHGF</a> transgenics express high levels of HGF and its receptor <a href="cope.cgi?key=met">c-met</a>.</span> </p><p><span style='mso-bidi-font-size:9.0pt; mso-bidi-font-family:"Times New Roman";color:black'>Both subunits of HGF are obtained by endoproteolytic cleavage of a common <a href="cope.cgi?key=preproprotein">preproprotein</a> of 728 amino acids (approximately 90 kDa) which itself is biologically inactive. The inactive precursor is mostly found in a matrix-associated form. Maturation of the precursor into the active heterodimer takes place in the extracellular environment and results from proteolytic cleavage by urokinase which thus acts as a HGF convertase.</span> </p><p><span style='mso-bidi-font-size:9.0pt; mso-bidi-font-family:"Times New Roman";color:black'>The inactive single-chain precursor of HGF secreted by the producing <a href="cope.cgi?key=cell%20types">cells</a> is converted to a biologically active heterodimer by a serine protease, the activity of which is induced in injured liver tissue. A <a href="cope.cgi?key=Cytokine%20Concentrations%20in%20Biological%20Fluids">serum</a> serine protease that activates single-chain HGF has been identified (see: <a href="cope.cgi?key=HGFA">HGFA</a>).</span> </p><p><span style='mso-bidi-font-size:9.0pt; mso-bidi-font-family:"Times New Roman";color:black'>An inhibitor of <a href="cope.cgi?key=HGF%20activator">HGF activator</a> (<b style="mso-bidi-font-weight:normal"><a href="cope.cgi?key=Hepatocyte%20growth%20factor%20activator%20inhibitor%2d1">Hepatocyte growth factor activator inhibitor-1</a></b>; abbr. <b style="mso-bidi-font-weight:normal"><a href="cope.cgi?key=HAI%2d1">HAI-1</a></b>) has been isolated by Shimomura et al (1997) from the <a href="cope.cgi?key=conditioned%20medium">conditioned medium</a> of the <a href="cope.cgi?key=Cytokine%20Inter%2dspecies%20Reactivities">human</a> MKN45 stomach carcinoma <a href="cope.cgi?key=Cell%20lines%20in%20Cytokine%20Research">cell line</a>. The sequence of the <a href="cope.cgi?key=cDNA">cDNA</a> suggests that the inhibitor is a member of the Kunitz family of serine protease inhibitors. A second inhibitor (<b style="mso-bidi-font-weight:normal"><a href="cope.cgi?key=Hepatocyte%20growth%20factor%20activator%20inhibitor%2d2">Hepatocyte growth factor activator inhibitor-2</a></b>; abbr. <b style="mso-bidi-font-weight:normal"><a href="cope.cgi?key=HAI%2d2">HAI-2</a></b>) has been isolated from the same <a href="cope.cgi?key=Cell%20lines%20in%20Cytokine%20Research">cell line</a> by Kawaguchi et al (1997). <a href="cope.cgi?key=HAI%2d2">HAI-2</a> is derived from a precursor protein of 252 amino acids and 2 is also a member of the Kunitz family of serine protease inhibitors. Both inhibitors are produced in a membrane-associated form and secreted in a proteolytically truncated form.</span> </p><p><b style="mso-bidi-font-weight:normal"><span style='mso-bidi-font-size:9.0pt;mso-bidi-font-family:"Times New Roman"; color:black'>GENE STRUCTURE</span></b> </p><p><span style='mso-bidi-font-size:9.0pt; mso-bidi-font-family:"Times New Roman";color:black'>The HGF gene has a length of approximately 70 kb and contains 18 exons. It encodes an mRNA of 6.3 kb. The <a href="cope.cgi?key=Cytokine%20Inter%2dspecies%20Reactivities">human</a> gene maps to chromosome 7q11.2-21.1. An <a href="cope.cgi?key=IL6%20responsive%20element">IL6 responsive element</a> (see also: <a href="cope.cgi?key=Gene%20expression">gene expression</a>) and a binding site for an IL6-specific <a href="cope.cgi?key=Transcription%20factors">transcription factor</a>, <a href="cope.cgi?key=C%2fEBP%2dbeta">C/EBP-beta</a> (see also: <a href="cope.cgi?key=IL6">IL6</a>) lies in close proximity to the transcription initiation site of the HGF gene.</span> </p><p><span style='mso-bidi-font-size:9.0pt; mso-bidi-font-family:"Times New Roman";color:black'>The <a href="cope.cgi?key=Cytokine%20Inter%2dspecies%20Reactivities">murine</a> HGF gene contains a variety of different putative regulatory elements, including four copies of the <a href="cope.cgi?key=IL6%20responsive%20element">IL6 responsive element</a> (<a href="cope.cgi?key=IL6RE">IL6RE</a>), two potential binding sites for <a href="cope.cgi?key=C%2fEBP%2dbeta">C/EBP-beta</a>, a <a href="cope.cgi?key=TGF%2dbeta%2d1%20inhibitory%20element">TGF-beta-1 inhibitory element</a> (<a href="cope.cgi?key=TIE">TIE</a> element), a <a href="cope.cgi?key=CAMP">cAMP</a> <a href="cope.cgi?key=response%20elements">response element</a> (<a href="cope.cgi?key=CRE">CRE</a>), two estrogen <a href="cope.cgi?key=response%20elements">response elements</a> (ERE), a potential vitamin D <a href="cope.cgi?key=response%20elements">response element</a> (VDRE) overlapping with a <a href="cope.cgi?key=Cytokine%20Inter%2dspecies%20Reactivities">chicken</a> <a href="cope.cgi?key=Ovalbumin">ovalbumin</a> <a href="cope.cgi?key=upstream">upstream</a> promoter (COUP) <a href="cope.cgi?key=Transcription%20factors">transcription factor</a> binding element, two liver-specific <a href="cope.cgi?key=Transcription%20factors">transcription factor</a> (C/EBP) binding sites, and a <a href="cope.cgi?key=B%2dcells">B-cell</a> and macrophage-specific transcriptional factor binding site (PU.1/ETS).</span> </p><p><b style="mso-bidi-font-weight:normal"><span style='mso-bidi-font-size:9.0pt;mso-bidi-font-family:"Times New Roman"; color:black'>RECEPTORS</span></b> </p><p><span style='mso-bidi-font-size:9.0pt; mso-bidi-font-family:"Times New Roman";color:black'>The <a href="cope.cgi?key=HGF%20receptor">HGF receptor</a> is encoded by the <a href="cope.cgi?key=met">met</a> <a href="cope.cgi?key=Proto%2doncogene">proto-oncogene</a> on <a href="cope.cgi?key=Cytokine%20Inter%2dspecies%20Reactivities">human</a> chromosome 7p11-4. This gene encodes a protein with intrinsic <a href="cope.cgi?key=PTK">tyrosine-specific protein kinase</a> activity in its intracellular <a href="cope.cgi?key=domain">domain</a>. The heavy chain is thought to play an important role in the interaction of HGF with its receptor and the light chain is further required for the tyrosine phosphorylation of the receptor.</span> </p><p><span style='mso-bidi-font-size:9.0pt; mso-bidi-font-family:"Times New Roman";color:black'>The phosphorylated receptor binds phosphatidyl inositol-3-kinase which is responsible for post receptor signaling.</span> </p><p><span style='mso-bidi-font-size:9.0pt; mso-bidi-font-family:"Times New Roman";color:black'>Alternative splicing leads to the formation of various isoforms of the receptor. It has been suggested that these isoforms are biologically active and may mediate different biologically responses. The existence of further non-met receptors for HGF has been suggested also.</span> </p><p>Ohnishi et al (2012) have reported that the beta chain of HGF utilizes <a href="cope.cgi?key=CD206">CD206</a> expressed on <a href="cope.cgi?key=Kupffer%20cells">Kupffer cells</a> and sinusoidal <a href="cope.cgi?key=endothelial%20cells">endothelial cells</a> as a receptor. Binding of HGF beta chain, to <a href="cope.cgi?key=CD206">CD206</a> enhances the ingestion of latex beads, or of <a href="cope.cgi?key=Apoptosis">apoptotic</a> <a href="cope.cgi?key=neutrophils">neutrophils</a>, suggesting that this complex may provide a new pathway for the enhancement of cell clearance systems, which is associated with resolution of <a href="cope.cgi?key=inflammation">inflammation</a>.  </p><p><b style="mso-bidi-font-weight:normal"><span style='mso-bidi-font-size:9.0pt;mso-bidi-font-family:"Times New Roman"; color:black'>BIOLOGICAL ACTIVITIES</span></b> </p><p><span style='mso-bidi-font-size:9.0pt; mso-bidi-font-family:"Times New Roman";color:black'>The biological activities of HGF are not <a href="cope.cgi?key=Cytokine%20Inter%2dspecies%20Reactivities">species-specific</a>.</span> </p><p><span style='mso-bidi-font-size:9.0pt; mso-bidi-font-family:"Times New Roman";color:black'>HGF is a hepatotrophic factor that stimulates the proliferation of <a href="cope.cgi?key=hepatocytes">hepatocytes</a> in vivo. HGF is the most potent known <a href="cope.cgi?key=Cell%20cycle">mitogen</a> for <a href="cope.cgi?key=hepatocytes">hepatocytes</a> in primary culture. It is one of the major <a href="cope.cgi?key=Cell%20cycle">mitogens</a> engaged in liver regeneration processes following partial hepatectomy and other liver injuries (see also: <a href="cope.cgi?key=inflammation">inflammation</a>, <a href="cope.cgi?key=Wound%20healing">wound healing</a>). HGF has been shown also to be involved in the regeneration of kidney tubules. It is a <a href="cope.cgi?key=Cell%20cycle">mitogen</a> for kidney <a href="cope.cgi?key=epithelial%20cells">epithelial cells</a>. In vitro HGF induces <a href="cope.cgi?key=endothelial%20cells">endothelial cells</a> to proliferate and migrate (see also: <a href="cope.cgi?key=Scatter%20factor">Scatter factor</a>).</span> </p><p><span style='mso-bidi-font-size:9.0pt; mso-bidi-font-family:"Times New Roman";color:black'>HGF and <a href="cope.cgi?key=EGF">EGF</a> activities are additive. The <a href="cope.cgi?key=Cell%20cycle">mitogenic</a> effect of HGF is enhanced by norepinephine. The biological activity of HGF can be inhibited by <a href="cope.cgi?key=Suramin">suramin</a>. HGF abolishes the inhibitory actions of <a href="cope.cgi?key=TGF%2dbeta">TGF-beta</a> on cellular proliferation. HGF has been shown also to be one of the <a href="cope.cgi?key=priming%20factors">priming factors</a> for <a href="cope.cgi?key=neutrophils">neutrophils</a> (see also: <a href="cope.cgi?key=Cell%20activation">cell activation</a>).</span> </p><p><span style='mso-bidi-font-size:9.0pt; mso-bidi-font-family:"Times New Roman";color:black'>At present HGF is the only known factor influencing the three-dimensional growth of <a href="cope.cgi?key=cell%20types">cells</a> in three-dimensional collagen gels where it leads to the formation of tubular structures in growing <a href="cope.cgi?key=epithelial%20cells">epithelial cells</a>. HGF is therefore a multifunctional <a href="cope.cgi?key=cytokines">cytokine</a> that acts as a <a href="cope.cgi?key=Cell%20cycle">mitogen</a>, a motogen (see: <a href="cope.cgi?key=Scatter%20factor">Scatter factor</a>) and a morphogen, explaining its functions in organogenesis and <a href="cope.cgi?key=Wound%20healing">tissue regeneration</a>.</span> </p><p><span style='mso-bidi-font-size:9.0pt; mso-bidi-font-family:"Times New Roman";color:black'>HGF also shows <a href="cope.cgi?key=Paracrine">paracrine</a> activities in that it is produced by kidney <a href="cope.cgi?key=mesangial%20cells">mesangial cells</a> and acts on renal <a href="cope.cgi?key=epithelial%20cells">epithelial cells</a>. HGF also stimulates the growth of <a href="cope.cgi?key=Cytokine%20Inter%2dspecies%20Reactivities">human</a> <a href="cope.cgi?key=melanoma%20cells">melanoma cells</a> and <a href="cope.cgi?key=Cytokine%20Inter%2dspecies%20Reactivities">murine</a> <a href="cope.cgi?key=keratinocytes">keratinocytes</a>. The growth of some <a href="cope.cgi?key=hepatocellular%20carcinoma">hepatocellular carcinomas</a> and some <a href="cope.cgi?key=Cytokine%20Inter%2dspecies%20Reactivities">human</a> tumor <a href="cope.cgi?key=Cell%20lines%20in%20Cytokine%20Research">cell lines</a> (B6/F1 <a href="cope.cgi?key=melanoma%20cells">melanoma</a>, KB-cells) is inhibited by HGF.</span> </p><p><span style='mso-bidi-font-size:9.0pt; mso-bidi-font-family:"Times New Roman";color:black'>In the <a href="cope.cgi?key=Cytokine%20Inter%2dspecies%20Reactivities">rabbit</a> cornea, highly purified HGF promotes <a href="cope.cgi?key=Neovascularization">neovascularization</a> at subnanomolar <a href="cope.cgi?key=Cytokine%20Concentrations%20in%20Biological%20Fluids">concentrations</a>.</span> </p><p><span style='mso-bidi-font-size:9.0pt; mso-bidi-font-family:"Times New Roman";color:black'>HGF synergizes with <a href="cope.cgi?key=IL3">IL3</a> and <a href="cope.cgi?key=GM%2dCSF">GM-CSF</a> to stimulate <a href="cope.cgi?key=Colony%20formation%20assay">colony formation</a> of <a href="cope.cgi?key=hematopoietic%20progenitor%20cells">hematopoietic progenitor cells</a> in vitro and may, therefore, also modulate <a href="cope.cgi?key=Hematopoiesis">hematopoiesis</a>.</span> </p><p><b style="mso-bidi-font-weight:normal"><span style='mso-bidi-font-size:9.0pt;mso-bidi-font-family:"Times New Roman"; color:black'>TRANSGENIC ANIMALS, KNOCK-OUT, AND ANTISENSE STUDIES</span></b> </p><p><span style='mso-bidi-font-size:9.0pt; mso-bidi-font-family:"Times New Roman";color:black'>The biological activities of HGF have been studied in <a href="cope.cgi?key=transgenic">transgenic</a> <a href="cope.cgi?key=Cytokine%20Inter%2dspecies%20Reactivities">mice</a> expressing the factor under the control of <a href="cope.cgi?key=albumin">albumin</a> regulatory sequences. <a href="cope.cgi?key=hepatocytes">Hepatocytes</a> of HGF-transgenic <a href="cope.cgi?key=Cytokine%20Inter%2dspecies%20Reactivities">mice</a> express increased levels of HGF as an <a href="cope.cgi?key=Autocrine">autocrine</a> growth modulator. The experiments also show that HGF increases growth and repair processes when expressed for long periods in the liver: the livers of HGF-transgenic <a href="cope.cgi?key=Cytokine%20Inter%2dspecies%20Reactivities">mice</a> recover completely in half the time needed for their normal siblings after partial hepatectomy. Levels of cellular <a href="cope.cgi?key=myc">myc</a> and <a href="cope.cgi?key=jun">jun</a> mRNA were increased in HGF-transgenic <a href="cope.cgi?key=Cytokine%20Inter%2dspecies%20Reactivities">mice</a>.</span> </p><p><span style='mso-bidi-font-size:9.0pt; mso-bidi-font-family:"Times New Roman";color:black'><br/> <b style="mso-bidi-font-weight:normal">DETECTION AND ASSAY METHODS</b></span> </p><p><span style='mso-bidi-font-size:9.0pt; mso-bidi-font-family:"Times New Roman";color:black'>A sensitive <a href="cope.cgi?key=ELISA">ELISA</a> assay is available. Other assay systems are based on the activity of HGF as <a href="cope.cgi?key=SF">SF</a> (<a href="cope.cgi?key=Scatter%20factor">scatter factor</a>). Proliferation of <a href="cope.cgi?key=CCL%2d64">CCL-64</a> <a href="cope.cgi?key=cell%20types">cells</a> induced by HGF has been used also as an assay. The induction of <a href="cope.cgi?key=IL11">IL11</a> by HGF in <a href="cope.cgi?key=SaOS%2d2">SaOS-2</a> <a href="cope.cgi?key=cell%20types">cells</a> has been used as a <a href="cope.cgi?key=bioassays">bioassay</a> for HGF. For further information see also subentry "Assays" in the reference section. For further information on assays for <a href="cope.cgi?key=cytokines">cytokines</a> see also: <a href="cope.cgi?key=bioassays">bioassays</a>, <a href="cope.cgi?key=Cytokine%20assays">cytokine assays</a>.</span> </p><p><b style="mso-bidi-font-weight:normal"><span style='mso-bidi-font-size:9.0pt;mso-bidi-font-family:"Times New Roman"; color:black'>CLINICAL USE AND SIGNIFICANCE</span></b> </p><p><span style='mso-bidi-font-size:9.0pt; mso-bidi-font-family:"Times New Roman";color:black'>This factor may be of clinical importance due to its involvement in <a href="cope.cgi?key=Wound%20healing">tissue regeneration</a> following hepatectomy.</span> </p><p><span style='mso-bidi-font-size:9.0pt; mso-bidi-font-family:"Times New Roman";color:black'><br/> </span><b style="mso-bidi-font-weight:normal"><span style='mso-bidi-font-size: 9.0pt;mso-bidi-font-family:"Times New Roman";color:#993300'>_____________________________________________________________________________</span></b><span style='mso-bidi-font-size:9.0pt;mso-bidi-font-family:"Times New Roman"; color:black'><br/> <br/> <b style="mso-bidi-font-weight:normal">(-4-)</b> see: <b style="mso-bidi-font-weight: normal"><a href="cope.cgi?key=Hepatoma%20growth%20factor">hepatoma growth factor</a></b></span> </p><p><span style='mso-bidi-font-size:9.0pt; mso-bidi-font-family:"Times New Roman";color:red'><br/> </span><b style="mso-bidi-font-weight:normal"><span style="color:red"><a href="cope.cgi?key=Copyright">Copyright</a> &#169; 2012 by H IBELGAUFTS. All rights reserved.</span></b><b style="mso-bidi-font-weight: normal"><span style='font-size:10.0pt;font-family:Times;mso-fareast-font-family: "Times New Roman"'><br/> </span><span style="color:red">ENTRY COMPLETED.</span></b> </p><p><span style='mso-bidi-font-size:9.0pt; mso-bidi-font-family:"Times New Roman";color:black'><br/> </span><b style="mso-bidi-font-weight:normal"><span style='mso-bidi-font-size: 9.0pt;mso-bidi-font-family:"Times New Roman";color:#993300'>_____________________________________________________________________________</span></b><span style='mso-bidi-font-size:9.0pt;mso-bidi-font-family:"Times New Roman"; color:black'><br/> <br/> <b style="mso-bidi-font-weight:normal">(-5-) </b>see: <b style="mso-bidi-font-weight: normal"><a href="cope.cgi?key=Hybridoma%20growth%20factor">hybridoma growth factor</a></b></span> </p><p><span style='mso-bidi-font-size:9.0pt; mso-bidi-font-family:"Times New Roman";color:red'><br/> </span><b style="mso-bidi-font-weight:normal"><span style="color:red"><a href="cope.cgi?key=Copyright">Copyright</a> &#169; 2012 by H IBELGAUFTS. All rights reserved.</span></b><b style="mso-bidi-font-weight: normal"><span style='font-size:10.0pt;font-family:Times;mso-fareast-font-family: "Times New Roman"'><br/> </span><span style="color:red">ENTRY COMPLETED.</span></b> </p><p><span style='mso-bidi-font-size:9.0pt; mso-bidi-font-family:"Times New Roman";color:black'><br/> </span><b style="mso-bidi-font-weight:normal"><span style='mso-bidi-font-size: 9.0pt;mso-bidi-font-family:"Times New Roman";color:#993300'>_____________________________________________________________________________</span></b><span style='mso-bidi-font-size:9.0pt;mso-bidi-font-family:"Times New Roman"; color:black'><br/> <br/> <b style="mso-bidi-font-weight:normal">(-6-) <a href="cope.cgi?key=Hypothalamic%20growth%20factor">hypothalamic growth factor</a></b></span> </p><p><span style='mso-bidi-font-size:9.0pt; mso-bidi-font-family:"Times New Roman";color:black'>This factor is identical with <a href="cope.cgi?key=bFGF">bFGF</a>.</span> </p><p><span style='mso-bidi-font-size:9.0pt; mso-bidi-font-family:"Times New Roman";color:red'><br/> </span><b style="mso-bidi-font-weight:normal"><span style="color:red"><a href="cope.cgi?key=Copyright">Copyright</a> &#169; 2012 by H IBELGAUFTS. All rights reserved.</span></b><b style="mso-bidi-font-weight: normal"><span style='font-size:10.0pt;font-family:Times;mso-fareast-font-family: "Times New Roman"'><br/> </span><span style="color:red">ENTRY COMPLETED.</span></b> </p><p><br/></p>

<h2>ICAM1</h2>

<h2>IFNA2</h2>

<h2>IFNG</h2><p><span style='mso-bidi-font-size:9.0pt; mso-bidi-font-family:"Times New Roman";color:black'>approved gene symbol for <a href="cope.cgi?key=IFN%2dgamma">IFN-gamma</a> [<a href="cope.cgi?key=Interferon%2dgamma">Interferon-gamma</a>]. See also: <a href="cope.cgi?key=IFN">IFN</a> for general information about <a href="cope.cgi?key=Interferons">interferons</a>.</span> </p><p><span style='mso-bidi-font-size:9.0pt; mso-bidi-font-family:"Times New Roman";color:red'><br/> </span><b style="mso-bidi-font-weight:normal"><span style="color:red"><a href="cope.cgi?key=Copyright">Copyright</a> &#169; 2012 by H IBELGAUFTS. All rights reserved.</span></b><b style="mso-bidi-font-weight: normal"><span style='font-size:10.0pt;font-family:Times;mso-fareast-font-family: "Times New Roman"'><br/> </span><span style="color:red">ENTRY COMPLETED.</span></b></p><p><br/></p>

<h2>IL12A</h2><p><span style='mso-bidi-font-size:9.0pt; mso-bidi-font-family:"Times New Roman";color:black'>[<a href="cope.cgi?key=IL12%2dalpha">IL12-alpha</a>] This term refers to the 35 kDa subunit of the heterodimeric protein <a href="cope.cgi?key=IL12">IL12</a>.</span> </p><p><span style='mso-bidi-font-size:9.0pt; mso-bidi-font-family:"Times New Roman";color:red'><br/> </span><b style="mso-bidi-font-weight:normal"><span style="color:red"><a href="cope.cgi?key=Copyright">Copyright</a> &#169; 2012 by H IBELGAUFTS. All rights reserved.</span></b><b style="mso-bidi-font-weight: normal"><span style='font-size:10.0pt;font-family:Times;mso-fareast-font-family: "Times New Roman"'><br/> </span><span style="color:red">ENTRY COMPLETED.</span></b></p><p><br/></p>

<h2>IL1RN</h2><p><span style='mso-bidi-font-size:9.0pt; mso-bidi-font-family:"Times New Roman";color:black'><a href="cope.cgi?key=IL1%20receptor%20antagonist">IL1 receptor antagonist</a>. See: <a href="cope.cgi?key=IL1ra">IL1ra</a>.</span> </p><p><span style='mso-bidi-font-size:9.0pt; mso-bidi-font-family:"Times New Roman";color:red'><br/> </span><b style="mso-bidi-font-weight:normal"><span style="color:red"><a href="cope.cgi?key=Copyright">Copyright</a> &#169; 2012 by H IBELGAUFTS. All rights reserved.</span></b><b style="mso-bidi-font-weight: normal"><span style='font-size:10.0pt;font-family:Times;mso-fareast-font-family: "Times New Roman"'><br/> </span><span style="color:red">ENTRY COMPLETED.</span></b></p><p><br/></p>

<h2>IL2RA</h2><p><span style='mso-bidi-font-size:9.0pt; mso-bidi-font-family:"Times New Roman";color:black'>[<a href="cope.cgi?key=interleukin%2d2%20receptor%2dalpha">interleukin-2 receptor-alpha</a>; <a href="cope.cgi?key=IL2R%2dalpha">IL2R-alpha</a>; <a href="cope.cgi?key=IL2%20receptor%2dalpha">IL2 receptor-alpha</a>] This is the approved gene symbol for one subunit of the receptor for <a href="cope.cgi?key=IL2">IL2</a>. The simple designation <a href="cope.cgi?key=IL2R">IL2R</a> [<a href="cope.cgi?key=interleukin%2d2%20receptor">interleukin-2 receptor</a>] is used also. The receptor has been identified originally as <a href="cope.cgi?key=TAC%20antigen">TAC antigen</a>. In older <a href="cope.cgi?key=Zzzz%20%2e%2e%2e%20zzzz%20%2e%2e%2e%20zzzz">publications</a> the has been referred to as <a href="cope.cgi?key=TCGFR">TCGFR</a> [<a href="cope.cgi?key=T%2dcell%20growth%20factor%20receptor">T-cell growth factor receptor</a>]. Because of disease associations with polymorphisms of the IL2RA gene, IL2RA is being referred to also as <a href="cope.cgi?key=IDDM10">IDDM10</a>. The <a href="cope.cgi?key=Cytokine%20Inter%2dspecies%20Reactivities">mouse</a> counterpart of IL2RA is known as <a href="cope.cgi?key=Ly43">Ly43</a> [<a href="cope.cgi?key=Lymphocyte%20antigen%2043">lymphocyte antigen 43</a>]. The <a href="cope.cgi?key=Cytokine%20Inter%2dspecies%20Reactivities">rat</a> counterpart is <a href="cope.cgi?key=OX39">OX39</a>.</span> </p><p><span style='mso-bidi-font-size:9.0pt; mso-bidi-font-family:"Times New Roman";color:black'>In the <a href="cope.cgi?key=nomenclature">nomenclature</a> of <a href="cope.cgi?key=CD%20antigens">CD antigens</a> the receptor has been given the designation <a href="cope.cgi?key=CD25">CD25</a>.</span> </p><p><span style='mso-bidi-font-size:9.0pt; mso-bidi-font-family:"Times New Roman";color:black'>The IL2RA gene has been <a href="cope.cgi?key=Gene%20library">cloned</a> and characterized by Nikaido et al (1983), Leonard et al (1984), Ishida et al (1985), Leonard et al 1985). The <a href="cope.cgi?key=IL2%20receptor">IL2 receptor</a> exists in 3 different forms: a high affinity dimer consisting of the alpha subunit IL2RA and the beta subunit (<a href="cope.cgi?key=IL2RB">IL2RB</a>), an intermediate affinity monomer (beta subunit), and a low affinity monomer (alpha subunit). IL2RA is not functional in <a href="cope.cgi?key=IL2">IL2</a> internalization and signal transduction ((Gnarra et al, 1990). Signalling through the high and intermediate affinity forms requires a heterotrimeric complex formed by association with a gamma subunit (<a href="cope.cgi?key=IL2RG">IL2RG</a>; <a href="cope.cgi?key=common%20gamma">common gamma</a>), which is shared also with receptors for other <a href="cope.cgi?key=cytokines">cytokines</a> (Wang et al, 2005; Stauber DJ et al, 2006).</span> </p><p><span style='mso-bidi-font-size:9.0pt; mso-bidi-font-family:"Times New Roman";color:red'><br/> </span><b style="mso-bidi-font-weight:normal"><span style="color:red"><a href="cope.cgi?key=Copyright">Copyright</a> &#169; 2012 by H IBELGAUFTS. All rights reserved.</span></b><b style="mso-bidi-font-weight: normal"><span style='font-size:10.0pt;font-family:Times;mso-fareast-font-family: "Times New Roman"'><br/> </span></b><span style='mso-bidi-font-size:9.0pt;mso-bidi-font-family:"Times New Roman"; color:red'>ENTRY LAST MODIFIED: November 2010</span> </p><p><br/></p>

<h2>IL12</h2><p><span style='mso-bidi-font-size:9.0pt; mso-bidi-font-family:"Times New Roman";color:black'><a href="cope.cgi?key=Interleukin%2d12">Interleukin-12</a>.</span> </p><p><span style='mso-bidi-font-size:9.0pt; mso-bidi-font-family:"Times New Roman";color:black'><br/> <b style="mso-bidi-font-weight:normal">ALTERNATIVE NAMES</b></span> </p><p><b style="mso-bidi-font-weight:normal"><span style='mso-bidi-font-size:9.0pt;mso-bidi-font-family:"Times New Roman"; color:black'><a href="cope.cgi?key=CLMF">CLMF</a></span></b><span style='mso-bidi-font-size:9.0pt;mso-bidi-font-family: "Times New Roman";color:black'> (<a href="cope.cgi?key=Cytotoxic%20lymphocyte%20maturation%20factor">cytotoxic lymphocyte maturation factor</a>);<br/> <b style="mso-bidi-font-weight:normal"><a href="cope.cgi?key=NKSF">NKSF</a></b> (<a href="cope.cgi?key=Natural%20killer%20cell%20stimulatory%20factor">natural killer cell stimulatory factor</a>);<br/> <b style="mso-bidi-font-weight:normal"><a href="cope.cgi?key=TcMF">TcMF</a></b> (<a href="cope.cgi?key=CTL%20maturation%20factor">CTL maturation factor</a>; see: <a href="cope.cgi?key=CLMF">CLMF</a>);<br/> <b style="mso-bidi-font-weight:normal"><a href="cope.cgi?key=TSF">TSF</a></b> (<a href="cope.cgi?key=T%2dcell%20stimulating%20factor">T-cell stimulating factor</a>).<br/> See also: individual entries for further information.</span> </p><p><span style='mso-bidi-font-size:9.0pt; mso-bidi-font-family:"Times New Roman";color:black'><br/> <b style="mso-bidi-font-weight:normal">SOURCES</b></span> </p><p><span style='mso-bidi-font-size:9.0pt; mso-bidi-font-family:"Times New Roman";color:black'>IL12 is secreted by peripheral <a href="cope.cgi?key=lymphocytes">lymphocytes</a> after induction.IL12 is produced by activated hematopoietic <a href="cope.cgi?key=phagocytes">phagocytic</a> <a href="cope.cgi?key=cell%20types">cells</a> (<a href="cope.cgi?key=monocytes">monocytes</a>, <a href="cope.cgi?key=macrophages">macrophages</a>, and <a href="cope.cgi?key=neutrophils">neutrophils</a>) and by <a href="cope.cgi?key=dendritic%20cells">dendritic cells</a> (Hsieh et al, 1993; Chan CW et al, 2006), but also by a variety of other <a href="cope.cgi?key=cell%20types">cell types</a>. The most powerful inducers of IL12 are bacteria, bacterial products, and parasites. IL12 is produced after stimulation with <a href="cope.cgi?key=Phorbol%20esters">Phorbol esters</a> or <a href="cope.cgi?key=Calcium%20ionophore">Calcium ionophore</a> by <a href="cope.cgi?key=Cytokine%20Inter%2dspecies%20Reactivities">human</a> <a href="cope.cgi?key=B%2dlymphoblastoid%20cells">B-lymphoblastoid cells</a>. The <a href="cope.cgi?key=Cytokine%20Inter%2dspecies%20Reactivities">human</a> <a href="cope.cgi?key=lymphoblastoid%20cells">lymphoblastoid cell</a> line NC37 secretes large amounts of the uncomplexed 40 kDa subunit of IL12.</span> </p><p><span style='mso-bidi-font-size:9.0pt; mso-bidi-font-family:"Times New Roman";color:black'><br/> <b style="mso-bidi-font-weight:normal">PROTEIN CHARACTERISTICS</b></span> </p><p><span style='mso-bidi-font-size:9.0pt; mso-bidi-font-family:"Times New Roman";color:black'>IL12 is a heterodimeric 70 kDa glycoprotein (<b style="mso-bidi-font-weight:normal"><a href="cope.cgi?key=IL12%2dp70">IL12-p70</a></b>) consisting of a 40 kDa subunit (<a href="cope.cgi?key=nomenclature">designated</a> <a href="cope.cgi?key=IL12B">IL12B</a>, <a href="cope.cgi?key=IL12%2dbeta">IL12-beta</a>, <a href="cope.cgi?key=IL12%2dp40">IL12-p40</a>; 40 kDa subunit, 306 amino acids; 10 % carbohydrate) and a 35 kDa subunit (<a href="cope.cgi?key=nomenclature">designated</a> <a href="cope.cgi?key=IL12A">IL12A</a>, <a href="cope.cgi?key=IL12%2dalpha">IL12-alpha</a>, <a href="cope.cgi?key=IL12%2dp35">IL12-p35</a>; <a href="cope.cgi?key=p35">p35</a>, 197 amino acids; 20 % carbohydrate) linked by disulfide bonds that are essential for the biological activity of IL12. <a href="cope.cgi?key=IL12%2dp40">IL12-p40</a> contains 10 cysteines and a binding site for heparin (see also: <a href="cope.cgi?key=HBGF">HBGF</a>, <a href="cope.cgi?key=Heparin%20binding%20growth%20factors">heparin binding growth factors</a>); <a href="cope.cgi?key=p35">p35</a> contains 7 cysteines.</span> </p><p><span style='mso-bidi-font-size:9.0pt; mso-bidi-font-family:"Times New Roman";color:black'><a href="cope.cgi?key=P40">p40</a> shows some homology with the extracellular <a href="cope.cgi?key=domain">domain</a> of the receptor for <a href="cope.cgi?key=IL6">IL6</a>. <a href="cope.cgi?key=p35">p35</a> and <a href="cope.cgi?key=IL6">IL6</a> probably are <a href="cope.cgi?key=homolog">homologous</a>. <a href="cope.cgi?key=P40">p40</a> has been shown to be a subunit of another <a href="cope.cgi?key=composite%20cytokine">composite cytokine</a>, <a href="cope.cgi?key=nomenclature">designated</a> <a href="cope.cgi?key=IL23">IL23</a>. The <a href="cope.cgi?key=P40">p40</a> subunit can also form a homodimer, <b style="mso-bidi-font-weight:normal"><a href="cope.cgi?key=IL12%2dp80">IL12-p80</a></b>, which act as an IL12 and <a href="cope.cgi?key=IL23">IL23</a> antagonist by competing at their receptors.</span> </p><p><span style='mso-bidi-font-size:9.0pt; mso-bidi-font-family:"Times New Roman";color:black'>Lieschke et al (1997) have recently described the construction of bioactive <a href="cope.cgi?key=Cytokine%20Inter%2dspecies%20Reactivities">murine</a> and <a href="cope.cgi?key=Cytokine%20Inter%2dspecies%20Reactivities">human</a> IL12 fusion proteins combining the two IL12 subunits in a single molecule. This <a href="cope.cgi?key=Designer%20cytokines">designer cytokine</a> (see also: <a href="cope.cgi?key=Muteins">Muteins</a>) retains antitumor activity in vivo. Anderson et al (1997) have described the construction of <b style="mso-bidi-font-weight:normal"><a href="cope.cgi?key=Flexi%2012">Flexi 12</a></b>, a single chain protein retaining all of the biological characteristics of the dimeric recombinant IL12.</span> </p><p><span style='mso-bidi-font-size:9.0pt; mso-bidi-font-family:"Times New Roman";color:black'>The <a href="cope.cgi?key=p35">p35</a> subunit of IL12 has been shown to heterodimerize with a protein known as <a href="cope.cgi?key=EBI%2d3">EBI-3</a> (<a href="cope.cgi?key=EBV%20induced%20gene%2d3">EBV induced gene-3</a>). <a href="cope.cgi?key=p28">p28</a> is related to the <a href="cope.cgi?key=p35">p35</a> subunit of IL12 and is one subunit of the <a href="cope.cgi?key=IL27">IL27</a> heterodimeric protein.</span> </p><p><span style='mso-bidi-font-size:9.0pt; mso-bidi-font-family:"Times New Roman";color:black'><br/> <b style="mso-bidi-font-weight:normal">GENE STRUCTURE</b></span> </p><p><span style='mso-bidi-font-size:9.0pt; mso-bidi-font-family:"Times New Roman";color:black'>The gene encoding the <a href="cope.cgi?key=P40">p40</a> subunit of IL12 (<a href="cope.cgi?key=IL12B">IL12B</a>; see also: <a href="cope.cgi?key=IL12%2dp40">IL12-p40</a>) maps to <a href="cope.cgi?key=Cytokine%20Inter%2dspecies%20Reactivities">human</a> chromosome 5q31-q33 in the same region that also harbors other <a href="cope.cgi?key=cytokines">cytokine</a> genes (see: <a href="cope.cgi?key=5q%20minus%20syndrome">5q minus syndrome</a>). The gene encoding the <a href="cope.cgi?key=p35">p35</a> subunit of IL12 (<a href="cope.cgi?key=IL12A">IL12A</a>; see also: <a href="cope.cgi?key=IL12%2dp35">IL12-p35</a>) maps to <a href="cope.cgi?key=Cytokine%20Inter%2dspecies%20Reactivities">human</a> chromosome 3p12-q13.2. The expression of the two genes is regulated independently of each other</span> </p><p><span style='mso-bidi-font-size:9.0pt; mso-bidi-font-family:"Times New Roman";color:black'><br/> <b style="mso-bidi-font-weight:normal">RECEPTORS</b></span> </p><p><span style='mso-bidi-font-size:9.0pt; mso-bidi-font-family:"Times New Roman";color:black'>The <a href="cope.cgi?key=IL12%20receptor">IL12 receptor</a> (<a href="cope.cgi?key=CD212">CD212</a>) appears to be a single protein of approximately 110 kDa.<b style="mso-bidi-font-weight: normal"> </b>Up to 1000-9000 high affinity IL12 receptors/cell are expressed on <a href="cope.cgi?key=peripheral%20blood%20mononuclear%20cells">peripheral blood mononuclear cells</a> activated by various <a href="cope.cgi?key=Cell%20cycle">mitogens</a> for <a href="cope.cgi?key=T%2dcells">T-cells</a> or by <a href="cope.cgi?key=IL2">IL2</a>. IL12 receptors are present on activated <a href="cope.cgi?key=T%2dcells">T-cells</a> expressing <a href="cope.cgi?key=CD4">CD4</a> and <a href="cope.cgi?key=CD8">CD8</a> and on activated <a href="cope.cgi?key=CD56">CD56(+)</a> <a href="cope.cgi?key=natural%20killer%20cells">natural killer cells</a>. Resting <a href="cope.cgi?key=peripheral%20blood%20mononuclear%20cells">peripheral blood mononuclear cells</a>, tonsillar <a href="cope.cgi?key=B%2dcells">B-cells</a>, or tonsillar <a href="cope.cgi?key=B%2dcells">B-cells</a> activated by anti-IgM/Dx, anti-IgM/Dx + <a href="cope.cgi?key=IL2">IL2</a>, or SAC + <a href="cope.cgi?key=IL2">IL2</a> do not express the receptor. High affinity IL12 receptors are expressed constitutively on a transformed <a href="cope.cgi?key=Cytokine%20Inter%2dspecies%20Reactivities">marmoset</a> NK-like <a href="cope.cgi?key=Cell%20lines%20in%20Cytokine%20Research">cell line</a>, HVS.SILVA 40.</span> </p><p><span style='mso-bidi-font-size:9.0pt; mso-bidi-font-family:"Times New Roman";color:black'>Binding of IL12 to its receptor can be prevented by monoclonal antibodies directed against the <a href="cope.cgi?key=P40">p40</a> subunit which therefore contains the binding site. The <a href="cope.cgi?key=P40">p40</a> subunit of IL12 shows homology with the extracellular <a href="cope.cgi?key=domain">domain</a> of the <a href="cope.cgi?key=IL6">IL6</a> receptor. For a virus-encoded <a href="cope.cgi?key=homolog">homolog</a> of the <a href="cope.cgi?key=P40">p40</a> subunit see also: (<a href="cope.cgi?key=EBI%2d3">EBI-3</a>: <a href="cope.cgi?key=EBV%20induced%20gene%2d3">EBV induced gene-3</a>).</span> </p><p><span style='mso-bidi-font-size:9.0pt; mso-bidi-font-family:"Times New Roman";color:black'><br/> <b style="mso-bidi-font-weight:normal">BIOLOGICAL ACTIVITIES</b></span> </p><p><span style='mso-bidi-font-size:9.0pt; mso-bidi-font-family:"Times New Roman";color:black'><a href="cope.cgi?key=Cytokine%20Inter%2dspecies%20Reactivities">Human</a> IL12 is not active in <a href="cope.cgi?key=Cytokine%20Inter%2dspecies%20Reactivities">murine</a> <a href="cope.cgi?key=lymphocytes">lymphocytes</a>. Hybrid heterodimers consisting of <a href="cope.cgi?key=Cytokine%20Inter%2dspecies%20Reactivities">murine</a> <a href="cope.cgi?key=p35">p35</a> and <a href="cope.cgi?key=Cytokine%20Inter%2dspecies%20Reactivities">human</a> <a href="cope.cgi?key=P40">p40</a> subunits retain bioactivity on <a href="cope.cgi?key=Cytokine%20Inter%2dspecies%20Reactivities">murine</a> <a href="cope.cgi?key=cell%20types">cells</a>; however, the combination of <a href="cope.cgi?key=Cytokine%20Inter%2dspecies%20Reactivities">human</a> <a href="cope.cgi?key=p35">p35</a> and <a href="cope.cgi?key=Cytokine%20Inter%2dspecies%20Reactivities">murine</a> <a href="cope.cgi?key=P40">p40</a> is completely inactive on <a href="cope.cgi?key=Cytokine%20Inter%2dspecies%20Reactivities">murine</a> <a href="cope.cgi?key=cell%20types">cells</a>. <a href="cope.cgi?key=Cytokine%20Inter%2dspecies%20Reactivities">Murine</a> IL12 is active on both <a href="cope.cgi?key=Cytokine%20Inter%2dspecies%20Reactivities">murine</a> and <a href="cope.cgi?key=Cytokine%20Inter%2dspecies%20Reactivities">human</a> <a href="cope.cgi?key=lymphocytes">lymphocytes</a>.</span> </p><p><span style='mso-bidi-font-size:9.0pt; mso-bidi-font-family:"Times New Roman";color:black'>The <a href="cope.cgi?key=P40">p40</a> subunit of <a href="cope.cgi?key=Cytokine%20Inter%2dspecies%20Reactivities">murine</a> IL12 subunit <a href="cope.cgi?key=P40">p40</a> (<a href="cope.cgi?key=IL12%2dp40">IL12-p40</a>) has been shown to specifically antagonize the effects of the IL12 heterodimer in different assay systems and to function as an endogenous specific inhibitor for the IL12 heterodimer (Mattner et al, 1993). Some <a href="cope.cgi?key=cell%20types">cells</a>, such as <a href="cope.cgi?key=microglial%20cells">microglia</a> and macrfophages, have been shown to produce the <a href="cope.cgi?key=IL12%2dp40">IL12-p40</a> subunit, but not IL12, under certain conditions (Constantinescu et al, 1996; Mottonen et al, 2002; Fernandez-Lago et al, 1999).</span> </p><p><span style='mso-bidi-font-size:9.0pt; mso-bidi-font-family:"Times New Roman";color:black'>IL12 stimulates the proliferation of <a href="cope.cgi?key=Cytokine%20Inter%2dspecies%20Reactivities">human</a> <a href="cope.cgi?key=lymphoblasts">lymphoblasts</a> following <a href="cope.cgi?key=Cell%20activation">cell activation</a> by phytohemagglutinin. IL12 activates <a href="cope.cgi?key=CD56">CD56(+)</a> <a href="cope.cgi?key=NK%2dcells">NK-cells</a>, and this activity is blocked by antibodies specific for <a href="cope.cgi?key=TNF%2dalpha">TNF-alpha</a>. IL12 promotes specific allogenic <a href="cope.cgi?key=CTL">CTL</a> reactions. IL12 synergizes also with anti-CD3 antibodies and with allogeneic stimulation in mixed <a href="cope.cgi?key=lymphocytes">lymphocyte</a> cultures in inducing <a href="cope.cgi?key=T%2dcells">T-cell</a> proliferation.</span> </p><p><span style='mso-bidi-font-size:9.0pt; mso-bidi-font-family:"Times New Roman";color:black'>In peripheral <a href="cope.cgi?key=lymphocytes">lymphocytes</a> of the Th1 <a href="cope.cgi?key=T%2dhelper">T-helper cell</a> type IL12 induces the synthesis of <a href="cope.cgi?key=IFN%2dgamma">IFN-gamma</a></span><span style='mso-bidi-font-family:"Times New Roman";color:black'> </span><span style='mso-bidi-font-size:9.0pt;mso-bidi-font-family:"Times New Roman"; color:black'>and <a href="cope.cgi?key=IL2">IL2</a>, and <a href="cope.cgi?key=TNF">TNF</a>. <a href="cope.cgi?key=TNF%2dalpha">TNF-alpha</a> also appears to be involved in mediating the effects of IL12 on <a href="cope.cgi?key=natural%20killer%20cells">natural killer cells</a> since the effects of IL12 are inhibited by an antibody directed against <a href="cope.cgi?key=TNF%2dalpha">TNF-alpha</a>. IL12 and <a href="cope.cgi?key=TNF%2dalpha">TNF-alpha</a> are costimulators for <a href="cope.cgi?key=IFN%2dgamma">IFN-gamma</a></span><span style='mso-bidi-font-family:"Times New Roman"; color:black'> </span><span style='mso-bidi-font-size:9.0pt;mso-bidi-font-family: "Times New Roman";color:black'>production with IL12 maximizing the <a href="cope.cgi?key=IFN%2dgamma">IFN-gamma</a> response; the production of IL12, <a href="cope.cgi?key=TNF">TNF</a>, and <a href="cope.cgi?key=IFN%2dgamma">IFN-gamma</a></span><span style='mso-bidi-font-family:"Times New Roman";color:black'> </span><span style='mso-bidi-font-size:9.0pt;mso-bidi-font-family:"Times New Roman"; color:black'>is inhibited by <a href="cope.cgi?key=IL10">IL10</a>. In Th2 <a href="cope.cgi?key=T%2dhelper">T-helper cells</a> IL12 reduces the synthesis of <a href="cope.cgi?key=IL4">IL4</a>, <a href="cope.cgi?key=IL5">IL5</a>, and <a href="cope.cgi?key=IL10">IL10</a>.</span> </p><p><span style='mso-bidi-font-size:9.0pt; mso-bidi-font-family:"Times New Roman";color:black'>IL12 synergises with suboptimal amounts of <a href="cope.cgi?key=IL2">IL2</a> in promoting the proliferation of <a href="cope.cgi?key=mononuclear%20cells">mononuclear cells</a> in the peripheral blood and in promoting the generation of <a href="cope.cgi?key=LAK%20cells">LAK cells</a> (<a href="cope.cgi?key=Lymphokines">lymphokine</a> activated <a href="cope.cgi?key=Killer%20cells">killer cells</a>). Picomolar <a href="cope.cgi?key=Cytokine%20Concentrations%20in%20Biological%20Fluids">concentrations</a> of IL12 are as effective as nanomolar <a href="cope.cgi?key=Cytokine%20Concentrations%20in%20Biological%20Fluids">concentrations</a> of <a href="cope.cgi?key=IL2">IL2</a> in augmenting the cytolytic activity of <a href="cope.cgi?key=natural%20killer%20cells">natural killer cells</a> expanded in vivo by <a href="cope.cgi?key=IL2">IL2</a>. IL12 also acts as a co-mitogen and potentiates the proliferation of resting peripheral <a href="cope.cgi?key=cell%20types">cells</a> induced by <a href="cope.cgi?key=IL2">IL2</a>.</span> </p><p><span style='mso-bidi-font-size:9.0pt; mso-bidi-font-family:"Times New Roman";color:black'>IL12 is involved probably also in the selection of immunoglobulin isotypes. At picomolar <a href="cope.cgi?key=Cytokine%20Concentrations%20in%20Biological%20Fluids">concentrations</a> IL12 markedly inhibits the synthesis of IgE by <a href="cope.cgi?key=peripheral%20blood%20mononuclear%20cells">peripheral blood mononuclear cells</a> stimulated with <a href="cope.cgi?key=IL4">IL4</a> also in the presence of antibodies directed against <a href="cope.cgi?key=IFN%2dgamma">IFN-gamma</a>.</span> </p><p><span style='mso-bidi-font-size:9.0pt; mso-bidi-font-family:"Times New Roman";color:black'><a href="cope.cgi?key=Cytokine%20Inter%2dspecies%20Reactivities">Murine</a> IL12 has been shown to alter <a href="cope.cgi?key=CD4">CD4(+)</a> subset <a href="cope.cgi?key=differentiation">differentiation</a> and to be involved in the induction of protective immunity against intracellular parasitic infections in <a href="cope.cgi?key=Cytokine%20Inter%2dspecies%20Reactivities">mice</a>. It cures <a href="cope.cgi?key=Cytokine%20Inter%2dspecies%20Reactivities">mice</a> infected with Leishmania major.</span> </p><p><span style='mso-bidi-font-size:9.0pt; mso-bidi-font-family:"Times New Roman";color:black'>IL12 enhances <a href="cope.cgi?key=myelopoiesis">myelopoiesis</a> of primitive bone marrow <a href="cope.cgi?key=progenitor%20cells">progenitor cells</a> induced by <a href="cope.cgi?key=SCF">SCF</a> (<a href="cope.cgi?key=Stem%20cell%20factor">stem cell factor</a>) and synergizes with <a href="cope.cgi?key=Colony%20stimulating%20factors">colony stimulating factors</a> (see: <a href="cope.cgi?key=CSF">CSF</a>) to induce proliferation. IL12 also has synergistic effects on more committed bone marrow <a href="cope.cgi?key=progenitor%20cells">progenitors</a>, synergising with <a href="cope.cgi?key=IL3">IL3</a>, <a href="cope.cgi?key=IL11">IL11</a>, or <a href="cope.cgi?key=IL3">IL3</a> plus <a href="cope.cgi?key=SCF">SCF</a>.</span> </p><p><span style='mso-bidi-font-size:9.0pt; mso-bidi-font-family:"Times New Roman";color:black'><br/> <b style="mso-bidi-font-weight:normal">TRANSGENIC ANIMALS, KNOCK-OUT, AND ANTISENSE STUDIES</b></span> </p><p><span style='mso-bidi-font-size:9.0pt; mso-bidi-font-family:"Times New Roman";color:black'>The biological consequences of IL12 deficiency have been studied in <a href="cope.cgi?key=transgenic">transgenic</a> <a href="cope.cgi?key=Knock%2dout">knock-out</a> <a href="cope.cgi?key=Cytokine%20Inter%2dspecies%20Reactivities">mice</a> generated from <a href="cope.cgi?key=ES%20cells">ES cells</a>. IL12 deficient <a href="cope.cgi?key=Cytokine%20Inter%2dspecies%20Reactivities">mice</a> are impaired but not completely lacking in the ability to produce <a href="cope.cgi?key=IFN%2dgamma">IFN-gamma</a> following <a href="cope.cgi?key=endotoxins">endotoxin</a> administration and to mount a Th1 <a href="cope.cgi?key=T%2dhelper">T-helper cell</a> response in vivo. Secretion of <a href="cope.cgi?key=IL4">IL4</a> is enhanced, while proliferation and secretion of <a href="cope.cgi?key=IL2">IL2</a> and <a href="cope.cgi?key=IL10">IL10</a> are normal following antigen stimulation. Delayed type hypersensitivity responses in mutant <a href="cope.cgi?key=Cytokine%20Inter%2dspecies%20Reactivities">mice</a> are significantly reduced while the generation of <a href="cope.cgi?key=cytotoxic%20T%2dlymphocytes">cytotoxic T-lymphocytes</a> is not compromised in the absence of IL12.</span> </p><p><span style='mso-bidi-font-size:9.0pt; mso-bidi-font-family:"Times New Roman";color:black'><br/> <b style="mso-bidi-font-weight:normal">CLINICAL USE AND SIGNIFICANCE</b></span> </p><p><span style='mso-bidi-font-size:9.0pt; mso-bidi-font-family:"Times New Roman";color:black'>IL12 is of potential clinical interest since it allows to reduce doses of <a href="cope.cgi?key=IL2">IL2</a> required for the generation of <a href="cope.cgi?key=LAK%20cells">LAK cells</a> (<a href="cope.cgi?key=Lymphokine%2dactivated%20killer%20cells">lymphokine-activated killer cells</a>). This may reduce the toxicity of higher doses of <a href="cope.cgi?key=IL2">IL2</a> used for <a href="cope.cgi?key=Adoptive%20immunotherapy">Adoptive immunotherapy</a>. IL12 may be useful in expanding an antigen-specific <a href="cope.cgi?key=T%2dcells">T-cell</a> population, as the culture of <a href="cope.cgi?key=cytotoxic%20T%2dlymphocytes">cytotoxic T-lymphocytes</a> with IL12 and low-dose <a href="cope.cgi?key=IL2">IL2</a> leads to proliferation only in response to an antigen co-signal. IL12 has been shown to augment natural killer-cell mediated cytotoxicity in a number of conditions, including patients with <a href="cope.cgi?key=hairy%20cells">hairy cell</a> <a href="cope.cgi?key=leukemia">leukemia</a>.</span> </p><p><span style='mso-bidi-font-size:9.0pt; mso-bidi-font-family:"Times New Roman";color:black'>The ability of IL12 to induce the synthesis of <a href="cope.cgi?key=IFN%2dgamma">IFN-gamma</a> and to stimulate the proliferation of resting peripheral <a href="cope.cgi?key=cell%20types">cells</a> may be of interest also.</span> </p><p><span style='mso-bidi-font-size:9.0pt; mso-bidi-font-family:"Times New Roman";color:black'>IL12 has been shown to inhibit the growth of a variety of experimental tumors in vivo and to have <a href="cope.cgi?key=angiogenesis%20factors">anti-angiogenic</a> effects in vivo, which are, at least in part, mediated by <a href="cope.cgi?key=IFN%2dgamma">IFN-gamma</a>. IL12 therefore seems to be a potential candidate also for the treatment of angiogenesis-dependent malignancies.</span> </p><p><span style='mso-bidi-font-size:9.0pt; mso-bidi-font-family:"Times New Roman";color:black'><br/> <b style="mso-bidi-font-weight:normal">DETECTION AND ASSAY METHODS</b></span> </p><p><span style='mso-bidi-font-size:9.0pt; mso-bidi-font-family:"Times New Roman";color:black'>IL12 can be assayed by its activity as <a href="cope.cgi?key=NKSF">NKSF</a> (<a href="cope.cgi?key=Natural%20killer%20cell%20stimulatory%20factor">natural killer cell stimulatory factor</a>) or <a href="cope.cgi?key=CLMF">CLMF</a> (<a href="cope.cgi?key=Cytotoxic%20lymphocyte%20maturation%20factor">cytotoxic lymphocyte maturation factor</a>). <a href="cope.cgi?key=Cytokine%20Inter%2dspecies%20Reactivities">Human</a> and <a href="cope.cgi?key=Cytokine%20Inter%2dspecies%20Reactivities">porcine</a> IL12 can be assayed in <a href="cope.cgi?key=10B10">10B10</a> <a href="cope.cgi?key=cell%20types">cells</a>. For further information on assays for <a href="cope.cgi?key=cytokines">cytokines</a> see also: <a href="cope.cgi?key=bioassays">bioassays</a>, <a href="cope.cgi?key=Cytokine%20assays">cytokine assays</a>. <a href="cope.cgi?key=Cytokine%20Inter%2dspecies%20Reactivities">Murine</a> IL12 can be measured in <a href="cope.cgi?key=bioassays">bioassays</a> using the <a href="cope.cgi?key=2D6">2D6</a> <a href="cope.cgi?key=Cell%20lines%20in%20Cytokine%20Research">cell line</a>.</span> </p><p><br/></p>

<h2>IL16</h2><p><span style='mso-bidi-font-size:9.0pt; mso-bidi-font-family:"Times New Roman";color:black'>[<a href="cope.cgi?key=Interleukin%2d16">Interleukin-16</a>] This factor has been described originally as <a href="cope.cgi?key=Lymphocyte%20chemoattractant%20factor">Lymphocyte chemoattractant factor</a> (<a href="cope.cgi?key=LCF">LCF</a>), which is produced by <a href="cope.cgi?key=CD4">CD4(+)</a> and <a href="cope.cgi?key=CD8">CD8(+)</a> <a href="cope.cgi?key=T%2dcells">T-cells</a> and acts as a <a href="cope.cgi?key=chemoattractants">chemoattractant</a> for <a href="cope.cgi?key=lymphocytes">lymphocytes</a>. The IL16 protein is derived from a much larger biologically inactive precursor (Baier et al, 1997; Bannert et al, 1996). Cleavage of bioactive secreted IL16 from its precursor is mediated by <a href="cope.cgi?key=Caspase%2d3">Caspase-3</a> (Wu et al, 1999). Bannert et al (1999) have <a href="cope.cgi?key=Gene%20library">cloned</a> the <a href="cope.cgi?key=Cytokine%20Inter%2dspecies%20Reactivities">murine</a> gene. Keane et al (1998) have reported a high degree of structural and functional similarity between <a href="cope.cgi?key=Cytokine%20Inter%2dspecies%20Reactivities">human</a> and <a href="cope.cgi?key=Cytokine%20Inter%2dspecies%20Reactivities">murine</a> IL16. A high level of similarity at the amino acid sequence level is observed also between <a href="cope.cgi?key=Cytokine%20Inter%2dspecies%20Reactivities">feline</a>, <a href="cope.cgi?key=Cytokine%20Inter%2dspecies%20Reactivities">human</a>, and <a href="cope.cgi?key=Cytokine%20Inter%2dspecies%20Reactivities">monkey</a> IL16 (Leutenegger et al, 1998). Kurscher and Yuzaki (1999) have described the identification of <a href="cope.cgi?key=NIL16">NIL16</a> (<a href="cope.cgi?key=Neuronal%20IL16">Neuronal IL16</a>) as a cytosolic long form of IL16 detected only in <a href="cope.cgi?key=neurons">neurons</a>.</span> </p><p><span style='mso-bidi-font-size:9.0pt; mso-bidi-font-family:"Times New Roman";color:black'>Zhang et al (2001) have reported that the large proform of <a href="cope.cgi?key=Cytokine%20Inter%2dspecies%20Reactivities">human</a> IL16 (631 amino acids) is cleaved into two functional proteins, a C-terminal secreted <a href="cope.cgi?key=cytokines">cytokine</a> and an N-terminal product, which localizes to the nucleus and affects the <a href="cope.cgi?key=Cell%20cycle">cell cycle</a>. Chupp et al (1998) have shown that &gt; 70 % of <a href="cope.cgi?key=CD4">CD4(+)</a> and <a href="cope.cgi?key=CD8">CD8(+)</a> <a href="cope.cgi?key=T%2dcells">T-cells</a> constitutively express IL16 protein, which is processed into bioactive secreted IL16 upon <a href="cope.cgi?key=Cell%20activation">cell activation</a>.</span> </p><p><span style='mso-bidi-font-size:9.0pt; mso-bidi-font-family:"Times New Roman";color:black'>IL16 is secreted mainly by <a href="cope.cgi?key=CD8">CD8(+)</a> <a href="cope.cgi?key=lymphocytes">lymphocytes</a> (Laberge et al, 1995; Schwab et al, 2001). The protein is produced by <a href="cope.cgi?key=B%2dcells">B-cells</a> (Sharma et al, 2000; Kaser et al, 2000), <a href="cope.cgi?key=neutrophils">neutrophils</a> (Schwab et al, 2001), <a href="cope.cgi?key=eosinophils">eosinophils</a> (Laberge et al, 1999; Dunzendorfer et al, 2003; Lim et al, 1996), <a href="cope.cgi?key=mast%20cells">mast cells</a> (Laberge et al, 1999; Middel et al, 2001; Rumsaeng et al, 1997), <a href="cope.cgi?key=monocytes">monocytes</a> (Elssner et al, 2004), <a href="cope.cgi?key=macrophages">macrophages</a> (Schwab et al, 2001; Reich et al, 2004), <a href="cope.cgi?key=microglial%20cells">microglial cells</a> (Schwab et al, 2001; Guo et al, 2004), <a href="cope.cgi?key=dendritic%20cells">dendritic cells</a> (Kaser et al, 1999; Reich et al, 2002), lung <a href="cope.cgi?key=epithelial%20cells">epithelial cells</a> (Yoshida et al, 2001; Arima et al, 1999; Little et al, 2003; Cheng et al, 2002; Bellini et al, 1993), <a href="cope.cgi?key=keratinocytes">keratinocytes</a> (Frezzolini et al, 2004), <a href="cope.cgi?key=thyrocytes">thyrocytes</a> (Gianoukakis et al, 2003), and <a href="cope.cgi?key=fibroblasts">fibroblasts</a> from several tissues (Sciaky et al, 2000; Franz et al, 1998; Pritchard et al, 2004). Preformed bioactive IL16 has been shown to be released from <a href="cope.cgi?key=CD8">CD8(+)</a> <a href="cope.cgi?key=T%2dcells">T-cells</a>, in contrast to <a href="cope.cgi?key=CD4%28%2b%29%20cells">CD4(+) cells</a>, after activation with serotonin or histamine (Laberge et al, 1996, 1995; Gantner et al, 2002).</span> </p><p><span style='mso-bidi-font-size:9.0pt; mso-bidi-font-family:"Times New Roman";color:black'>IL16 is a <a href="cope.cgi?key=chemoattractants">chemoattractant</a> for a variety of <a href="cope.cgi?key=cell%20types">cell types</a> that express the cell surface antigen <a href="cope.cgi?key=CD4">CD4</a> (Cruikshank et al, 2000), including <a href="cope.cgi?key=CD4">CD4(+)</a> <a href="cope.cgi?key=T%2dcells">T-cells</a> (Cruikshank et al, 1994; Caufour et al, 2001; Hidi et al, 2000; Center and Cruikshank, 1982), <a href="cope.cgi?key=Th1%20cells">Th1 cells</a> (Lynch et al, 2003), <a href="cope.cgi?key=dendritic%20cells">dendritic cells</a> (Kaser et al, 2000, 1999), <a href="cope.cgi?key=monocytes">monocytes</a> (Cruikshank et al, 1987), <a href="cope.cgi?key=macrophages">macrophages</a> (Laberge et al, 1999), <a href="cope.cgi?key=eosinophils">eosinophils</a> (Cheng et al, 2002; Rand et al, 1991, Ferland et al, 2004), <a href="cope.cgi?key=Langerhans%20cells">Langerhans cells</a> (Stoitzner et al, 2001). IL16 appears to signal via <a href="cope.cgi?key=CD4">CD4</a> (Bandeira-Melo et al, 2002; Cruikshank et al, 1994).</span> </p><p><span style='mso-bidi-font-size:9.0pt; mso-bidi-font-family:"Times New Roman";color:black'>Asadullah et al (2000) have implicated IL16 in growth and skin homing of cutaneous <a href="cope.cgi?key=T%2dcells">T-cell</a> <a href="cope.cgi?key=Lymphoma">lymphomas</a>.</span> </p><p><span style='mso-bidi-font-size:9.0pt; mso-bidi-font-family:"Times New Roman";color:black'>Mathy et al (200) have reported that <a href="cope.cgi?key=CD14">CD14(+)</a> <a href="cope.cgi?key=CD4">CD4(+)</a> <a href="cope.cgi?key=monocytes">monocytes</a> and maturing <a href="cope.cgi?key=macrophages">macrophages</a>, but not <a href="cope.cgi?key=CD4">CD4(+)</a> <a href="cope.cgi?key=T%2dcells">T-cells</a>, secrete <a href="cope.cgi?key=IL1%2dbeta">IL1-beta</a>, <a href="cope.cgi?key=IL6">IL6</a>, <a href="cope.cgi?key=IL15">IL15</a> and <a href="cope.cgi?key=TNF%2dalpha">TNF-alpha</a> in response to IL16 stimulation. IL16 upregulates expression of <a href="cope.cgi?key=IL2%20receptor">IL2 receptor</a> and <a href="cope.cgi?key=CD80">CD80</a>, but downregulates <a href="cope.cgi?key=CD4">CD4</a> and <a href="cope.cgi?key=CD86">CD86</a> surface expression in <a href="cope.cgi?key=monocyte%2dderived%20macrophages">monocyte-derived macrophages</a> and also reduces expression of <a href="cope.cgi?key=CCR5">CCR5</a> and <a href="cope.cgi?key=CXCR4">CXCR4</a> (Hermann et al, 1999). IL16 upregulates expression of <a href="cope.cgi?key=IL2%20receptor">IL2 receptor</a> and <a href="cope.cgi?key=CD83">CD83</a> in <a href="cope.cgi?key=monocyte%2dderived%20dendritic%20cells">monocyte-derived dendritic cells</a> but does not change levels of expression of <a href="cope.cgi?key=CD4">CD4</a>, <a href="cope.cgi?key=CD80">CD80</a> and <a href="cope.cgi?key=CD86">CD86</a> in these <a href="cope.cgi?key=cell%20types">cells</a> (Hermann et al, 1999).</span> </p><p><span style='mso-bidi-font-size:9.0pt; mso-bidi-font-family:"Times New Roman";color:black'>IL16 has been shown to upregulate <a href="cope.cgi?key=IL2%20receptor">IL2 receptor</a> (<a href="cope.cgi?key=CD25">CD25</a>) on <a href="cope.cgi?key=CD4">CD4(+)</a> <a href="cope.cgi?key=T%2dcells">T-cells</a> (Cruikshank et al, 1994, 1987), and thus influences <a href="cope.cgi?key=Cell%20activation">cell activation</a> of these <a href="cope.cgi?key=cell%20types">cells</a>, which depends on <a href="cope.cgi?key=IL2">IL2</a>. Ogasawara et al (1999) have reported that IL16 suppreses mitogen-induced production of <a href="cope.cgi?key=IL2">IL2</a> by <a href="cope.cgi?key=CD4">CD4(+)</a> <a href="cope.cgi?key=T%2dcells">T-cells</a>. IL16 also induces the transient loss of responsiveness via the <a href="cope.cgi?key=T%2dcells">T-cell</a> receptor (Cruikshank et al, 1996; Theodore et al, 1996). IL16 acts as both primer and modulator of <a href="cope.cgi?key=T%2dlymphocytes">T-lymphocyte</a> growth (Wilson et al, 2004).</span> </p><p><span style='mso-bidi-font-size:9.0pt; mso-bidi-font-family:"Times New Roman";color:black'>Bandeira-Melo et al (2002) have reported that IL16 promotes release of leukotrienes and <a href="cope.cgi?key=IL4">IL4</a> from <a href="cope.cgi?key=Cytokine%20Inter%2dspecies%20Reactivities">human</a> <a href="cope.cgi?key=eosinophils">eosinophils</a>.</span> </p><p><span style='mso-bidi-font-size:9.0pt; mso-bidi-font-family:"Times New Roman";color:black'>IL16 has been shown to suppress the replication of HIV and SIV (Baier et al, 1995). Idziorek et al (1998) have reported that recombinant <a href="cope.cgi?key=Cytokine%20Inter%2dspecies%20Reactivities">human</a> IL16 inhibits HIV-1 replication and protects against <a href="cope.cgi?key=cell%20death">cell death</a> by <a href="cope.cgi?key=Apoptosis">apoptosis</a>. Amiel et al (1999) have reported that IL16 inhibits <a href="cope.cgi?key=Cytokine%20Inter%2dspecies%20Reactivities">human</a> immunodeficiency virus replication in <a href="cope.cgi?key=cell%20types">cells</a> from infected subjects and that <a href="cope.cgi?key=Cytokine%20Concentrations%20in%20Biological%20Fluids">serum</a> IL16 levels drop with disease progression. Truong et al (1999) have reported that IL16 inhibits <a href="cope.cgi?key=Cytokine%20Inter%2dspecies%20Reactivities">human</a> immunodeficiency virus type 1 entry and replication in <a href="cope.cgi?key=macrophages">macrophages</a> and in <a href="cope.cgi?key=dendritic%20cells">dendritic cells</a>.</span> </p><p><span style='mso-bidi-font-size:9.0pt; mso-bidi-font-family:"Times New Roman";color:black'>Van Drenth et al (2000) have reported that IL16, the natural ligand of <a href="cope.cgi?key=CD4">CD4</a>, causes desensitization of one of the <a href="cope.cgi?key=Chemokines">chemokine</a> receptors, <a href="cope.cgi?key=CXCR4">CXCR4</a>, which is a <a href="cope.cgi?key=coreceptor">coreceptor</a> for <a href="cope.cgi?key=CD4">CD4</a> for binding of <a href="cope.cgi?key=HIV%2d1%20gp120">HIV-1 gp120</a> protein. Mashikian et al (1999) have reported<b style="mso-bidi-font-weight:normal"> </b>that IL16 also causes desensitization of the <a href="cope.cgi?key=CCR5">CCR5</a> receptor.</span> </p><p><span style='mso-bidi-font-size:9.0pt; mso-bidi-font-family:"Times New Roman";color:black'>Pinsonneault et al (2001) have reported that IL16 inhibits <a href="cope.cgi?key=IL5">IL5</a> production by antigen-stimulated <a href="cope.cgi?key=T%2dcells">T-cells</a> in atopic subjects.</span> </p><p><span style='mso-bidi-font-size:9.0pt; mso-bidi-font-family:"Times New Roman";color:black'>IL16 derived from <a href="cope.cgi?key=CD8">CD8(+)</a> <a href="cope.cgi?key=T%2dcells">T-cells</a> has been implicated in the induction of <a href="cope.cgi?key=CD4">CD4(+)</a> <a href="cope.cgi?key=T%2dcells">T-cell</a> abnormalities in systemic lupus erythematosus (Lee et al, 1998; Sekigawa et al, 2000). Upregulation of IL16 expression has been implicated in the pathogenesis of chronic intestinal <a href="cope.cgi?key=inflammation">inflammation</a> and could lead to increased secretion of other <a href="cope.cgi?key=pro%2dinflammatory%20cytokines">pro-inflammatory cytokines</a> in <a href="cope.cgi?key=inflammation">Inflammatory</a> bowel disease (Seegert et al, 2001). Hessel et al (1998) have reported that IL16 plays an important role in airway hyper-responsiveness and upregulation of IgE, but is not important for <a href="cope.cgi?key=eosinophils">eosinophil</a> accumulation in a <a href="cope.cgi?key=Cytokine%20Inter%2dspecies%20Reactivities">mouse</a> model of allergic asthma. Franz et al (1998) have implicated IL16 in rheumatoid arthritis since IL16, produced by <a href="cope.cgi?key=synovial%20fibroblasts">synovial fibroblasts</a>, mediates chemoattraction for <a href="cope.cgi?key=CD4">CD4(+)</a> <a href="cope.cgi?key=T%2dcells">T-cells</a> in rheumatoid arthritis.</span> </p><p><span style='mso-bidi-font-size:9.0pt; mso-bidi-font-family:"Times New Roman";color:black'><br/> IL16 is generally assumed to utilize <a href="cope.cgi?key=CD4">CD4</a> as a receptor (Center et al, 1996). Liu et al (1999) have identified the <a href="cope.cgi?key=CD4">CD4</a> <a href="cope.cgi?key=domain">domain</a> required for IL16 binding and <a href="cope.cgi?key=lymphocytes">lymphocyte</a> activation. However, Mathy et al (2000) have reported that <a href="cope.cgi?key=CD4">CD4</a> is not required for the functional activity of IL16 in <a href="cope.cgi?key=Cytokine%20Inter%2dspecies%20Reactivities">murine</a> <a href="cope.cgi?key=monocytes">monocytes</a>. Their observation that <a href="cope.cgi?key=cell%20types">cells</a> from <a href="cope.cgi?key=CD4">CD4</a> <a href="cope.cgi?key=Knock%2dout">knock-out</a> <a href="cope.cgi?key=Cytokine%20Inter%2dspecies%20Reactivities">mice</a> are as responsive to IL16 as their <a href="cope.cgi?key=CD4">CD4</a> wild-type equivalents and that the effects of IL16 cannot be inhibited by soluble <a href="cope.cgi?key=CD4">CD4</a> in these <a href="cope.cgi?key=Cytokine%20Inter%2dspecies%20Reactivities">mice</a> suggests that another molecule acts as the major receptor. Stoitzner et al (2001) have reported also that IL16 supports the migration of <a href="cope.cgi?key=Langerhans%20cells">Langerhans cells</a> through mechanisms partly independent of <a href="cope.cgi?key=CD4">CD4</a>.</span> </p><p><span style='mso-bidi-font-size:9.0pt; mso-bidi-font-family:"Times New Roman";color:red'><br/> </span><b style="mso-bidi-font-weight:normal"><span style="color:red"><a href="cope.cgi?key=Copyright">Copyright</a> &#169; 2012 by H IBELGAUFTS. All rights reserved.</span></b><b style="mso-bidi-font-weight: normal"><span style='font-size:10.0pt;font-family:Times;mso-fareast-font-family: "Times New Roman"'><br/> </span></b><span style='mso-bidi-font-size:9.0pt;mso-bidi-font-family:"Times New Roman"; color:red'>ENTRY LAST MODIFIED: January 2005</span> </p><p><br/></p>

<h2>IL18</h2><p><span style='mso-bidi-font-size:9.0pt; mso-bidi-font-family:"Times New Roman";color:black'>[<a href="cope.cgi?key=Interleukin%2d18">Interleukin-18</a>] The gene encoding this nonglycosylated protein of 24 kDa has been identified originally as <a href="cope.cgi?key=IGIF">IGIF</a> (<a href="cope.cgi?key=IFN%2dgamma%20inducing%20factor">IFN-gamma inducing factor</a>). It encodes an inducer of <a href="cope.cgi?key=IFN%2dgamma">IFN-gamma</a> production by <a href="cope.cgi?key=T%2dcells">T-cells</a> (Okamura et al, 1995; Micalef et al, 1997) and <a href="cope.cgi?key=natural%20killer%20cells">natural killer cells</a> (Tsutsui et al, 1996) that is a more potent inducer than <a href="cope.cgi?key=IL12">IL12</a>. Alternative designations are <a href="cope.cgi?key=IL1%2dgamma">IL1-gamma</a> and <a href="cope.cgi?key=IL1F4">IL1F4</a>. <a href="cope.cgi?key=Cytokine%20Inter%2dspecies%20Reactivities">Human</a> recombinant IL18 is marketed as <b style="mso-bidi-font-weight:normal"><a href="cope.cgi?key=Iboctadekin">Iboctadekin</a></b> (GlaxoSmithKline).</span> </p><p><span style='mso-bidi-font-size:9.0pt; mso-bidi-font-family:"Times New Roman";color:black'>The proteins from <a href="cope.cgi?key=Cytokine%20Inter%2dspecies%20Reactivities">murine</a> (192 amino acids) and <a href="cope.cgi?key=Cytokine%20Inter%2dspecies%20Reactivities">human</a> IL18 (193 amino acids) sources show 65 % homology. <a href="cope.cgi?key=Cytokine%20Inter%2dspecies%20Reactivities">Rat</a> and <a href="cope.cgi?key=Cytokine%20Inter%2dspecies%20Reactivities">murine</a> IL18 display 91 % homology (nucleotide and amino acid level). IL18 does not display sequence similarities to other known proteins but a survey of the sequence by fold recognition methods demonstrates that it belongs to the <a href="cope.cgi?key=IL1%20family">IL1 family</a> of <a href="cope.cgi?key=cytokines">cytokines</a> (Ushio et al, 1996).</span> </p><p><span style='mso-bidi-font-size:9.0pt; mso-bidi-font-family:"Times New Roman";color:black'>IL18 lacks a classical <a href="cope.cgi?key=Signal%20sequence">signal sequence</a> necessary for secretion (Okamura et al, 1995; Ushio et al, 1996; Gu et al, 1997). IL18 is synthesized as a biologically inactive precursor protein that has limited biological activity. The proform of IL18 is processed by one of the <a href="cope.cgi?key=Caspases">caspases</a>, <a href="cope.cgi?key=Caspase%2d1">Caspase-1</a>, to generate the 18 kDa bioactive molecule (Gu et al, 1997; Ghayur et al, 1997). Other proteases such as <a href="cope.cgi?key=neutrophils">neutrophil</a> <a href="cope.cgi?key=Proteinase%2d3">proteinase-3</a> (<a href="cope.cgi?key=Myeloblastin">Myeloblastin</a>) may provide activation pathways that are independent of <a href="cope.cgi?key=Caspases">caspases</a> (Sugawara et al, 2001).</span> </p><p><span style='mso-bidi-font-size:9.0pt; mso-bidi-font-family:"Times New Roman";color:black'>Kikkawa et al (2001) have demonstrated that <a href="cope.cgi?key=monocytes">monocytes</a> and <a href="cope.cgi?key=macrophages">macrophages</a> produce large amounts of various IL18 <a href="cope.cgi?key=Cytokine%20Inter%2dspecies%20Reactivities">species</a>. Some of them are inactive dimers while others have weak <a href="cope.cgi?key=IFN%2dgamma">IFN-gamma</a> inducing activity. <b style="mso-bidi-font-weight:normal"><a href="cope.cgi?key=IL18%20type%202">IL18 type 2</a></b> is a fragment of IL18 that possesses little activity as an inducer of <a href="cope.cgi?key=IFN%2dgamma">IFN-gamma</a>. This variant is bound to IgM in <a href="cope.cgi?key=Cytokine%20Concentrations%20in%20Biological%20Fluids">plasma</a> and is found at high levels in approximately 30 % of normal subjects (Shida et al, 2001). The authors suggest that this variant may play some roles in the development of <a href="cope.cgi?key=Th2%20cells">Th2 cell</a> responses involving IgE production in association with atopic lesions.</span> </p><p><span style='mso-bidi-font-size:9.0pt; mso-bidi-font-family:"Times New Roman";color:black'>The <a href="cope.cgi?key=Cytokine%20Inter%2dspecies%20Reactivities">human</a> gene has been mapped to chromosome 11q22.2-q22.3 (Nolan et al, 1998).</span> </p><p><span style='mso-bidi-font-size:9.0pt; mso-bidi-font-family:"Times New Roman";color:black'>IL18 is produced during the acute immune response by <a href="cope.cgi?key=macrophages">macrophages</a> and immature <a href="cope.cgi?key=dendritic%20cells">dendritic cells</a>. IL18 is expressed by a variety of immune and non-immune <a href="cope.cgi?key=cell%20types">cells</a>, including <a href="cope.cgi?key=monocytes">monocytes</a> and <a href="cope.cgi?key=macrophages">macrophages</a> (Okamura et al, 1995; Ushio et al, 1996), <a href="cope.cgi?key=Kupffer%20cells">Kupffer cells</a> (Okamura et al, 1995; Seki et al, 2001), <a href="cope.cgi?key=T%2dcells">T-cells</a> and <a href="cope.cgi?key=B%2dcells">B-cells</a> (Nakanishi et al, 2001); Klein et al, 1999), <a href="cope.cgi?key=dendritic%20cells">dendritic cells</a> (Stober et al, 2001; Gardella et al, 2000; Stoll et al, 1998; de Saint-Vis et al, 1998), <a href="cope.cgi?key=osteoblasts">osteoblasts</a> (Udagawa et al, 1997; Torigoe et al, 1997), epidermal <a href="cope.cgi?key=keratinocytes">keratinocytes</a> (Stoll et al, 1997), intestinal <a href="cope.cgi?key=epithelial%20cells">epithelial cells</a> (Takeuchi et al, 1997; Pizarro et al, 1999), corneal <a href="cope.cgi?key=epithelial%20cells">epithelial cells</a> (Burbach et al, 2001), glucocorticoid-secreting adrenal cortex <a href="cope.cgi?key=cell%20types">cells</a> (Conti et al, 1997), <a href="cope.cgi?key=astrocytes">astrocytes</a>, and <a href="cope.cgi?key=microglial%20cells">microglial cells</a> (Conti et al, 1999; Suk et al, 2001).</span> </p><p><span style='mso-bidi-font-size:9.0pt; mso-bidi-font-family:"Times New Roman";color:black'>Acute cold stress strongly induces <a href="cope.cgi?key=IGIF">IGIF</a> <a href="cope.cgi?key=Gene%20expression">gene expression</a> in <a href="cope.cgi?key=Cytokine%20Inter%2dspecies%20Reactivities">rats</a> (Conti et al, 1997). <a href="cope.cgi?key=Cytokine%20Inter%2dspecies%20Reactivities">rat</a> <a href="cope.cgi?key=IGIF">IGIF</a> has been shown to be expressed in the adrenal gland of reserpine-treated <a href="cope.cgi?key=Cytokine%20Inter%2dspecies%20Reactivities">rats</a> (Conti et al, 1997). Park et al (2001) have reported an enhanced IL18 expression in common skin tumors.</span> </p><p><span style='mso-bidi-font-size:9.0pt; mso-bidi-font-family:"Times New Roman";color:black'>IL18 is one of the <a href="cope.cgi?key=pro%2dinflammatory%20cytokines">pro-inflammatory cytokines</a>. The activities of IL18 appear to be <a href="cope.cgi?key=Cytokine%20Inter%2dspecies%20Reactivities">species</a> specific. An important function of IL18 is the regulation of functionally distinct subsets of <a href="cope.cgi?key=T%2dhelper">T-helper cells</a> required for cell mediated immune responses (Nakanishi et al, 2001). IL18 functions as a growth and <a href="cope.cgi?key=Differentiation%20factor">differentiation factor</a> for <a href="cope.cgi?key=Th1%20cells">Th1 cells</a>. IL18 upregulates <a href="cope.cgi?key=FAS%20ligand">FAS ligand</a> mediated cytotoxic activitiy of <a href="cope.cgi?key=Cytokine%20Inter%2dspecies%20Reactivities">murine</a> <a href="cope.cgi?key=natural%20killer%20cells">natural killer cells</a> (Tao et al, 1996; Tsutsui et al, 1996). IL18 is part of a complex regulatory circuit involved in causing <a href="cope.cgi?key=cell%20death">cell death</a> by <a href="cope.cgi?key=Apoptosis">apoptosis</a>. The expression of the receptor for <a href="cope.cgi?key=FAS%20ligand">FAS ligand</a>, <a href="cope.cgi?key=FAS">FAS</a> antigen, is upregulated by <a href="cope.cgi?key=IFN%2dgamma">IFN-gamma</a> (Watanabe-Fukunaga et al, 1992) that itself is induced by IL18.</span> </p><p><span style='mso-bidi-font-size:9.0pt; mso-bidi-font-family:"Times New Roman";color:black'>IL18 is a pleiotropic <a href="cope.cgi?key=cytokines">cytokine</a>. IL18 induces activated <a href="cope.cgi?key=B%2dcells">B-cells</a> to produce <a href="cope.cgi?key=IFN%2dgamma">IFN-gamma</a> that inhibits IgE production (Yoshimoto et al, 1997). IL18 has been shown to strongly augment the production of <a href="cope.cgi?key=IFN%2dgamma">IFN-gamma</a> by <a href="cope.cgi?key=T%2dcells">T-cells</a> and <a href="cope.cgi?key=NK%2dcells">NK-cells</a> (Micallef et al, 1996). The ability of IL18 to enhance <a href="cope.cgi?key=IFN%2dgamma">IFN-gamma</a> production by <a href="cope.cgi?key=NK%2dcells">NK-cells</a> is dependent on the presence of <a href="cope.cgi?key=IL12">IL12</a> (Walker et al, 1999). <a href="cope.cgi?key=IGIF">IGIF</a> enhances <a href="cope.cgi?key=T%2dcells">T-cell</a> proliferation apparently through an <a href="cope.cgi?key=IL2">IL2</a> dependent pathway (Micallef et al, 1996).</span> </p><p><span style='mso-bidi-font-size:9.0pt; mso-bidi-font-family:"Times New Roman";color:black'>Park et al (2001) have shown that IL18 is an <a href="cope.cgi?key=angiogenesis%20factors">angiogenic</a> mediator that induces migration of <a href="cope.cgi?key=MVEC">microvascular endothelial cells</a> and causes tube formation by <a href="cope.cgi?key=endothelial%20cells">endothelial cells</a> in a <a href="cope.cgi?key=Matrigel">matrigel</a> matrix in vitro. It also induces <a href="cope.cgi?key=Angiogenesis">angiogenesis</a> in vivo in a <a href="cope.cgi?key=Matrigel%20plug%20assay">matrigel plug assay</a>.</span> </p><p><span style='mso-bidi-font-size:9.0pt; mso-bidi-font-family:"Times New Roman";color:black'>IL18 has been found to enhance also the production of <a href="cope.cgi?key=GM%2dCSF">GM-CSF</a>. Udagawa et al (1997) have shown that IL18 produced by osteoblastic <a href="cope.cgi?key=stromal%20cells">stromal cells</a> acts via <a href="cope.cgi?key=GM%2dCSF">GM-CSF</a> and not via <a href="cope.cgi?key=IFN%2dgamma">IFN-gamma</a> to inhibit <a href="cope.cgi?key=osteoclasts">osteoclast</a> formation.</span> </p><p><span style='mso-bidi-font-size:9.0pt; mso-bidi-font-family:"Times New Roman";color:black'>Morel et al (2001) have observed that IL18 induces the expression of the <a href="cope.cgi?key=CXC%2dChemokines">CXC-Chemokines</a> <a href="cope.cgi?key=IL8">IL8</a>, <a href="cope.cgi?key=MGSA">MGSA</a>, <a href="cope.cgi?key=ENA%2d78">ENA-78</a> in <a href="cope.cgi?key=rheumatoid%20arthritis%20synovial%20fibroblasts">rheumatoid arthritis synovial fibroblast</a>. It does not appear to induce the production of <a href="cope.cgi?key=MIP%2d1%2dalpha">MIP-1-alpha</a>.</span> </p><p><span style='mso-bidi-font-size:9.0pt; mso-bidi-font-family:"Times New Roman";color:black'>IL18 inhibits <a href="cope.cgi?key=osteoclasts">osteoclast</a> formation via <a href="cope.cgi?key=T%2dcells">T-cell</a> production of <a href="cope.cgi?key=GM%2dCSF">GM-CSF</a> (Udagawa et al, 1997; Horwood et al, 1998, 2001).</span> </p><p><span style='mso-bidi-font-size:9.0pt; mso-bidi-font-family:"Times New Roman";color:black'>By stimulating <a href="cope.cgi?key=immune%20cells">immune cells</a> IL18 also exibits a strong antitumoral activity, protecting experimental animals against repeated challenges with tumor <a href="cope.cgi?key=cell%20types">cells</a> <a href="cope.cgi?key=cell%20types">cells</a> (Micallef et al, 1997). In an attempt of cancer <a href="cope.cgi?key=Gene%20therapy">gene therapy</a>, Osaki et al (1999) have introduced the IL18 gene into <a href="cope.cgi?key=Cytokine%20Inter%2dspecies%20Reactivities">murine</a> tumors and observed a potent antitumor effects mediated by local expression of IL18. Kishida et al (2001) have reported that the simultaneous expression of IL18 and <a href="cope.cgi?key=IL12">IL12</a> by engineered <a href="cope.cgi?key=melanoma%20cells">melanoma cells</a> induces significant antitumor effects in <a href="cope.cgi?key=Cytokine%20Inter%2dspecies%20Reactivities">mice</a>.</span> </p><p><span style='mso-bidi-font-size:9.0pt; mso-bidi-font-family:"Times New Roman";color:black'>A protective effect of IL18 against the development of chronic graft-versus-host disease in the <a href="cope.cgi?key=Cytokine%20Inter%2dspecies%20Reactivities">mouse</a> has been demonstrated by Okamoto et al (2000). Reddy et al (2001) have shown that the inhibition of Il18 accelerates mortality caused by acute graft-versus-host disease in a bone marrow transplant model and that is due to increased <a href="cope.cgi?key=FAS">FAS</a> antigen mediated donor <a href="cope.cgi?key=T%2dcells">T-cell</a> <a href="cope.cgi?key=Apoptosis">apoptosis</a>. Leung et al (2001) have demonstrated that IL18 activates <a href="cope.cgi?key=Cytokine%20Inter%2dspecies%20Reactivities">human</a> <a href="cope.cgi?key=neutrophils">neutrophils</a> and that IL18 administration promotes accumulation of <a href="cope.cgi?key=neutrophils">neutrophils</a> in vivo, whereas IL18 neutralization suppresses the severity of footpad <a href="cope.cgi?key=inflammation">inflammation</a> following carrageenan injection.</span> </p><p><span style='mso-bidi-font-size:9.0pt; mso-bidi-font-family:"Times New Roman";color:black'>Abnormal expression of IL18 has been observed in autoimmune non <a href="cope.cgi?key=obese">obese</a> diabetic (NOD) <a href="cope.cgi?key=Cytokine%20Inter%2dspecies%20Reactivities">mice</a> and to be closely associated with development of diabetes (Rothe et al, 1997). Pizarro et al (1999) have detected increased IL18 mRNA and protein expression that intestinal <a href="cope.cgi?key=epithelial%20cells">epithelial cells</a> and lamina propria <a href="cope.cgi?key=mononuclear%20cells">mononuclear cells</a> in Crohn's disease tissue express elevated levels of IL18.</span> </p><p><span style='mso-bidi-font-size:9.0pt; mso-bidi-font-family:"Times New Roman";color:black'>IL18 mediates infection resistance against a variety of pathogens, mainly due to the induction of <a href="cope.cgi?key=IFN%2dgamma">IFN-gamma</a> expression. IL18 plays a critical role in the defense against intracellular bacteria, including Listeria, Shigella, Salmonella, and Mycobacterium tuberculosis (Biet et al, 2002). Liver damage in <a href="cope.cgi?key=Cytokine%20Inter%2dspecies%20Reactivities">mice</a> caused by treatment with Propionibacterium acnes and septic <a href="cope.cgi?key=shock">shock</a> induced by challenge with <a href="cope.cgi?key=Lipopolysaccharides">lipopolysaccharides</a> can be prevented by administration of anti-IGIF antibodies (Okamura et al, 1995).</span> </p><p><span style='mso-bidi-font-size:9.0pt; mso-bidi-font-family:"Times New Roman";color:black'>IL18, together with other <a href="cope.cgi?key=cytokines">cytokines</a>, may play a role in the development of hepatic metastases of <a href="cope.cgi?key=melanoma%20cells">melanoma</a> in vivo through upregulating the expression of vascular cell adhesion molecule 1 and <a href="cope.cgi?key=melanoma%20cells">melanoma cell</a> adherence (Vidal-Vanaclocha et al, 2000).</span> </p><p><span style='mso-bidi-font-size:9.0pt; mso-bidi-font-family:"Times New Roman";color:black'>IL18 appears to play a direct neuromodulatory role in synaptic plasticity and impairs long-term potentiation and NMDA receptor mediated transmission in the <a href="cope.cgi?key=Cytokine%20Inter%2dspecies%20Reactivities">rat</a> hippocampus in vitro (Curran et al, 2001).</span> </p><p><span style='mso-bidi-font-size:9.0pt; mso-bidi-font-family:"Times New Roman";color:black'>The expression of functional IL18 and IL18 receptor on <a href="cope.cgi?key=Cytokine%20Inter%2dspecies%20Reactivities">human</a> atheroma-associated <a href="cope.cgi?key=endothelial%20cells">endothelial cells</a>, <a href="cope.cgi?key=smooth%20muscle%20cells">smooth muscle cells</a>, and <a href="cope.cgi?key=mononuclear%20phagocytes">mononuclear phagocytes</a>, and its ability to induce <a href="cope.cgi?key=IFN%2dgamma">IFN-gamma</a> expression in <a href="cope.cgi?key=smooth%20muscle%20cells">smooth muscle cells</a>, suggests a <a href="cope.cgi?key=Paracrine">paracrine</a> <a href="cope.cgi?key=inflammation">pro-inflammatory</a> role in atherogenesis (Gerdes et al, 2002).</span> </p><p><span style='mso-bidi-font-size:9.0pt; mso-bidi-font-family:"Times New Roman";color:black'>Ogura et al (2001) have reported that IL18 stimulates <a href="cope.cgi?key=CD4">CD4(+)</a> <a href="cope.cgi?key=T%2dcells">T-cells</a> and <a href="cope.cgi?key=macrophages">macrophages</a> to secrete <a href="cope.cgi?key=IL5">IL5</a>, <a href="cope.cgi?key=GM%2dCSF">GM-CSF</a>, <a href="cope.cgi?key=IL6">IL6</a>, and <a href="cope.cgi?key=G%2dCSF">G-CSF</a> in the absence of <a href="cope.cgi?key=IL12">IL12</a>, which in turn induces <a href="cope.cgi?key=hematopoietic%20cells">hematopoietic cell</a> proliferation causing neutrophilia and eosinophilia in <a href="cope.cgi?key=Cytokine%20Inter%2dspecies%20Reactivities">mice</a>.</span> </p><p><span style='mso-bidi-font-size:9.0pt; mso-bidi-font-family:"Times New Roman";color:black'>Wang et al (2001) have reported that vaccination with IL18 gene-modified, superantigen-coated tumor <a href="cope.cgi?key=cell%20types">cells</a> elicits potent antitumor immune responses.</span> </p><p><b style="mso-bidi-font-weight:normal"><span style='mso-bidi-font-size:9.0pt;mso-bidi-font-family:"Times New Roman"; color:black'>TRANSGENIC ANIMALS, KNOCK-OUT, AND ANTISENSE STUDIES</span></b> </p><p><span style='mso-bidi-font-size:9.0pt; mso-bidi-font-family:"Times New Roman";color:black'>Wei et al (1999, 2001) have generated <a href="cope.cgi?key=transgenic">transgenic</a> <a href="cope.cgi?key=Knock%2dout">knock-out</a> <a href="cope.cgi?key=Cytokine%20Inter%2dspecies%20Reactivities">mice</a> lacking expression of IL18. These <a href="cope.cgi?key=Cytokine%20Inter%2dspecies%20Reactivities">mice</a> are viable and fertile. There are no evident histopathologic abnormalities. The animals are susceptible to infections by the protozoan parasite Leishmania major. Infected <a href="cope.cgi?key=Cytokine%20Inter%2dspecies%20Reactivities">mice</a> produce significantly lower levels of <a href="cope.cgi?key=IFN%2dgamma">IFN-gamma</a> and larger amounts of <a href="cope.cgi?key=IL4">IL4</a> compared with similarly infected heterozygous or wild-type <a href="cope.cgi?key=Cytokine%20Inter%2dspecies%20Reactivities">mice</a>. Infections of <a href="cope.cgi?key=Knock%2dout">knock-out</a> <a href="cope.cgi?key=Cytokine%20Inter%2dspecies%20Reactivities">mice</a> with Staphylococcus aureus, are less severe than similar infections in wild-type <a href="cope.cgi?key=Cytokine%20Inter%2dspecies%20Reactivities">mice</a>. Mutant <a href="cope.cgi?key=Cytokine%20Inter%2dspecies%20Reactivities">mice</a> develop significantly more severe septic arthritis than control <a href="cope.cgi?key=Cytokine%20Inter%2dspecies%20Reactivities">mice</a>. This is accompanied by a reduction in the levels of antigen induced splenic <a href="cope.cgi?key=T%2dcells">T-cell</a> proliferation, decreased synthesis of <a href="cope.cgi?key=IFN%2dgamma">IFN-gamma</a> and <a href="cope.cgi?key=TNF%2dalpha">TNF-alpha</a>, but increased production of <a href="cope.cgi?key=IL4">IL4</a>.</span> </p><p><span style='mso-bidi-font-size:9.0pt; mso-bidi-font-family:"Times New Roman";color:black'>Wei et al (1999, 2001) also have reported a reduced incidence and severity of collagen induced arthritis in <a href="cope.cgi?key=Cytokine%20Inter%2dspecies%20Reactivities">mice</a> lacking IL18 and that treatment with recombinant IL18 completely reverses the disease of the IL18 <a href="cope.cgi?key=Knock%2dout">knock-out</a> <a href="cope.cgi?key=Cytokine%20Inter%2dspecies%20Reactivities">mice</a> to that of the wild-type <a href="cope.cgi?key=Cytokine%20Inter%2dspecies%20Reactivities">mice</a>.</span> </p><p><b style="mso-bidi-font-weight:normal"><span style='mso-bidi-font-size:9.0pt;mso-bidi-font-family:"Times New Roman"; color:black'>RECEPTORS</span></b> </p><p><span style='mso-bidi-font-size: 9.0pt;mso-bidi-font-family:"Times New Roman";color:black'>A functional component of the <a href="cope.cgi?key=Cytokine%20Inter%2dspecies%20Reactivities">human</a> receptor for <a href="cope.cgi?key=IGIF">IGIF</a> has been identified in the Hodgkin's disease <a href="cope.cgi?key=Cell%20lines%20in%20Cytokine%20Research">cell line</a>, L428 (Torigue et al, 1997). The <a href="cope.cgi?key=cell%20types">cells</a> express approximately 18,000 binding sites/cell. The dissociation constant of IL18 binding to L428 <a href="cope.cgi?key=cell%20types">cells</a> is about 18.5 nM. The <a href="cope.cgi?key=Gene%20library">cloned</a> receptor component was shown to be identical with <a href="cope.cgi?key=IL1Rrp">IL1Rrp</a> [<a href="cope.cgi?key=IL1%20receptor%2drelated%20protein">IL1 receptor-related protein</a>). Expression of the <a href="cope.cgi?key=IL1Rrp">IL1Rrp</a> <a href="cope.cgi?key=cDNA">cDNA</a> in COS-1 <a href="cope.cgi?key=cell%20types">cells</a> has been shown to confer IL18 binding properties on the <a href="cope.cgi?key=cell%20types">cells</a> and the capacity for signal transduction. This receptor is being referred to now as </span><b style="mso-bidi-font-weight:normal"><a href="cope.cgi?key=IL18R1">IL18R1</a> </b>[<a href="cope.cgi?key=interleukin%2d18%20receptor%2d1">interleukin-18 receptor-1</a>; <a href="cope.cgi?key=IL18R%2dalpha">IL18R-alpha</a>] or <b style="mso-bidi-font-weight:normal"><a href="cope.cgi?key=IL18RA">IL18RA</a></b> [<a href="cope.cgi?key=interleukin%2d18%20receptor%2dalpha">interleukin-18 receptor-alpha</a>].  </p><p><span style='mso-bidi-font-size: 9.0pt;mso-bidi-font-family:"Times New Roman";color:black'>Debets et al (2000) have shown that a highly specific IL18 receptor is formed together with <a href="cope.cgi?key=IL1RAPL">IL1RAPL</a> [<a href="cope.cgi?key=IL1%20receptor%20accessory%20protein%2dlike">IL1 receptor accessory protein-like</a>]. This receptor is the same as </span><b style="mso-bidi-font-weight:normal"><a href="cope.cgi?key=IL18RAP">IL18RAP</a> </b>[<a href="cope.cgi?key=IL18%20receptor%20accessory%20protein">IL18 receptor accessory protein</a>], which is the approved gene symbol for a protein that has been described also as <a href="cope.cgi?key=AcPL">AcPL</a> [<a href="cope.cgi?key=accessory%20protein%2dlike%20subunit">accessory protein-like subunit</a>]. The protein is being referred to also as <b style="mso-bidi-font-weight:normal"><a href="cope.cgi?key=IL18RB">IL18RB</a></b> [<a href="cope.cgi?key=IL18R%2dbeta">IL18R-beta</a>].  </p><p><span style='mso-bidi-font-size:9.0pt; mso-bidi-font-family:"Times New Roman";color:black'>Some of the bioactivities of IL18 are modulated by a secreted binding protein, <b style="mso-bidi-font-weight: normal"><a href="cope.cgi?key=IL18BP">IL18BP</a> </b>[<a href="cope.cgi?key=IL18%20binding%20protein">IL18 binding protein</a>].</span> </p><p><b style="mso-bidi-font-weight:normal"><span style='mso-bidi-font-size:9.0pt;mso-bidi-font-family:"Times New Roman"; color:black'>DETECTION AND ASSAY METHODS</span></b> </p><p><span style='mso-bidi-font-size:9.0pt; mso-bidi-font-family:"Times New Roman";color:black'>Taniguchi et al (1997) have developed an <a href="cope.cgi?key=ELISA">ELISA</a> (see also: <a href="cope.cgi?key=Cytokine%20assays">cytokine assays</a>) specific for <a href="cope.cgi?key=Cytokine%20Inter%2dspecies%20Reactivities">human</a> IL18 <a href="cope.cgi?key=ELISA">ELISA</a>. This assay has a minimum detection limit of 10 pg/mL and does not react with heat-denatured <a href="cope.cgi?key=Cytokine%20Inter%2dspecies%20Reactivities">human</a> IL18. There is no cross-reactivity with other <a href="cope.cgi?key=cytokines">cytokines</a>. Taniguchi et al (1998) have established also <a href="cope.cgi?key=cell%20types">cells</a> useful for <a href="cope.cgi?key=bioassays">bioassays</a> of <a href="cope.cgi?key=Cytokine%20Inter%2dspecies%20Reactivities">murine</a> IL18 by transfection of the <a href="cope.cgi?key=Cytokine%20Inter%2dspecies%20Reactivities">murine</a> IL18 receptor gene into <a href="cope.cgi?key=KG%2d1">KG-1</a> <a href="cope.cgi?key=cell%20types">cells</a>. Konishi et al (1997) have described sensitive <a href="cope.cgi?key=bioassays">bioassays</a> for <a href="cope.cgi?key=Cytokine%20Inter%2dspecies%20Reactivities">human</a> IL18 using the <a href="cope.cgi?key=Cytokine%20Inter%2dspecies%20Reactivities">human</a> <a href="cope.cgi?key=myelomonocytic%20cells">myelomonocytic cell</a> line, <a href="cope.cgi?key=KG%2d1">KG-1</a>.</span> </p><p><span style='mso-bidi-font-size:9.0pt; mso-bidi-font-family:"Times New Roman";color:red'><br/> </span><b style="mso-bidi-font-weight:normal"><span style="color:red"><a href="cope.cgi?key=Copyright">Copyright</a> &#169; 2012 by H IBELGAUFTS. All rights reserved.</span></b><b style="mso-bidi-font-weight: normal"><span style='font-size:10.0pt;font-family:Times;mso-fareast-font-family: "Times New Roman"'><br/> </span></b><span style='mso-bidi-font-size:9.0pt;mso-bidi-font-family:"Times New Roman"; color:red'>ENTRY LAST MODIFIED: March 2002</span> </p><p><br/></p>

<h2>IL3</h2><p><span style='mso-bidi-font-size:9.0pt; mso-bidi-font-family:"Times New Roman";color:black'><a href="cope.cgi?key=Interleukin%2d3">Interleukin-3</a>.</span> </p><p><span style='mso-bidi-font-size:9.0pt; mso-bidi-font-family:"Times New Roman";color:black'><br/> <b style="mso-bidi-font-weight:normal">ALTERNATIVE NAMES</b></span> </p><p><b style="mso-bidi-font-weight:normal"><span style='mso-bidi-font-size:9.0pt;mso-bidi-font-family:"Times New Roman"; color:black'><a href="cope.cgi?key=20%2dalpha%2dhydroxysteroid%20dehydrogenase%20inducing%20factor">20-alpha-hydroxysteroid dehydrogenase inducing factor</a></span></b> </p><p><b style="mso-bidi-font-weight:normal"><span style='mso-bidi-font-size:9.0pt;mso-bidi-font-family:"Times New Roman"; color:black'><a href="cope.cgi?key=BP">BP</a></span></b><span style='mso-bidi-font-size:9.0pt;mso-bidi-font-family: "Times New Roman";color:black'> (<a href="cope.cgi?key=Burst%20promoting%20activity">burst promoting activity</a>);<br/> <b style="mso-bidi-font-weight:normal"><a href="cope.cgi?key=BPA">BPA</a></b> (<a href="cope.cgi?key=Blood%20progenitor%20activator">blood progenitor activator</a>);<br/> <b style="mso-bidi-font-weight:normal"><a href="cope.cgi?key=BPA">BPA</a></b> (<a href="cope.cgi?key=Burst%20promoting%20activity">burst promoting activity</a>);<br/> <b style="mso-bidi-font-weight:normal"><a href="cope.cgi?key=CFU%2dS">CFU-S</a></b> (<a href="cope.cgi?key=Colony%2dforming%20unit%20spleen">colony-forming unit spleen</a>);<br/> <b style="mso-bidi-font-weight:normal"><a href="cope.cgi?key=CFU%2dSA">CFU-SA</a></b> (<a href="cope.cgi?key=Colony%2dforming%20unit%20stimulating%20activity">colony-forming unit stimulating activity</a>);<br/> <b style="mso-bidi-font-weight:normal"><a href="cope.cgi?key=CSF%2d2%2dalpha">CSF-2-alpha</a></b></span><span style='mso-bidi-font-family:"Times New Roman";color:black'> </span><span style='mso-bidi-font-size:9.0pt;mso-bidi-font-family:"Times New Roman"; color:black'>(<a href="cope.cgi?key=Colony%20stimulating%20factor%2d2%2dalpha">colony stimulating factor-2-alpha</a>);<br/> <b style="mso-bidi-font-weight:normal"><a href="cope.cgi?key=CSF%2d2%2dbeta">CSF-2-beta</a></b></span><span style='mso-bidi-font-family:"Times New Roman";color:black'> </span><span style='mso-bidi-font-size:9.0pt;mso-bidi-font-family:"Times New Roman"; color:black'>(<a href="cope.cgi?key=Colony%20stimulating%20factor%2d2%2dbeta">colony stimulating factor-2-beta</a>);<br/> <b style="mso-bidi-font-weight:normal"><a href="cope.cgi?key=EC%20IL3">EC IL3</a></b> (<a href="cope.cgi?key=Epidermal%20cell%20IL3">epidermal cell IL3</a>);<br/> <b style="mso-bidi-font-weight:normal"><a href="cope.cgi?key=ECSF">ECSF</a></b> (<a href="cope.cgi?key=Erythroid%20colony%20stimulating%20factor">erythroid colony stimulating factor</a>);<br/> <b style="mso-bidi-font-weight:normal"><a href="cope.cgi?key=EK%2dderived%20basophil%20promoting%20activity">EK-derived basophil promoting activity</a></b> (EK = epidermal <a href="cope.cgi?key=keratinocytes">keratinocyte</a>);<br/> <b style="mso-bidi-font-weight:normal"><a href="cope.cgi?key=Eo%2dCSF">Eo-CSF</a></b> (<a href="cope.cgi?key=Eosinophil%20colony%20stimulating%20factor">eosinophil colony stimulating factor</a>);<br/> <b style="mso-bidi-font-weight:normal"><a href="cope.cgi?key=HCGF">HCGF</a></b> (<a href="cope.cgi?key=Hematopoietic%20cell%20growth%20factor">Hematopoietic cell growth factor</a>);<br/> <b style="mso-bidi-font-weight:normal"><a href="cope.cgi?key=HCSF">HCSF</a></b> (<a href="cope.cgi?key=Histamine%2dproducing%20cell%20stimulating%20factor">histamine-producing cell stimulating factor</a>);<br/> <b style="mso-bidi-font-weight:normal"><a href="cope.cgi?key=Hemopoietin%2d2">Hemopoietin-2</a></b>;<br/> <b style="mso-bidi-font-weight:normal"><a href="cope.cgi?key=HP2">HP2</a></b> (<a href="cope.cgi?key=Hematopoietin%2d2">Hematopoietin-2</a>);<br/> <b style="mso-bidi-font-weight:normal"><a href="cope.cgi?key=HPGF">HPGF</a></b> (<a href="cope.cgi?key=Hematopoietic%20cell%20growth%20factor">hematopoietic cell growth factor</a>);<br/> <b style="mso-bidi-font-weight:normal"><a href="cope.cgi?key=Maturation%20inducer%20activity">Maturation inducer activity</a></b>;<br/> <b style="mso-bidi-font-weight:normal"><a href="cope.cgi?key=MCGF">MCGF</a></b> (<a href="cope.cgi?key=Mast%20cell%20growth%20factor">mast cell growth factor</a>);<br/> <b style="mso-bidi-font-weight:normal"><a href="cope.cgi?key=MCSA">MCSA</a></b> (<a href="cope.cgi?key=Multi%2dcolony%20stimulating%20activity">multi-colony stimulating activity</a>);<br/> <b style="mso-bidi-font-weight:normal"><a href="cope.cgi?key=MEG%2dCSA">MEG-CSA</a></b> (<a href="cope.cgi?key=Megakaryocyte%20colony%20stimulating%20activity">megakaryocyte colony stimulating activity</a>);<br/> <b style="mso-bidi-font-weight:normal"><a href="cope.cgi?key=Meg%2dCSF">Meg-CSF</a></b> (<a href="cope.cgi?key=Megakaryocyte%20colony%20stimulating%20factor">megakaryocyte colony stimulating factor</a>);<br/> <b style="mso-bidi-font-weight:normal"><a href="cope.cgi?key=MGF">MGF</a></b> (<a href="cope.cgi?key=Mast%20cell%20growth%20factor">mast cell growth factor</a>);<br/> <b style="mso-bidi-font-weight:normal"><a href="cope.cgi?key=Mixed%20colony%20stimulating%20factor">Mixed colony stimulating factor</a></b>;<br/> <b style="mso-bidi-font-weight:normal"><a href="cope.cgi?key=Multi%2dCSF">Multi-CSF</a></b> (<a href="cope.cgi?key=Multi%2dcolony%20stimulating%20factor">Multi-colony stimulating factor</a>);<br/> <b style="mso-bidi-font-weight:normal"><a href="cope.cgi?key=multi%2dHGF">multi-HGF</a></b> (<a href="cope.cgi?key=Multilineage%20hemopoietic%20growth%20factor">multilineage hemopoietic growth factor</a>);<br/> <b style="mso-bidi-font-weight:normal"><a href="cope.cgi?key=Multipoietin">Multipoietin</a></b>;<br/> <b style="mso-bidi-font-weight:normal"><a href="cope.cgi?key=NC%20cell%20growth%20factor">NC cell growth factor</a></b> (<a href="cope.cgi?key=Natural%20cytotoxic%20cell%20growth%20factor">natural cytotoxic cell growth factor</a>);<br/> <b style="mso-bidi-font-weight:normal"><a href="cope.cgi?key=Neutrophil%2dgranulocyte%20colony%20stimulating%20factor">Neutrophil-granulocyte colony stimulating factor</a></b>;<br/> <b style="mso-bidi-font-weight:normal"><a href="cope.cgi?key=PCSA">PCSA</a></b> (<a href="cope.cgi?key=P%20cell%20stimulating%20activity">P cell stimulating activity</a>);<br/> <b style="mso-bidi-font-weight:normal"><a href="cope.cgi?key=PCSF">PCSF</a></b> (<a href="cope.cgi?key=P%20cell%20stimulating%20factor">P cell stimulating factor</a>);<br/> <b style="mso-bidi-font-weight:normal"><a href="cope.cgi?key=P%2dFactor">P-Factor</a></b>;<br/> <b style="mso-bidi-font-weight:normal"><a href="cope.cgi?key=Pluripotential%20stem%20cell%2dsupporting%20factor">Pluripotential stem cell-supporting factor</a></b>;<br/> <b style="mso-bidi-font-weight:normal"><a href="cope.cgi?key=PSF">PSF</a></b> (<a href="cope.cgi?key=Persisting%20cell%20stimulating%20factor">persisting cell stimulating factor</a>);<br/> <b style="mso-bidi-font-weight:normal"><a href="cope.cgi?key=PSF">PSF</a></b> (<a href="cope.cgi?key=P%20cell%20stimulating%20factor">P cell stimulating factor</a>);<br/> <b style="mso-bidi-font-weight:normal"><a href="cope.cgi?key=PSF">PSF</a></b> (<a href="cope.cgi?key=Progenitor%20stimulating%20factor">progenitor stimulating factor</a>);<br/> <b style="mso-bidi-font-weight:normal"><a href="cope.cgi?key=PSH">PSH</a></b> (<a href="cope.cgi?key=panspecific%20hemopoietin">panspecific hemopoietin</a>);<br/> <b style="mso-bidi-font-weight:normal"><a href="cope.cgi?key=SA">SA</a></b> (<a href="cope.cgi?key=Synergistic%20activity">synergistic activity</a>);<br/> <b style="mso-bidi-font-weight:normal"><a href="cope.cgi?key=SAF">SAF</a></b> (<a href="cope.cgi?key=Stem%20cell%20activating%20factor">stem cell activating factor</a>);<br/> <b style="mso-bidi-font-weight:normal"><a href="cope.cgi?key=Thy1%20inducing%20factor">Thy1 inducing factor</a></b>;<br/> <b style="mso-bidi-font-weight:normal"><a href="cope.cgi?key=WEHI%203%20growth%20factor">WEHI 3 growth factor</a></b>;<br/> <b style="mso-bidi-font-weight:normal"><a href="cope.cgi?key=WEHI%203%20hematopoietic%20growth%20factor">WEHI 3 hematopoietic growth factor</a></b>;<br/> <b style="mso-bidi-font-weight:normal"><a href="cope.cgi?key=WGF">WGF</a></b> (<a href="cope.cgi?key=WEHI%203%20growth%20factor">WEHI 3 growth factor</a>).<br/> See also: individual entries for further information.</span> </p><p><span style='mso-bidi-font-size:9.0pt; mso-bidi-font-family:"Times New Roman";color:black'><br/> <b style="mso-bidi-font-weight:normal">SOURCES</b></span> </p><p><span style='mso-bidi-font-size:9.0pt; mso-bidi-font-family:"Times New Roman";color:black'>IL3 is produced mainly by <a href="cope.cgi?key=T%2dcells">T-cells</a> following <a href="cope.cgi?key=Cell%20activation">cell activation</a> by antigens and <a href="cope.cgi?key=Cell%20cycle">mitogens</a>, but also by <a href="cope.cgi?key=keratinocytes">keratinocytes</a>, <a href="cope.cgi?key=NK%2dcells">NK-cells</a>, <a href="cope.cgi?key=mast%20cells">mast cells</a>, <a href="cope.cgi?key=endothelial%20cells">endothelial cells</a>, and <a href="cope.cgi?key=monocytes">monocytes</a>. Some <a href="cope.cgi?key=Cell%20lines%20in%20Cytokine%20Research">cell lines</a> produce IL3 constitutively. Substances that inhibit the activation of <a href="cope.cgi?key=T%2dlymphocytes">T-lymphocytes</a> such as glucocorticoids or <a href="cope.cgi?key=CsA">CsA</a> (<a href="cope.cgi?key=Cyclosporin%20A">Cyclosporin A</a>) also inhibit the production of IL3. For the constitutive synthesis of IL3 see also: <a href="cope.cgi?key=IAP">IAP</a> (<a href="cope.cgi?key=Intracisternal%20A%20particles">intracisternal A particles</a>).</span> </p><p><span style='mso-bidi-font-size:9.0pt; mso-bidi-font-family:"Times New Roman";color:black'>IL3 may be associated with the <a href="cope.cgi?key=extracellular%20matrix">extracellular matrix</a> in the form of complexes with <a href="cope.cgi?key=glycosaminoglycan">heparan sulfate</a>/proteoglycan. It can thus be stored in a biologically inactive form but it may exert <a href="cope.cgi?key=Juxtacrine">juxtacrine</a> activities also. The molecular mechanisms underlying the release from <a href="cope.cgi?key=extracellular%20matrix">extracellular matrix</a> stores is still unknown.</span> </p><p><span style='mso-bidi-font-size:9.0pt; mso-bidi-font-family:"Times New Roman";color:black'><br/> <b style="mso-bidi-font-weight:normal">PROTEIN CHARACTERISTICS</b></span> </p><p><span style='mso-bidi-font-size:9.0pt; mso-bidi-font-family:"Times New Roman";color:black'><a href="cope.cgi?key=Cytokine%20Inter%2dspecies%20Reactivities">Human</a> IL3 is a protein of 15-17 kDa (133 amino acids). It is synthesized as a precursor containing a hydrophobic secretory <a href="cope.cgi?key=Signal%20sequence">signal sequence</a> of 19 amino acids. IL3 contains two putative glycosylation sites at positions 15 and 70 and contains a single disulfide bond (Cys16/84). The analysis of bacterial-derived recombinant IL3 (see also: <a href="cope.cgi?key=recombinant%20cytokines">Recombinant cytokines</a>) shows that glycosylation is not required for the activity of IL3.</span> </p><p><span style='mso-bidi-font-size:9.0pt; mso-bidi-font-family:"Times New Roman";color:black'>IL3 sequences are evolutionarily less well conserved. <a href="cope.cgi?key=Cytokine%20Inter%2dspecies%20Reactivities">Human</a> and <a href="cope.cgi?key=Cytokine%20Inter%2dspecies%20Reactivities">murine</a> IL3 show approximately 29 % homology at the protein level while <a href="cope.cgi?key=Cytokine%20Inter%2dspecies%20Reactivities">murine</a> and <a href="cope.cgi?key=Cytokine%20Inter%2dspecies%20Reactivities">rat</a> IL3 show approximately 54 % homology. <b style="mso-bidi-font-weight:normal"><a href="cope.cgi?key=IL3%2dalpha">IL3-alpha</a></b> and <b style="mso-bidi-font-weight:normal"><a href="cope.cgi?key=IL3%2dbeta">IL3-beta</a></b> are two isoforms of <a href="cope.cgi?key=Cytokine%20Inter%2dspecies%20Reactivities">rat</a> IL3.</span> </p><p><span style='mso-bidi-font-size:9.0pt; mso-bidi-font-family:"Times New Roman";color:black'><br/> <b style="mso-bidi-font-weight:normal">GENE STRUCTURE</b></span> </p><p><span style='mso-bidi-font-size:9.0pt; mso-bidi-font-family:"Times New Roman";color:black'>The <a href="cope.cgi?key=Cytokine%20Inter%2dspecies%20Reactivities">human</a> IL3 has a length of approximately 2.2 kb and contains five exons. The gene maps to <a href="cope.cgi?key=Cytokine%20Inter%2dspecies%20Reactivities">human</a> chromosome 5q23-31. <a href="cope.cgi?key=Cytokine%20Inter%2dspecies%20Reactivities">Murine</a> and <a href="cope.cgi?key=Cytokine%20Inter%2dspecies%20Reactivities">human</a> IL3 genes structurally resemble each other but at the nucleotide level the homology is approximately 49 %. The <a href="cope.cgi?key=Cytokine%20Inter%2dspecies%20Reactivities">murine</a> IL3 gene maps to chromosome 17.</span> </p><p><span style='mso-bidi-font-size:9.0pt; mso-bidi-font-family:"Times New Roman";color:black'>The <a href="cope.cgi?key=Cytokine%20Inter%2dspecies%20Reactivities">human</a> IL3 gene is located in close vicinity to other <a href="cope.cgi?key=cytokines">cytokine</a> genes, including those encoding <a href="cope.cgi?key=GM%2dCSF">GM-CSF</a>, <a href="cope.cgi?key=M%2dCSF">M-CSF</a>, <a href="cope.cgi?key=IL4">IL4</a> and <a href="cope.cgi?key=IL5">IL5</a> The distance between the IL3 and the <a href="cope.cgi?key=GM%2dCSF">GM-CSF</a> gene is approximately 9 kb with the IL3 gene on the 5'side of the <a href="cope.cgi?key=GM%2dCSF">GM-CSF</a> gene. Deletions of the IL3/GM-CSF locus are observed frequently in patients with myelodysplastic syndrome (see also: <a href="cope.cgi?key=5q%20minus%20syndrome">5q minus syndrome</a>).</span> </p><p><span style='mso-bidi-font-size:9.0pt; mso-bidi-font-family:"Times New Roman";color:black'><br/> <b style="mso-bidi-font-weight:normal">RECEPTORS</b></span> </p><p><span style='mso-bidi-font-size:9.0pt; mso-bidi-font-family:"Times New Roman";color:black'>IL3 receptors are expressed on <a href="cope.cgi?key=macrophages">macrophages</a>, <a href="cope.cgi?key=mast%20cells">mast cells</a>, <a href="cope.cgi?key=eosinophils">eosinophils</a>, <a href="cope.cgi?key=megakaryocytes">megakaryocytes</a>, <a href="cope.cgi?key=basophils">basophils</a>, bone marrow <a href="cope.cgi?key=progenitor%20cells">progenitor cells</a>, and various <a href="cope.cgi?key=leukemia">myeloid leukemia</a> <a href="cope.cgi?key=cell%20types">cells</a>.</span> </p><p><span style='mso-bidi-font-size:9.0pt; mso-bidi-font-family:"Times New Roman";color:black'>IL3/receptor complexes have a Kdis of 10**-9 - 10**-10<sup> </sup>M. Binding of IL3 to its receptor causes specific phosphorylation of a 150 kDa membrane glycoprotein.</span> </p><p><span style='mso-bidi-font-size:9.0pt; mso-bidi-font-family:"Times New Roman";color:black'>Biological activities are also detected at the <a href="cope.cgi?key=Cytokine%20Concentrations%20in%20Biological%20Fluids">concentration</a> range of 10**-13 - 10**-15<sup> </sup>M which suggests the existence either of other high affinity receptor conformations or other receptors.</span> </p><p><span style='mso-bidi-font-size:9.0pt; mso-bidi-font-family:"Times New Roman";color:black'>The high affinity IL3 receptor is formed by aggregation of the IL3-specific subunit of the receptor with another subunit called GM-Rbeta</span><span style='mso-bidi-font-family: "Times New Roman";color:black'> </span><span style='mso-bidi-font-size:9.0pt; mso-bidi-font-family:"Times New Roman";color:black'>which constitutes the larger subunit of the receptor for <a href="cope.cgi?key=GM%2dCSF">GM-CSF</a> and is involved also as a subunit in the formation of <a href="cope.cgi?key=IL5">IL5</a> receptors (see also: <a href="cope.cgi?key=AIC2A">AIC2A</a>). This subunit which is common to all three receptors is called also <a href="cope.cgi?key=beta%20c">Beta c</a> or <a href="cope.cgi?key=common%20beta">common beta</a>. In the <a href="cope.cgi?key=nomenclature">nomenclature</a> of <a href="cope.cgi?key=CD%20antigens">CD antigens</a> this common protein has been given the designation <a href="cope.cgi?key=CD131">CD131</a>. See also the <a href="cope.cgi?key=transgenic">Transgenic</a> /Knock-out/Antisense Studies section of this entry for details on <a href="cope.cgi?key=Cytokine%20Inter%2dspecies%20Reactivities">mice</a> not expressing the <a href="cope.cgi?key=common%20beta">common beta</a> subunit of the receptor complex.</span> </p><p><span style='mso-bidi-font-size:9.0pt; mso-bidi-font-family:"Times New Roman";color:black'>Binding of IL3 to its receptor causes the phosphorylation of the receptor and also of some other cytoplasmic proteins (p70, p56, <a href="cope.cgi?key=p38">p38</a>) and also activates protein kinase C in IL3 dependent <a href="cope.cgi?key=Cell%20lines%20in%20Cytokine%20Research">cell lines</a> (see also: <a href="cope.cgi?key=Factor%2ddependent%20cell%20lines">Factor-dependent cell lines</a>). The non-receptor <a href="cope.cgi?key=PTK">tyrosine kinase</a> <a href="cope.cgi?key=lyn">lyn</a> has been implicated in IL3 mediated signal transduction processes (see also: <a href="cope.cgi?key=PTK">PTK</a>; <a href="cope.cgi?key=Protein%20tyrosine%20kinase">protein tyrosine kinase</a>).</span> </p><p><span style='mso-bidi-font-size:9.0pt; mso-bidi-font-family:"Times New Roman";color:black'>For a protein involved in signal transduction see also: <a href="cope.cgi?key=CIS">CIS</a> (<a href="cope.cgi?key=cytokine%20inducible%20SH2%2dcontaining%20protein">cytokine inducible SH2-containing protein</a>).</span> </p><p><span style='mso-bidi-font-size:9.0pt; mso-bidi-font-family:"Times New Roman";color:black'><br/> <b style="mso-bidi-font-weight:normal">BIOLOGICAL ACTIVITIES</b></span> </p><p><span style='mso-bidi-font-size:9.0pt; mso-bidi-font-family:"Times New Roman";color:black'>The biological activities of IL3 are <a href="cope.cgi?key=Cytokine%20Inter%2dspecies%20Reactivities">species-specific</a>. The plethora of biological activities is exemplified by the many different acronyms under which IL3 has been described. IL3 is a <a href="cope.cgi?key=Growth%20factors">growth factor</a> that establishes the link between the immune system and the hematopoietic system (see also: <a href="cope.cgi?key=Hematopoiesis">hematopoiesis</a>). It supports the proliferation and development of almost all types of <a href="cope.cgi?key=hematopoietic%20progenitor%20cells">hematopoietic progenitor cells</a> (see also: <a href="cope.cgi?key=CFU">CFU</a>). In rhesus <a href="cope.cgi?key=Cytokine%20Inter%2dspecies%20Reactivities">monkeys</a> IL3 causes the expansion of all types of circulating <a href="cope.cgi?key=hematopoietic%20progenitor%20cells">hematopoietic progenitor cells</a>. IL3 also supports the <a href="cope.cgi?key=differentiation">differentiation</a> of early non-lineage-committed <a href="cope.cgi?key=hematopoietic%20progenitor%20cells">hematopoietic progenitor cells</a> into colonies of <a href="cope.cgi?key=granulocytes">granulocytes</a>, <a href="cope.cgi?key=macrophages">macrophages</a>, <a href="cope.cgi?key=erythroid%20cells">erythroid cells</a>, <a href="cope.cgi?key=megakaryocytes">megakaryocytes</a>, and <a href="cope.cgi?key=mast%20cells">mast cells</a> (see also: <a href="cope.cgi?key=Colony%20formation%20assay">Colony formation assay</a>). IL3 also stimulates clonal growth of non-hematopoietic <a href="cope.cgi?key=stromal%20cells">stromal cells</a> in <a href="cope.cgi?key=bone%20marrow%20culture">bone marrow cultures</a> (see also: <a href="cope.cgi?key=BMC">BMC</a>, <a href="cope.cgi?key=bone%20marrow%20culture">bone marrow culture</a>). IL3 is one of the <a href="cope.cgi?key=priming%20factors">priming factors</a> for <a href="cope.cgi?key=hematopoietic%20stem%20cells">hematopoietic stem cells</a> in vitro and in vivo (see also: <a href="cope.cgi?key=Cell%20activation">cell activation</a>) that makes the <a href="cope.cgi?key=cell%20types">cells</a> responsive to later-acting factors such as <a href="cope.cgi?key=Epo">Epo</a>, <a href="cope.cgi?key=GM%2dCSF">GM-CSF</a> and <a href="cope.cgi?key=IL6">IL6</a>. IL3 also induces the increased expression of receptors for <a href="cope.cgi?key=Colony%20stimulating%20factors">colony stimulating factors</a> (see: <a href="cope.cgi?key=CSF">CSF</a>). At pico- to nanomolar <a href="cope.cgi?key=Cytokine%20Concentrations%20in%20Biological%20Fluids">concentrations</a> IL3 is a <a href="cope.cgi?key=chemoattractants">chemoattractant</a> for <a href="cope.cgi?key=eosinophils">eosinophils</a> and also influences the <a href="cope.cgi?key=chemotaxis">chemotactic</a> behavior of these <a href="cope.cgi?key=cell%20types">cells</a> in response to other chemotactically active factors (see also: <a href="cope.cgi?key=chemotaxis">Chemotaxis</a>).</span> </p><p><span style='mso-bidi-font-size:9.0pt; mso-bidi-font-family:"Times New Roman";color:black'>IL3 does not appear to be an obligatory factor in normal <a href="cope.cgi?key=Hematopoiesis">hematopoiesis</a>. The athymic <a href="cope.cgi?key=Nude">nude</a> <a href="cope.cgi?key=Cytokine%20Inter%2dspecies%20Reactivities">mouse</a> (see also: <a href="cope.cgi?key=Immunodeficient%20mice">Immunodeficient mice</a>) which lacks <a href="cope.cgi?key=T%2dcells">T-cells</a> responsible for IL3 production displays a normal pattern of hematopoietic development. In the <a href="cope.cgi?key=lymphoid%20cells">lymphoid lineage</a> IL3 supports the growth of preB-cells.</span> </p><p><span style='mso-bidi-font-size:9.0pt; mso-bidi-font-family:"Times New Roman";color:black'>Experiments with an <a href="cope.cgi?key=Oncogene">oncogene</a> encoding a <a href="cope.cgi?key=PTK">tyrosine-specific protein kinase</a> show that the expression of the oncogene-encoded <a href="cope.cgi?key=PTK">tyrosine kinase</a> abolishes IL3 requirements (and also <a href="cope.cgi?key=GM%2dCSF">GM-CSF</a> and <a href="cope.cgi?key=IL4">IL4</a> requirements) in factor-dependent <a href="cope.cgi?key=cell%20types">cells</a>. The exact mechanism by which these factors regulate proliferation and <a href="cope.cgi?key=differentiation">differentiation</a> is still unknown.</span> </p><p><span style='mso-bidi-font-size:9.0pt; mso-bidi-font-family:"Times New Roman";color:black'>IL3 induces the proliferation of <a href="cope.cgi?key=mast%20cells">mast cells</a> and <a href="cope.cgi?key=macrophages">macrophages</a> and causes the synthesis of histamines by <a href="cope.cgi?key=mast%20cells">mast cells</a> and phagocytosis in <a href="cope.cgi?key=macrophages">macrophages</a>. In <a href="cope.cgi?key=mast%20cells">mast cells</a> IL3 prevents the expression of MHC class 2 molecules normally induced by <a href="cope.cgi?key=IFN%2dgamma">IFN-gamma</a>.</span> </p><p><span style='mso-bidi-font-size:9.0pt; mso-bidi-font-family:"Times New Roman";color:black'>IL3 induces the expression of complement factor C3a receptors in <a href="cope.cgi?key=basophils">basophils</a> at nanomolar <a href="cope.cgi?key=Cytokine%20Concentrations%20in%20Biological%20Fluids">concentrations</a>. A transient stimulation by IL3 is required to make <a href="cope.cgi?key=basophils">basophils</a> responsive for further <a href="cope.cgi?key=Cell%20activation">cell activation</a> by <a href="cope.cgi?key=IL8">IL8</a> which by itself does not possess histamine releasing activity. Tissue <a href="cope.cgi?key=mast%20cells">mast cells</a> do not respond to IL3. In <a href="cope.cgi?key=macrophages">macrophages</a> stimulated with <a href="cope.cgi?key=endotoxins">bacterial lipopolysaccharides</a>. IL3 significantly enhances the secretion of other <a href="cope.cgi?key=cytokines">cytokines</a> including <a href="cope.cgi?key=IL1">IL1</a>, <a href="cope.cgi?key=IL6">IL6</a> and <a href="cope.cgi?key=TNF">TNF</a>. In vitro IL3 also stimulates the proliferation of <a href="cope.cgi?key=keratinocytes">keratinocytes</a>. This observation has been made also in rhesus <a href="cope.cgi?key=Cytokine%20Inter%2dspecies%20Reactivities">monkeys</a> treated with recombinant IL3 (see also: <a href="cope.cgi?key=recombinant%20cytokines">Recombinant cytokines</a>) but at present it is unclear whether IL3 is involved in skin reactions associated with the growth of <a href="cope.cgi?key=keratinocytes">keratinocytes</a> and acanthosis.</span> </p><p><span style='mso-bidi-font-size:9.0pt; mso-bidi-font-family:"Times New Roman";color:black'>IL3 also specifically induces the production of enzymes involved in cellular metabolism, <a href="cope.cgi?key=differentiation">differentiation</a> and DNA/RNA metabolism. Among other things IL3 induces the expression of 20-alpha-steroid dehydrogenase and of histidine and Ornithine decarboxylase.</span> </p><p><span style='mso-bidi-font-size:9.0pt; mso-bidi-font-family:"Times New Roman";color:black'><br/> <b style="mso-bidi-font-weight:normal">TRANSGENIC ANIMALS, KNOCK-OUT, AND ANTISENSE STUDIES</b></span> </p><p><span style='mso-bidi-font-size:9.0pt; mso-bidi-font-family:"Times New Roman";color:black'>The consequences of a deregulated expression of IL3 in <a href="cope.cgi?key=astrocytes">astrocytes</a> have been studied in <a href="cope.cgi?key=transgenic">transgenic</a> <a href="cope.cgi?key=Cytokine%20Inter%2dspecies%20Reactivities">mice</a> expressing a <a href="cope.cgi?key=Cytokine%20Inter%2dspecies%20Reactivities">murine</a> glial fibrillary acidic protein fusion gene. Chiang et al (1996) have shown that chronic CNS production of low levels of IL3 promotes the recruitment, proliferation and activation of <a href="cope.cgi?key=microglial%20cells">microglial cells</a> in white matter regions with consequent primary demyelination and motor disease. These features resemble those found in <a href="cope.cgi?key=Cytokine%20Inter%2dspecies%20Reactivities">human</a> <a href="cope.cgi?key=inflammation">inflammatory</a> demyelinating diseases including multiple sclerosis and HIV leukoencephalopathy.</span> </p><p><span style='mso-bidi-font-size:9.0pt; mso-bidi-font-family:"Times New Roman";color:black'>Robb et al (1995) have created <a href="cope.cgi?key=transgenic">transgenic</a> <a href="cope.cgi?key=Knock%2dout">knock-out</a> <a href="cope.cgi?key=Cytokine%20Inter%2dspecies%20Reactivities">mice</a> with a <a href="cope.cgi?key=null%20mutations">null mutation</a> of the gene encoding the <a href="cope.cgi?key=common%20beta">common beta</a> subunit (<a href="cope.cgi?key=beta%20c">beta C</a>) of the <a href="cope.cgi?key=GM%2dCSF">GM-CSF</a>, IL3, and <a href="cope.cgi?key=IL5">IL5</a> receptor complexes. Homozygous deletion mutants exhibit normal development and survive to young adult life. They develop pulmonary peribronchovascular lymphoid infiltrates and areas resembling alveolar proteinosis. <a href="cope.cgi?key=eosinophils">Eosinophil</a> numbers in peripheral blood and bone marrow of homozygous deletion mutants are reduced, while other hematological parameters are normal. <a href="cope.cgi?key=bone%20marrow%20cells">Bone marrow cells</a> from homozygous deletion mutants do not show high-affinity binding of <a href="cope.cgi?key=GM%2dCSF">GM-CSF</a>, while <a href="cope.cgi?key=cell%20types">cells</a> from heterozygous animals show an intermediate number of high-affinity receptors. In clonal cultures of <a href="cope.cgi?key=bone%20marrow%20cells">bone marrow cells</a> derived from homozygous deletion mutants, even high <a href="cope.cgi?key=Cytokine%20Concentrations%20in%20Biological%20Fluids">concentrations</a> of <a href="cope.cgi?key=GM%2dCSF">GM-CSF</a> and <a href="cope.cgi?key=IL5">IL5</a> do not stimulate <a href="cope.cgi?key=Colony%20formation%20assay">colony formation</a> (see also: <a href="cope.cgi?key=Colony%20formation%20assay">Colony formation assay</a>). Differences in the systemic clearance and distribution of <a href="cope.cgi?key=GM%2dCSF">GM-CSF</a> between mutant and wild-type littermates are not observed.</span> </p><p><span style='mso-bidi-font-size:9.0pt; mso-bidi-font-family:"Times New Roman";color:black'>Nishinakamura et al (1996) have crossed beta-c mutant <a href="cope.cgi?key=Cytokine%20Inter%2dspecies%20Reactivities">mice</a> with <a href="cope.cgi?key=Cytokine%20Inter%2dspecies%20Reactivities">mice</a> deficient for IL3. The double-mutant <a href="cope.cgi?key=Cytokine%20Inter%2dspecies%20Reactivities">mice</a> lacking all IL3, <a href="cope.cgi?key=GM%2dCSF">GM-CSF</a>, and <a href="cope.cgi?key=IL5">IL5</a> functions are apparently normal and fertile. The animals show the same reduced numbers of <a href="cope.cgi?key=eosinophils">eosinophils</a> and a lack of eosinophilic response to parasites as beta-c mutant <a href="cope.cgi?key=Cytokine%20Inter%2dspecies%20Reactivities">mice</a>. The immune response of the double mutant <a href="cope.cgi?key=Cytokine%20Inter%2dspecies%20Reactivities">mice</a> to Listeria mono-cytogenes is normal. Hematopoietic recovery after treatment with <a href="cope.cgi?key=Fluorouracil">Fluorouracil</a> is also normal. These findings suggest the existence of alternative mechanism to produce <a href="cope.cgi?key=blood%20cells">blood cells</a> that do not depend on the presence of IL3, <a href="cope.cgi?key=GM%2dCSF">GM-CSF</a>, and <a href="cope.cgi?key=IL5">IL5</a> (see also: <a href="cope.cgi?key=Hematopoiesis">hematopoiesis</a>, <a href="cope.cgi?key=hematopoietic%20stem%20cells">hematopoietic stem cells</a>).</span> </p><p><span style='mso-bidi-font-size:9.0pt; mso-bidi-font-family:"Times New Roman";color:black'><br/> <b style="mso-bidi-font-weight:normal">DETECTION AND ASSAY METHODS</b></span> </p><p><span style='mso-bidi-font-size:9.0pt; mso-bidi-font-family:"Times New Roman";color:black'>IL3 can be detected in <a href="cope.cgi?key=bioassays">bioassays</a> employing responsive <a href="cope.cgi?key=Cell%20lines%20in%20Cytokine%20Research">cell lines</a> (see: <a href="cope.cgi?key=AML%2d193">AML-193</a>; <a href="cope.cgi?key=32D">32D</a>; <a href="cope.cgi?key=B6SUt%2dA">B6SUt-A</a>; <a href="cope.cgi?key=B13">B13</a>; <a href="cope.cgi?key=Da">Da</a>; <a href="cope.cgi?key=Ea3%2e17">Ea3.17</a>; <a href="cope.cgi?key=FDCP1">FDCP1</a>; <a href="cope.cgi?key=GF%2dD8">GF-D8</a>; <a href="cope.cgi?key=IC%2d2">IC-2</a>; <a href="cope.cgi?key=KMT%2d2">KMT-2</a>; <a href="cope.cgi?key=L138%2e8A">L138.8A</a>; <a href="cope.cgi?key=LyD9">LyD9</a>; <a href="cope.cgi?key=MO7E">MO7E</a>; <a href="cope.cgi?key=NFS%2d60">NFS-60</a>; <a href="cope.cgi?key=PT%2d18">PT-18</a>; <a href="cope.cgi?key=TALL%2d103">TALL-103</a>; <a href="cope.cgi?key=TF%2d1">TF-1</a>; <a href="cope.cgi?key=TMD2">TMD2</a>; <a href="cope.cgi?key=UT%2d7">UT-7</a>). A sensitive <a href="cope.cgi?key=ELISA">ELISA</a> test for IL3 is also available. An alternative and entirely different detection method is <a href="cope.cgi?key=RT%2dPCR%20quantitation%20of%20cytokines">RT-PCR quantitation of cytokines</a>. For further information see also subentry "Assays" in the reference section. For further information on assays for <a href="cope.cgi?key=cytokines">cytokines</a> see also: <a href="cope.cgi?key=bioassays">bioassays</a>, <a href="cope.cgi?key=Cytokine%20assays">cytokine assays</a>.</span> </p><p><span style='mso-bidi-font-size:9.0pt; mso-bidi-font-family:"Times New Roman";color:black'><br/> <b style="mso-bidi-font-weight:normal">CLINICAL USE AND SIGNIFICANCE</b></span> </p><p><span style='mso-bidi-font-size:9.0pt; mso-bidi-font-family:"Times New Roman";color:black'>IL3 alone or in combination with other <a href="cope.cgi?key=Colony%20stimulating%20factors">colony stimulating factors</a> (see also: <a href="cope.cgi?key=CSF">CSF</a>) or <a href="cope.cgi?key=Epo">Epo</a> is probably useful in the reconstitution of bone marrow and in stimulating <a href="cope.cgi?key=erythropoiesis">erythropoiesis</a> (see also: <a href="cope.cgi?key=Hematopoiesis">hematopoiesis</a>). IL3 also appears a valuable substance in view of its ability to stimulate the proliferation of very immature <a href="cope.cgi?key=hematopoietic%20progenitor%20cells">hematopoietic progenitor cells</a> such as <a href="cope.cgi?key=CFU%2dGEMM">CFU-GEMM</a>, <a href="cope.cgi?key=BFU%2dE">BFU-E</a>, and <a href="cope.cgi?key=CFU%2dGM">CFU-GM</a>, which can be enhanced even more by simultaneous administration of other factors such as <a href="cope.cgi?key=GM%2dCSF">GM-CSF</a>. These effects can be exploited in the generation of <a href="cope.cgi?key=stem%20cells">stem cells</a>, allowing <a href="cope.cgi?key=Stem%20cell%20separation">stem cell separation</a> and re-infusion into patients undergoing, for example, intensive chemotherapy. It may be useful also in the treatment of anemic patients with congenital defects such as <a href="cope.cgi?key=BFU%2dE">BFU-E</a> deficiency. IL3 appears to be of limited benefit in patients who are severely aplastic after autologous bone marrow transplantation and have very low levels of bone marrow <a href="cope.cgi?key=progenitor%20cells">progenitors</a>.</span> </p><p><span style='mso-bidi-font-size:9.0pt; mso-bidi-font-family:"Times New Roman";color:black'>In patients with myelodysplastic syndromes, who frequently present with anemia, leukopenia and thrombocytopenia due to defective maturation of <a href="cope.cgi?key=bone%20marrow%20cells">bone marrow cells</a> initial phase I/II trials with IL3 have demonstrated an increase in the counts of <a href="cope.cgi?key=neutrophils">neutrophils</a> in 59 %, of counts of <a href="cope.cgi?key=platelets">platelets</a> in 34 %, and in counts of <a href="cope.cgi?key=reticulocytes">reticulocytes</a> in 25 % of the patients.</span> </p><p><span style='mso-bidi-font-size:9.0pt; mso-bidi-font-family:"Times New Roman";color:black'>It has been demonstrated that IL3 administered subcutaneously appears to be an interesting <a href="cope.cgi?key=Hematopoietic%20growth%20factors">hematopoietic growth factor</a> (see also: <a href="cope.cgi?key=Hematopoietins">Hematopoietins</a>) for reduction of chemotherapy induced myelotoxicity in patients with advanced ovarian cancer.</span> </p><p><span style='mso-bidi-font-size:9.0pt; mso-bidi-font-family:"Times New Roman";color:black'>IL3 is probably of major importance in the treatment of thrombopenias, secondary hematopoietic insufficiencies and certain types of refractory anemia. The administration of IL3 followed by subsequent course of <a href="cope.cgi?key=IL6">IL6</a> greatly improves <a href="cope.cgi?key=platelets">platelet</a> counts. This combination, therefore, may allow an effective control of thrombocytopenias and severe bleeding frequently associated with this condition.</span> </p><p><span style='mso-bidi-font-size:9.0pt; mso-bidi-font-family:"Times New Roman";color:black'>Some monocytic and <a href="cope.cgi?key=leukemia">myeloid leukemias</a> the growth of which is inhibited almost completely by antibodies directed against IL3 have been described in the <a href="cope.cgi?key=Cytokine%20Inter%2dspecies%20Reactivities">mouse</a> These <a href="cope.cgi?key=leukemia">leukemias</a> are characterized by the overexpression of the IL3 gene. In <a href="cope.cgi?key=Cytokine%20Inter%2dspecies%20Reactivities">humans</a>, however, such cases have not been described to date. A number of malignant myeloid and lymphoid <a href="cope.cgi?key=leukemia">leukemias</a> respond to IL3. In vitro <a href="cope.cgi?key=ALL">ALL</a> <a href="cope.cgi?key=Blast%20cells">blast cells</a> can be made more responsive to cytotoxic drugs such as cytosine arabinoside by treatment with IL3. At present it is unclear whether this also occurs in vivo.</span> </p><p><br/></p>

<h2>IL6</h2><p><span style='mso-bidi-font-size:9.0pt; mso-bidi-font-family:"Times New Roman";color:black'><a href="cope.cgi?key=Interleukin%2d6">Interleukin-6</a>.</span> </p><p><span style='mso-bidi-font-size:9.0pt; mso-bidi-font-family:"Times New Roman";color:black'><br/> <b style="mso-bidi-font-weight:normal">ALTERNATIVE NAMES</b></span> </p><p><b style="mso-bidi-font-weight:normal"><span style='mso-bidi-font-size:9.0pt;mso-bidi-font-family:"Times New Roman"; color:black'><a href="cope.cgi?key=26%20kDa%20protein">26 kDa protein</a></span></b><span style='mso-bidi-font-size:9.0pt; mso-bidi-font-family:"Times New Roman";color:black'>;<br/> <b style="mso-bidi-font-weight:normal"><a href="cope.cgi?key=BCDF">BCDF</a></b> (<a href="cope.cgi?key=B%2dcell%20differentiation%20factors">B-cell differentiation factors</a>);<br/> <b style="mso-bidi-font-weight:normal"><a href="cope.cgi?key=BCSF">BCSF</a></b> (<a href="cope.cgi?key=B%2dcell%20stimulating%20factor">B-cell stimulating factor</a>);<br/> <b style="mso-bidi-font-weight:normal"><a href="cope.cgi?key=BSF%2d2">BSF-2</a></b> (<a href="cope.cgi?key=B%2dcell%20stimulating%20factor%2d2">B-cell stimulating factor-2</a>);<br/> <b style="mso-bidi-font-weight:normal"><a href="cope.cgi?key=BSF%2dp2">BSF-p2</a></b> (<a href="cope.cgi?key=B%2dcell%20stimulating%20factor%20p2">B-cell stimulating factor p2</a>);<br/> <b style="mso-bidi-font-weight:normal"><a href="cope.cgi?key=CDF">CDF</a></b> (<a href="cope.cgi?key=CAT%20development%20factor">CAT development factor</a>, <a href="cope.cgi?key=Choline%20acetyltransferase%20development%20factor">choline acetyltransferase development factor</a>);<br/> <b style="mso-bidi-font-weight:normal"><a href="cope.cgi?key=CDF">CDF</a></b> (<a href="cope.cgi?key=cytolytic%20differentiation%20factor%20for%20T%2dlymphocytes">Cytolytic differentiation factor for T-lymphocytes</a>);<br/> <b style="mso-bidi-font-weight:normal"><a href="cope.cgi?key=CDF">CDF</a></b> (<a href="cope.cgi?key=cytolytic%20T%2dlymphocyte%20differentiation%20factor">Cytolytic T-lymphocyte differentiation factor</a>);<br/> <b style="mso-bidi-font-weight:normal"><a href="cope.cgi?key=CDF">CDF</a></b> (<a href="cope.cgi?key=Cytotoxic%20T%2dcell%20differentiation%20factor">cytotoxic T-cell differentiation factor</a>);<br/> <b style="mso-bidi-font-weight:normal"><a href="cope.cgi?key=CPA">CPA</a></b> (<a href="cope.cgi?key=Colony%20promoting%20activity">colony promoting activity</a>);<br/> <b style="mso-bidi-font-weight:normal"><a href="cope.cgi?key=CSF%2d309">CSF-309</a></b> (<a href="cope.cgi?key=Hematopoietic%20colony%20stimulating%20factor%2d309">Hematopoietic colony stimulating factor-309</a>);<br/> <b style="mso-bidi-font-weight:normal"><a href="cope.cgi?key=DIF">DIF</a></b> (<a href="cope.cgi?key=Differentiation%20inducing%20factor">differentiation inducing factor</a>);<br/> <b style="mso-bidi-font-weight:normal"><a href="cope.cgi?key=Differentiation%20inducing%20factor%20for%20human%20monoblastic%20leukemia%20cells">Differentiation inducing factor for human monoblastic leukemia cells</a></b>;<br/> <b style="mso-bidi-font-weight:normal"><a href="cope.cgi?key=FDGI">FDGI</a></b> (<a href="cope.cgi?key=Fibroblast%2dderived%20growth%20inhibitor">fibroblast-derived growth inhibitor</a>);<br/> <b style="mso-bidi-font-weight:normal"><a href="cope.cgi?key=Fibroblast%20derived%20differentiation%20inducing%20factor%20for%20human%20monoblastic%20leukemia%20cells">Fibroblast derived differentiation inducing factor for human monoblastic leukemia cells</a></b>;<br/> <b style="mso-bidi-font-weight:normal"><a href="cope.cgi?key=FSF">FSF</a> </b>(<a href="cope.cgi?key=Fibronectin%20stimulating%20factor">Fibronectin stimulating factor</a>);<br/> <b style="mso-bidi-font-weight:normal"><a href="cope.cgi?key=HGF">HGF</a></b> (<a href="cope.cgi?key=Hybridoma%20growth%20factor">hybridoma growth factor</a>);<br/> <b style="mso-bidi-font-weight:normal"><a href="cope.cgi?key=HGI">HGI</a></b> (<a href="cope.cgi?key=Hepatocyte%20growth%20inhibitory%20factor">Hepatocyte growth inhibitory factor</a>);<br/> <b style="mso-bidi-font-weight:normal"><a href="cope.cgi?key=HP1">HP1</a></b>;<br/> <b style="mso-bidi-font-weight:normal"><a href="cope.cgi?key=HPGF">HPGF</a></b> (<a href="cope.cgi?key=Hybridoma%2fplasmacytoma%20growth%20factor">hybridoma/plasmacytoma growth factor</a>);<br/> <b style="mso-bidi-font-weight:normal"><a href="cope.cgi?key=HSF">HSF</a></b> (<a href="cope.cgi?key=Hepatocyte%20stimulating%20factor">hepatocyte stimulating factor</a>);<br/> <b style="mso-bidi-font-weight:normal"><a href="cope.cgi?key=HSF%2d1">HSF-1</a></b> (<a href="cope.cgi?key=Hepatocyte%20stimulating%20factor%2d1">hepatocyte stimulating factor-1</a>);<br/> <b style="mso-bidi-font-weight:normal"><a href="cope.cgi?key=IFN%2dbeta%2d2">IFN-beta-2</a></b> (<a href="cope.cgi?key=Interferon%2dbeta%2d2">Interferon-beta-2</a>);<br/> <b style="mso-bidi-font-weight:normal"><a href="cope.cgi?key=ILHP1">ILHP1</a></b> (<a href="cope.cgi?key=Interleukin%2dhemopoietin%2d1">Interleukin-hemopoietin-1</a>);<br/> <b style="mso-bidi-font-weight:normal"><a href="cope.cgi?key=ILHP1">ILHP1</a></b> (<a href="cope.cgi?key=Interleukin%2dhybridoma%2fplasmacytoma%2d1">interleukin-hybridoma/plasmacytoma-1</a>);<br/> <b style="mso-bidi-font-weight:normal"><a href="cope.cgi?key=L%2dGI%20factor">L-GI factor</a></b> (<a href="cope.cgi?key=Cytokine%20Inter%2dspecies%20Reactivities">murine</a> <a href="cope.cgi?key=Lung%2dderived%20growth%20inhibitory%20factor">lung-derived growth inhibitory factor</a>);<br/> <b style="mso-bidi-font-weight:normal"><a href="cope.cgi?key=L%2dHGF">L-HGF</a></b> (<a href="cope.cgi?key=L929%2dderived%20hybridoma%20growth%20factor">L929-derived hybridoma growth factor</a>, see also: <a href="cope.cgi?key=L929">L929</a>);<br/> <b style="mso-bidi-font-weight:normal"><a href="cope.cgi?key=MGI%2d2A">MGI-2A</a></b> (<a href="cope.cgi?key=Macrophage%2dgranulocyte%20inducer%2d2A">Macrophage-granulocyte inducer-2A</a>);<br/> <b style="mso-bidi-font-weight:normal"><a href="cope.cgi?key=Mk%20potentiator">Mk potentiator</a></b>;<br/> <b style="mso-bidi-font-weight:normal"><a href="cope.cgi?key=Myeloma%20GF">Myeloma GF</a></b> (<a href="cope.cgi?key=Myeloma%20growth%20factor">myeloma growth factor</a>);<br/> <b style="mso-bidi-font-weight:normal"><a href="cope.cgi?key=Natural%20killer%20cell%20activity%2daugmenting%20factor">Natural killer cell activity-augmenting factor</a></b><br/> <b style="mso-bidi-font-weight:normal"><a href="cope.cgi?key=NKAF">NKAF</a></b> (<a href="cope.cgi?key=Natural%20killer%20cell%20activating%20factor">natural killer cell activating factor</a>);<br/> <b style="mso-bidi-font-weight:normal"><a href="cope.cgi?key=PCT%2dGF">PCT-GF</a></b> (<a href="cope.cgi?key=Plasmacytoma%20growth%20factor">plasmacytoma growth factor</a>);<br/> <b style="mso-bidi-font-weight:normal"><a href="cope.cgi?key=TAF">TAF</a></b> (<a href="cope.cgi?key=T%2dcell%20activating%20factor">T-cell activating factor</a>);<br/> <b style="mso-bidi-font-weight:normal"><a href="cope.cgi?key=Thymocyte%20growth%20factor">Thymocyte growth factor</a></b>;<br/> <b style="mso-bidi-font-weight:normal"><a href="cope.cgi?key=TPO">TPO</a></b> (<a href="cope.cgi?key=Thrombopoietin">thrombopoietin</a>);<br/> <b style="mso-bidi-font-weight:normal"><a href="cope.cgi?key=TSF">TSF</a></b> (<a href="cope.cgi?key=Thymocyte%20stimulating%20factor">thymocyte stimulating factor</a>);<br/> <b style="mso-bidi-font-weight:normal"><a href="cope.cgi?key=WI%2d26%2dVA4%20factor">WI-26-VA4 factor</a></b>.<br/> See also: individual entries for further information.</span> </p><p><span style='mso-bidi-font-size:9.0pt; mso-bidi-font-family:"Times New Roman";color:black'><br/> <b style="mso-bidi-font-weight:normal">SOURCES</b></span> </p><p><span style='mso-bidi-font-size:9.0pt; mso-bidi-font-family:"Times New Roman";color:black'>IL6 is produced by many different <a href="cope.cgi?key=cell%20types">cell types</a>. The main sources in vivo are stimulated <a href="cope.cgi?key=monocytes">monocytes</a>, <a href="cope.cgi?key=fibroblasts">fibroblasts</a>, and <a href="cope.cgi?key=endothelial%20cells">endothelial cells</a>. <a href="cope.cgi?key=macrophages">Macrophages</a>, <a href="cope.cgi?key=T%2dcells">T-cells</a> and <a href="cope.cgi?key=B%2dlymphocytes">B-lymphocytes</a>, <a href="cope.cgi?key=granulocytes">granulocytes</a>, <a href="cope.cgi?key=smooth%20muscle%20cells">smooth muscle cells</a>, <a href="cope.cgi?key=eosinophils">eosinophils</a>, <a href="cope.cgi?key=chondrocytes">chondrocytes</a>, <a href="cope.cgi?key=osteoblasts">osteoblasts</a>, <a href="cope.cgi?key=mast%20cells">mast cells</a>, <a href="cope.cgi?key=glial%20cells">glial cells</a>, and <a href="cope.cgi?key=keratinocytes">keratinocytes</a> also produce IL6 after stimulation. Glioblastoma <a href="cope.cgi?key=cell%20types">cells</a> constitutively produce IL6 and the factor can be detected also in the cerebrospinal fluid. <a href="cope.cgi?key=Cytokine%20Inter%2dspecies%20Reactivities">Human</a> milk also contains IL6 (see: <a href="cope.cgi?key=MGF">MGF</a>, <a href="cope.cgi?key=Milk%20growth%20factor">milk growth factor</a>).</span> </p><p><span style='mso-bidi-font-size:9.0pt; mso-bidi-font-family:"Times New Roman";color:black'>Cardiac myxomas and cervical and bladder carcinomas secrete large amounts of IL6 into the <a href="cope.cgi?key=conditioned%20medium">conditioned medium</a>. Very high levels of IL6 are also detected in the synovial fluid of patients with rheumatoid arthritis but not with osteoarthritis.</span> </p><p><span style='mso-bidi-font-size:9.0pt; mso-bidi-font-family:"Times New Roman";color:black'>Physiological stimuli for the synthesis of IL6 are <a href="cope.cgi?key=IL1">IL1</a>, <a href="cope.cgi?key=bacterial%20endotoxins">bacterial endotoxins</a>, <a href="cope.cgi?key=TNF">TNF</a>, <a href="cope.cgi?key=PDGF">PDGF</a>, and <a href="cope.cgi?key=Oncostatin%20M">Oncostatin M</a>. In <a href="cope.cgi?key=fibroblasts">fibroblasts</a> the synthesis of IL6 is stimulated by <a href="cope.cgi?key=IFN%2dbeta">IFN-beta</a>, <a href="cope.cgi?key=TNF%2dalpha">TNF-alpha</a>, <a href="cope.cgi?key=PDGF">PDGF</a>, and viral infections. In thymic <a href="cope.cgi?key=stromal%20cells">stromal cells</a> the synthesis of IL6 can be induced by <a href="cope.cgi?key=NGF">NGF</a>. IL6 can also stimulate or inhibits its own synthesis, depending upon the <a href="cope.cgi?key=cell%20types">cell type</a>. For the constitutive production of IL6 see also: <a href="cope.cgi?key=IAP">IAP</a> (<a href="cope.cgi?key=Intracisternal%20A%20particles">intracisternal A particles</a>). In epithelial, endothelial, and <a href="cope.cgi?key=fibroblastic%20cells">fibroblastic cells</a> secretion of IL6 is induced by <a href="cope.cgi?key=IL17">IL17</a>.</span> </p><p><span style='mso-bidi-font-size:9.0pt; mso-bidi-font-family:"Times New Roman";color:black'>IL6 is produced also in the anterior lobe of the pituitary and can be induced by <a href="cope.cgi?key=bacterial%20endotoxins">bacterial endotoxins</a> and all substances elevating intracellular levels of <a href="cope.cgi?key=CAMP">cAMP</a> (prostaglandin <a href="cope.cgi?key=E2">E2</a>, forskolin, cholera toxin). <a href="cope.cgi?key=VIP">VIP</a> (<a href="cope.cgi?key=Vasoactive%20intestinal%20peptide">vasoactive intestinal peptide</a>) also stimulates the synthesis of IL6 in the anterior lobe of the pituitary while <a href="cope.cgi?key=Growth%20hormone%20releasing%20hormone">Growth hormone releasing hormone</a> is inactive. Macrolide antibiotics spiramycin and erythromycin stimulate the synthesis of IL6 in <a href="cope.cgi?key=Cytokine%20Inter%2dspecies%20Reactivities">human</a> <a href="cope.cgi?key=monocytes">monocytes</a> following <a href="cope.cgi?key=Cell%20activation">cell activation</a> by <a href="cope.cgi?key=endotoxins">bacterial lipopolysaccharides</a> but not the synthesis of <a href="cope.cgi?key=IL1">IL1</a> or <a href="cope.cgi?key=TNF%2dalpha">TNF-alpha</a>.</span> </p><p><span style='mso-bidi-font-size:9.0pt; mso-bidi-font-family:"Times New Roman";color:black'>Glucocorticoids inhibit the synthesis of IL6 and <a href="cope.cgi?key=IL4">IL4</a> or <a href="cope.cgi?key=TGF%2dbeta">TGF-beta</a> reduce its synthesis. The synthesis of IL6 by <a href="cope.cgi?key=Cytokine%20Inter%2dspecies%20Reactivities">human</a> alveolar <a href="cope.cgi?key=macrophages">macrophages</a> is inhibited by <a href="cope.cgi?key=IL4">IL4</a>.</span> </p><p><span style='mso-bidi-font-size:9.0pt; mso-bidi-font-family:"Times New Roman";color:black'>In <a href="cope.cgi?key=Cytokine%20Concentrations%20in%20Biological%20Fluids">serum</a> IL6 is complexed with <a href="cope.cgi?key=Alpha%2d2%2dMacroglobulin">Alpha-2-Macroglobulin</a> (Alpha2M) which protects IL6 from cleavage by proteases and possibly functions as a transport protein.</span> </p><p><span style='mso-bidi-font-size:9.0pt; mso-bidi-font-family:"Times New Roman";color:black'>The release of IL6 from isolated <a href="cope.cgi?key=Cytokine%20Inter%2dspecies%20Reactivities">rat</a> <a href="cope.cgi?key=macrophages">macrophages</a> in culture is stimulated by <a href="cope.cgi?key=Histogranin">Histogranin</a>.</span> </p><p><span style='mso-bidi-font-size:9.0pt; mso-bidi-font-family:"Times New Roman";color:black'><br/> <b style="mso-bidi-font-weight:normal">PROTEIN CHARACTERISTICS</b></span> </p><p><span style='mso-bidi-font-size:9.0pt; mso-bidi-font-family:"Times New Roman";color:black'>IL6 is a protein of 185 amino acids glycosylated at positions 73 and 172. It is synthesized as a precursor protein of 212 amino acids. <a href="cope.cgi?key=monocytes">Monocytes</a> express at least five different molecular forms of IL6 with molecular masses of 21.5-28 kDa. They mainly differ by post-translational alterations such as glycosylation and phosphorylation.</span> </p><p><span style='mso-bidi-font-size:9.0pt; mso-bidi-font-family:"Times New Roman";color:black'>IL6 isolated from various <a href="cope.cgi?key=cell%20types">cell types</a> shows some microheterogeneity in its N-terminus. A 42-45 kDa form has been observed in <a href="cope.cgi?key=Cytokine%20Concentrations%20in%20Biological%20Fluids">plasma</a> that is probably complexed with a carrier protein <a href="cope.cgi?key=Alpha%2d2%2dMacroglobulin">Alpha-2-Macroglobulin</a> (Alpha2M) <a href="cope.cgi?key=Cytokine%20Inter%2dspecies%20Reactivities">Murine</a> and <a href="cope.cgi?key=Cytokine%20Inter%2dspecies%20Reactivities">human</a> IL6 show 65 % sequence homology at the DNA level and 42 % homology at the protein level. For a truncated form of IL6 with antagonist activities see: <a href="cope.cgi?key=tIL6">tIL6</a>.</span> </p><p><span style='mso-bidi-font-size:9.0pt; mso-bidi-font-family:"Times New Roman";color:black'>IL6 is a member of a family of <a href="cope.cgi?key=cytokines">cytokines</a>, which also includes <a href="cope.cgi?key=LIF">LIF</a>, <a href="cope.cgi?key=CNTF">CNTF</a>, <a href="cope.cgi?key=Oncostatin%20M">Oncostatin M</a>, <a href="cope.cgi?key=IL11">IL11</a>, and <a href="cope.cgi?key=CT%2d1">CT-1</a>. All known members of the IL6 <a href="cope.cgi?key=Cytokine%20families">cytokine family</a> induce hepatic expression of <a href="cope.cgi?key=Acute%20phase%20proteins">acute phase proteins</a>.</span> </p><p><b style="mso-bidi-font-weight:normal"><span style='mso-bidi-font-size:9.0pt;mso-bidi-font-family:"Times New Roman"; color:black'><a href="cope.cgi?key=IL6%2dDelta%2d4">IL6-Delta-4</a></span></b><span style='mso-bidi-font-size:9.0pt; mso-bidi-font-family:"Times New Roman";color:black'> is an isoform constituting a splice variant of IL6 that lacks exon 4. The protein lacks two amino acids necessary for IL6 homodimerization and two of six amino acids required for interaction with IL6 receptor-beta. This isoform forms a stable complex with IL6 receptor-alpha. <a href="cope.cgi?key=IL6%2dDelta%2d4">IL6-Delta-4</a> may compete with native IL6 for binding to the IL6 receptor-alpha and regulate IL6 bioactivities because of its inability to transmit IL6 receptor-beta-mediated signaling (Bihl et al, 2002).</span> </p><p><span style='mso-bidi-font-size:9.0pt; mso-bidi-font-family:"Times New Roman";color:black'>Fischer et al (1997) have described the construction of a stable and highly bioactive <a href="cope.cgi?key=Designer%20cytokines">designer cytokine</a> (see also: <a href="cope.cgi?key=Muteins">Muteins</a>) consisting of a fusion protein between IL6 and a soluble IL6 receptor. This hybrid, <a href="cope.cgi?key=nomenclature">designated</a> <b style="mso-bidi-font-weight:normal"><a href="cope.cgi?key=H%2dIL6">H-IL6</a> </b>(<b style="mso-bidi-font-weight:normal"><a href="cope.cgi?key=Hyper%2dIL6">Hyper-IL6</a></b>), has been used for the expansion of <a href="cope.cgi?key=Cytokine%20Inter%2dspecies%20Reactivities">human</a> <a href="cope.cgi?key=hematopoietic%20progenitor%20cells">hematopoietic progenitor cells</a> (see also: <a href="cope.cgi?key=Hematopoiesis">hematopoiesis</a>, <a href="cope.cgi?key=hematopoietic%20stem%20cells">hematopoietic stem cells</a>) and is useful in cases in which <a href="cope.cgi?key=cell%20types">cells</a> do not respond to IL6 but require a stable complex consisting of IL6 and a soluble IL6 receptor.</span> </p><p><span style='mso-bidi-font-size:9.0pt; mso-bidi-font-family:"Times New Roman";color:black'>For a <a href="cope.cgi?key=Cytokine%20Inter%2dspecies%20Reactivities">human</a> recombinant fusion protein consisting of IL6 and <a href="cope.cgi?key=IL2">IL2</a> see: <a href="cope.cgi?key=CH925">CH925</a>. For a virus-encoded <a href="cope.cgi?key=homolog">homolog</a> of IL6 see: <a href="cope.cgi?key=viral%20IL6">viral IL6</a>.</span> </p><p><span style='mso-bidi-font-size:9.0pt; mso-bidi-font-family:"Times New Roman";color:black'>For a series of artificial <a href="cope.cgi?key=cytokines">cytokines</a> derived from sequences of <a href="cope.cgi?key=Cytokine%20Inter%2dspecies%20Reactivities">human</a> IL6 and GCSF (<a href="cope.cgi?key=nomenclature">termed</a> <a href="cope.cgi?key=Harlequin%20molecules">Harlequin molecules</a>) see: <a href="cope.cgi?key=Muteins">Muteins</a>.</span> </p><p><span style='mso-bidi-font-size:9.0pt; mso-bidi-font-family:"Times New Roman";color:black'><br/> <b style="mso-bidi-font-weight:normal">GENE STRUCTURE</b></span> </p><p><span style='mso-bidi-font-size:9.0pt; mso-bidi-font-family:"Times New Roman";color:black'>The <a href="cope.cgi?key=Cytokine%20Inter%2dspecies%20Reactivities">human</a> IL6 gene has a length of approximately 5 kb and contains five exons. It maps to <a href="cope.cgi?key=Cytokine%20Inter%2dspecies%20Reactivities">human</a> chromosome 7p21-p14 between the markers D7S135 and D7S370. The <a href="cope.cgi?key=Cytokine%20Inter%2dspecies%20Reactivities">murine</a> gene maps to chromosome 5. The nucleotide sequences of IL6 and <a href="cope.cgi?key=G%2dCSF">G-CSF</a> genes resemble each other in a way suggesting a possible evolutionary relationship.</span> </p><p><span style='mso-bidi-font-size:9.0pt; mso-bidi-font-family:"Times New Roman";color:black'>The IL6 gene promoter contains many different regulatory elements allowing the induction of expression by various stimuli, including glucocorticoids and <a href="cope.cgi?key=CAMP">cAMP</a> (see also: <a href="cope.cgi?key=Gene%20expression">gene expression</a>). The <a href="cope.cgi?key=NF%2dkappa%2dB">NF-kappa-B</a> binding site is responsible in non-lymphoid <a href="cope.cgi?key=cell%20types">cells</a> for the induction of the IL6 <a href="cope.cgi?key=Gene%20expression">gene expression</a> by <a href="cope.cgi?key=IL1">IL1</a> or <a href="cope.cgi?key=TNF">TNF</a>. In <a href="cope.cgi?key=lymphoid%20cells">lymphoid cells</a> a factor related to the rel <a href="cope.cgi?key=Oncogene">oncogene</a> (IL6kB binding factor II) functions as a repressor that prevents the interaction of <a href="cope.cgi?key=Transcription%20factors">transcription factors</a> with the IL6-kappa-B binding site.</span> </p><p><span style='mso-bidi-font-size:9.0pt; mso-bidi-font-family:"Times New Roman";color:black'><br/> <b style="mso-bidi-font-weight:normal">RECEPTORS</b></span> </p><p><span style='mso-bidi-font-size:9.0pt; mso-bidi-font-family:"Times New Roman";color:black'>The IL6 receptor is expressed on <a href="cope.cgi?key=T%2dcells">T-cells</a>, mitogen-activated <a href="cope.cgi?key=B%2dcells">B-cells</a>, peripheral <a href="cope.cgi?key=monocytes">monocytes</a> and some macrophage- and <a href="cope.cgi?key=B%2dcells">B-cell derived</a> tumor <a href="cope.cgi?key=cell%20types">cell types</a>. It is not expressed in resting <a href="cope.cgi?key=B%2dcells">B-cells</a> but in resting <a href="cope.cgi?key=T%2dcells">T-cells</a>. In <a href="cope.cgi?key=hepatocytes">hepatocytes</a> the IL6 receptor expression is enhanced after treatment with IL6 or <a href="cope.cgi?key=IL1">IL1</a>. In several <a href="cope.cgi?key=cell%20types">cell types</a> the expression of the IL6 receptor is also enhanced by glucocorticoids. For the over-expression of the IL6 receptor see also: <a href="cope.cgi?key=IAP">IAP</a> (<a href="cope.cgi?key=Intracisternal%20A%20particles">intracisternal A particles</a>). The IL6 receptor gene maps to <a href="cope.cgi?key=Cytokine%20Inter%2dspecies%20Reactivities">human</a> chromosome 1q21.</span> </p><p><span style='mso-bidi-font-size:9.0pt; mso-bidi-font-family:"Times New Roman";color:black'>The IL6 receptor is a strongly glycosylated protein of 80 kDa and a length of 449 amino acids. It has been <a href="cope.cgi?key=nomenclature">designated</a> <b style="mso-bidi-font-weight:normal"><a href="cope.cgi?key=CD126">CD126</a></b>. It is synthesized as a precursor of 468 amino acids. The molecular structure resembles that of receptors for <a href="cope.cgi?key=M%2dCSF">M-CSF</a>, <a href="cope.cgi?key=PDGF">PDGF</a> and <a href="cope.cgi?key=IL1">IL1</a> in that the receptor contains an immunoglobulin-like sequence <a href="cope.cgi?key=domain">domain</a> in the aminoterminal region of the extracellular receptor <a href="cope.cgi?key=domain">domain</a>.</span> </p><p><span style='mso-bidi-font-size:9.0pt; mso-bidi-font-family:"Times New Roman";color:black'>The intracellular <a href="cope.cgi?key=domain">domain</a> of the IL6 receptor has a length of approximately 82 amino acids and does not show any homology to other proteins involved in intracellular signal transduction.</span> </p><p><span style='mso-bidi-font-size:9.0pt; mso-bidi-font-family:"Times New Roman";color:black'>Two different forms of the receptor have been described that bind IL6 with different affinities (Kdis = 10**-9 and 10**-11 M) and most likely arise by post-translational modification of the same receptor protein.</span> </p><p><span style='mso-bidi-font-size:9.0pt; mso-bidi-font-family:"Times New Roman";color:black'>Biological activities of IL6 have been found also at <a href="cope.cgi?key=Cytokine%20Concentrations%20in%20Biological%20Fluids">concentrations</a> of 10**-13 - 10**-15<sup> </sup>M suggesting either the existence of other high-affinity receptor conformations or the existence of further receptor molecules with higher affinities.</span> </p><p><span style='mso-bidi-font-size:9.0pt; mso-bidi-font-family:"Times New Roman";color:black'>IL6 receptor mediated signal transduction involves protein kinase C and also adenylate cyclase.</span> </p><p><span style='mso-bidi-font-size:9.0pt; mso-bidi-font-family:"Times New Roman";color:black'>The complex formed between IL6 and its receptor associates with a transmembrane glycoprotein, <a href="cope.cgi?key=gp130">gp130</a> (918 amino acids; cytoplasmic <a href="cope.cgi?key=domain">domain</a> of 277 amino acids), that is involved in signal transduction. Binding of IL6 to its receptor leads to disulfide-linked homodimerization of <a href="cope.cgi?key=gp130">gp130</a> and the associated activation of a <a href="cope.cgi?key=PTK">tyrosine kinase</a> as the first step of signal transduction. <a href="cope.cgi?key=gp130">gp130</a> is expressed also in <a href="cope.cgi?key=cell%20types">cells</a> that do not express IL6 receptors. It has been found to be a component of other receptors, including those for <a href="cope.cgi?key=IL11">IL11</a>, <a href="cope.cgi?key=LIF">LIF</a>, <a href="cope.cgi?key=Oncostatin%20M">Oncostatin M</a>, and <a href="cope.cgi?key=CNTF">CNTF</a> (<a href="cope.cgi?key=Ciliary%20neurotrophic%20factor">ciliary neurotrophic factor</a>), and <a href="cope.cgi?key=CT%2d1">CT-1</a>. This explains why <a href="cope.cgi?key=LIF">LIF</a>, <a href="cope.cgi?key=CNTF">CNTF</a> and IL6 share many biological activities although the factors themselves are not related to each other. A factor resembling <a href="cope.cgi?key=STAT%20proteins">STAT proteins</a>, <a href="cope.cgi?key=nomenclature">termed</a> <a href="cope.cgi?key=LIL%20factor">LIL factor</a>, has been found to be involved in signaling pathways of IL6, and also of <a href="cope.cgi?key=IL1">IL1</a> and <a href="cope.cgi?key=endotoxins">bacterial lipopolysaccharides</a>.</span> </p><p><span style='mso-bidi-font-size:9.0pt; mso-bidi-font-family:"Times New Roman";color:black'>A soluble form of the IL6 receptor (see: <a href="cope.cgi?key=IL6R%2dSUP">IL6R-SUP</a>; <a href="cope.cgi?key=IL6%20receptor%20soluble%20urinary%20protein">IL6 receptor soluble urinary protein</a>) has been described also that also interacts with <a href="cope.cgi?key=gp130">gp130</a>. These soluble receptors probably function as physiological regulators of <a href="cope.cgi?key=cytokines">cytokine</a> activities (see also: <a href="cope.cgi?key=Cytokine%20inhibitors">Cytokine inhibitors</a>) by inhibiting receptor binding or act as transport proteins. Similar soluble receptors or binding proteins have been described also for <a href="cope.cgi?key=IL1">IL1</a> (see: <a href="cope.cgi?key=IL1ra">IL1ra</a>, <a href="cope.cgi?key=IL1%20receptor%20antagonist">IL1 receptor antagonist</a>), <a href="cope.cgi?key=IL2">IL2</a>, <a href="cope.cgi?key=IL4">IL4</a>, <a href="cope.cgi?key=IL7">IL7</a>, <a href="cope.cgi?key=TNF%2dalpha">TNF-alpha</a>, <a href="cope.cgi?key=IGF">IGF</a>, and <a href="cope.cgi?key=IFN%2dgamma">IFN-gamma</a>.</span> </p><p><span style='mso-bidi-font-size:9.0pt; mso-bidi-font-family:"Times New Roman";color:black'>Some <a href="cope.cgi?key=cell%20types">cells</a>, including <a href="cope.cgi?key=hematopoietic%20progenitor%20cells">hematopoietic progenitor cells</a> and <a href="cope.cgi?key=neuronal%20cells">neuronal cells</a>, are only responsive towards a combination of IL6 and soluble IL6 receptor but not to IL6 alone.</span> </p><p><span style='mso-bidi-font-size:9.0pt; mso-bidi-font-family:"Times New Roman";color:black'><br/> <b style="mso-bidi-font-weight:normal">BIOLOGICAL ACTIVITIES</b></span> </p><p><span style='mso-bidi-font-size:9.0pt; mso-bidi-font-family:"Times New Roman";color:black'><a href="cope.cgi?key=Cytokine%20Inter%2dspecies%20Reactivities">Human</a> IL6 is biologically active in <a href="cope.cgi?key=Cytokine%20Inter%2dspecies%20Reactivities">monkeys</a>, <a href="cope.cgi?key=Cytokine%20Inter%2dspecies%20Reactivities">rats</a>, and <a href="cope.cgi?key=Cytokine%20Inter%2dspecies%20Reactivities">mice</a>. <a href="cope.cgi?key=Cytokine%20Inter%2dspecies%20Reactivities">Murine</a> IL6 is not active in <a href="cope.cgi?key=Cytokine%20Inter%2dspecies%20Reactivities">human</a> <a href="cope.cgi?key=cell%20types">cells</a>.</span> </p><p><span style='mso-bidi-font-size:9.0pt; mso-bidi-font-family:"Times New Roman";color:black'>The plethora of biological activities is exemplified by the many different acronyms under which IL6 has been described. IL6 is a pleiotropic <a href="cope.cgi?key=cytokines">cytokine</a> influencing antigen-specific immune responses and <a href="cope.cgi?key=inflammation">inflammatory reactions</a>. It is one of the major physiological mediators of <a href="cope.cgi?key=Acute%20phase%20reaction">acute phase reaction</a>.</span> </p><p><span style='mso-bidi-font-size:9.0pt; mso-bidi-font-family:"Times New Roman";color:black'>In <a href="cope.cgi?key=hepatocytes">hepatocytes</a> IL6 in combination with glucocorticoids induces the synthesis of metallothioneins and increases intracellular zinc levels, thus preventing CCL<sub>4</sub> induced hepatotoxicity.</span> </p><p><span style='mso-bidi-font-size:9.0pt; mso-bidi-font-family:"Times New Roman";color:black'>IL6 is a that promotes survival of cholinergic <a href="cope.cgi?key=neurons">neurons</a> in culture (see also: <a href="cope.cgi?key=Neurotrophic%20factors">neurotrophic factors</a>). Some <a href="cope.cgi?key=neuronal%20cells">neuronal cell</a> lines can be induced to differentiate by IL6. For other <a href="cope.cgi?key=Neurotrophic%20factors">neurotrophic factors</a> see also: <a href="cope.cgi?key=Neurotrophins">Neurotrophins</a>.</span> </p><p><span style='mso-bidi-font-size:9.0pt; mso-bidi-font-family:"Times New Roman";color:black'>IL6, like <a href="cope.cgi?key=IL1">IL1</a>, stimulates the synthesis of <a href="cope.cgi?key=ACTH">ACTH</a> (<a href="cope.cgi?key=Corticotropin">Corticotropin</a>) in the pituitary. Glucocorticoids synthesized in response to <a href="cope.cgi?key=ACTH">ACTH</a> inhibit the production of IL6, <a href="cope.cgi?key=IL1">IL1</a> and <a href="cope.cgi?key=TNF">TNF</a> in vivo, thus establishing a sort of negative feedback loop between the immune system and neuroendocrine functions. In <a href="cope.cgi?key=astrocytes">astrocytes</a> IL6 induces the synthesis of <a href="cope.cgi?key=NGF">NGF</a>.</span> </p><p><span style='mso-bidi-font-size:9.0pt; mso-bidi-font-family:"Times New Roman";color:black'>IL6 is a <a href="cope.cgi?key=B%2dcell%20differentiation%20factor">B-cell differentiation factor</a> in vivo and in vitro (see also: <a href="cope.cgi?key=BCDF">BCDF</a>) and an activation factor for <a href="cope.cgi?key=T%2dcells">T-cells</a> (see also: <a href="cope.cgi?key=Cell%20activation">cell activation</a>). In the presence of <a href="cope.cgi?key=IL2">IL2</a> IL6 induces the <a href="cope.cgi?key=differentiation">differentiation</a> of mature and immature <a href="cope.cgi?key=T%2dcells">T-cells</a> into <a href="cope.cgi?key=cytotoxic%20T%2dcells">cytotoxic T-cells</a>. IL6 also induces the proliferation of <a href="cope.cgi?key=thymocytes">thymocytes</a> and probably plays a role in the development of thymic <a href="cope.cgi?key=T%2dcells">T-cells</a>.</span> </p><p><span style='mso-bidi-font-size:9.0pt; mso-bidi-font-family:"Times New Roman";color:black'>IL6 is capable of inducing the final maturation of <a href="cope.cgi?key=B%2dcells">B-cells</a> into immunoglobulin-secreting <a href="cope.cgi?key=plasma%20cells">plasma cells</a> if the <a href="cope.cgi?key=cell%20types">cells</a> have been pre-activated by <a href="cope.cgi?key=IL4">IL4</a>. In <a href="cope.cgi?key=B%2dcells">B-cells</a> IL6 stimulates the secretion of antibodies to such a degree that <a href="cope.cgi?key=Cytokine%20Concentrations%20in%20Biological%20Fluids">serum</a> IgG1 levels can rise 120-400-fold.</span> </p><p><span style='mso-bidi-font-size:9.0pt; mso-bidi-font-family:"Times New Roman";color:black'>IL6 at <a href="cope.cgi?key=Cytokine%20Concentrations%20in%20Biological%20Fluids">concentrations</a> of only 0.002 ng/mL is one of the major <a href="cope.cgi?key=Autocrine">autocrine</a> growth modulator for many <a href="cope.cgi?key=Cytokine%20Inter%2dspecies%20Reactivities">human</a> myelomas. The growth of these <a href="cope.cgi?key=cell%20types">cells</a> can be inhibited by monoclonal antibodies directed against IL6. It can be inhibited also by the introduction of <a href="cope.cgi?key=Antisense">antisense RNA</a> against IL6 or by <a href="cope.cgi?key=IL4">IL4</a>. The growth-inhibitory effects of corticosteroids on myeloma <a href="cope.cgi?key=cell%20types">cells</a> is probably due to the steroid induced reduction in the expression of <a href="cope.cgi?key=IL5">IL5</a>. The growth of <a href="cope.cgi?key=Cytokine%20Inter%2dspecies%20Reactivities">human</a> IL6 dependent myeloma <a href="cope.cgi?key=cell%20types">cells</a> (see also: <a href="cope.cgi?key=Factor%2ddependent%20cell%20lines">Factor-dependent cell lines</a>) can be inhibited also by <a href="cope.cgi?key=IFN%2dgamma">IFN-gamma</a>. IL6 may function also as an <a href="cope.cgi?key=Autocrine">autocrine</a> growth modulator for other tumor types, some of which have been found to secrete IL6 constitutively. IL6 has been shown to be an <a href="cope.cgi?key=Autocrine">autocrine</a> modulator of growth for in vitro cervical tumor cell growth. On the other hand IL6 blocks the growth of some solid tumors such as mammary carcinomas, cervical carcinomas, <a href="cope.cgi?key=Cytokine%20Inter%2dspecies%20Reactivities">human</a> lung cancer <a href="cope.cgi?key=Cell%20lines%20in%20Cytokine%20Research">cell lines</a>, <a href="cope.cgi?key=histiocytes">histiocytic</a> <a href="cope.cgi?key=Lymphoma">lymphomas</a>, and <a href="cope.cgi?key=melanoma%20cells">melanomas</a>. The growth-inhibitory effects are probably compensated by an IL6 induced reduction in cell-to-cell interactions, which also promotes increased metastasizing potential.</span> </p><p><span style='mso-bidi-font-size:9.0pt; mso-bidi-font-family:"Times New Roman";color:black'>IL6 has been found to be expressed in <a href="cope.cgi?key=Cytokine%20Inter%2dspecies%20Reactivities">murine</a> <a href="cope.cgi?key=blastocyst">blastocysts</a> before hematopoietic <a href="cope.cgi?key=differentiation">differentiation</a> <a href="cope.cgi?key=Hematopoietic%20growth%20factors">hematopoietic growth factor</a>. This suggests that IL6 also regulates the growth and development of <a href="cope.cgi?key=trophoblasts">trophoblasts</a> or <a href="cope.cgi?key=embryonic%20stem%20cells">embryonic stem cells</a>.</span> </p><p><span style='mso-bidi-font-size:9.0pt; mso-bidi-font-family:"Times New Roman";color:black'>IL6 and <a href="cope.cgi?key=IL3">IL3</a> synergise in vitro in promoting the proliferation of multipotent <a href="cope.cgi?key=hematopoietic%20progenitor%20cells">hematopoietic progenitor cells</a>. IL6 is also a <a href="cope.cgi?key=Thrombopoietin">thrombopoietin</a> that induces the maturation of <a href="cope.cgi?key=megakaryocytes">megakaryocytes</a> in vitro and increases <a href="cope.cgi?key=platelets">platelet</a> counts in vivo. In <a href="cope.cgi?key=Cytokine%20Inter%2dspecies%20Reactivities">murine</a>, but not in <a href="cope.cgi?key=Cytokine%20Inter%2dspecies%20Reactivities">human</a> <a href="cope.cgi?key=bone%20marrow%20culture">bone marrow cultures</a> (see also: <a href="cope.cgi?key=BMC">BMC</a>, <a href="cope.cgi?key=bone%20marrow%20culture">bone marrow culture</a>) IL6 shows activities resembling those of <a href="cope.cgi?key=GM%2dCSF">GM-CSF</a>.</span> </p><p><span style='mso-bidi-font-size:9.0pt; mso-bidi-font-family:"Times New Roman";color:black'><a href="cope.cgi?key=plasmacytoma">Plasmacytoma</a> <a href="cope.cgi?key=cell%20types">cells</a> produce IL6 and also the IL6 receptor. It has been suggested that these <a href="cope.cgi?key=cell%20types">cells</a> are stimulated in an <a href="cope.cgi?key=Autocrine">autocrine</a> fashion. A <a href="cope.cgi?key=Paracrine">paracrine</a> mechanism involving the presence of two different cell populations, one producing the factor and the other expressing the receptor, has been described also.</span> </p><p><span style='mso-bidi-font-size:9.0pt; mso-bidi-font-family:"Times New Roman";color:black'><br/> <b style="mso-bidi-font-weight:normal">TRANSGENIC ANIMALS, KNOCK-OUT, AND ANTISENSE STUDIES</b></span> </p><p><span style='mso-bidi-font-size:9.0pt; mso-bidi-font-family:"Times New Roman";color:black'>The consequences of a deregulated expression of IL6 have been evaluated in <a href="cope.cgi?key=transgenic">transgenic</a> <a href="cope.cgi?key=Cytokine%20Inter%2dspecies%20Reactivities">mice</a> expressing the <a href="cope.cgi?key=Cytokine%20Inter%2dspecies%20Reactivities">human</a> IL6 gene. These animals display dramatically elevated <a href="cope.cgi?key=Cytokine%20Concentrations%20in%20Biological%20Fluids">serum</a> levels of IL6 and polyclonal IgG1. In addition one observes a massive plasmacytosis and all typical indications of a proliferative mesangial glomerulonephritis, which is probably due to the excessive overproduction of the <a href="cope.cgi?key=cytokines">cytokine</a>.</span> </p><p><span style='mso-bidi-font-size:9.0pt; mso-bidi-font-family:"Times New Roman";color:black'><a href="cope.cgi?key=transgenic">Transgenic</a> <a href="cope.cgi?key=Cytokine%20Inter%2dspecies%20Reactivities">mice</a> expressing the IL6 gene under the control of the <a href="cope.cgi?key=Cytokine%20Inter%2dspecies%20Reactivities">human</a> keratin gene promoter express IL6 in <a href="cope.cgi?key=squamous%20epithelial%20cells">squamous epithelial cells</a>. These <a href="cope.cgi?key=Cytokine%20Inter%2dspecies%20Reactivities">mice</a> are much smaller than normal <a href="cope.cgi?key=Cytokine%20Inter%2dspecies%20Reactivities">mice</a> and they also show a retarded development of the coat. An increased proliferation of epidermal <a href="cope.cgi?key=cell%20types">cells</a> and an infiltration of <a href="cope.cgi?key=leukocytes">leukocytes</a> are not observed. Other <a href="cope.cgi?key=transgenic">transgenic</a> <a href="cope.cgi?key=Cytokine%20Inter%2dspecies%20Reactivities">mice</a> constitutively expressing <a href="cope.cgi?key=Cytokine%20Inter%2dspecies%20Reactivities">murine</a> IL6 at a level sufficient to induce IL6-responsive genes show less <a href="cope.cgi?key=immature%20B%2dcells">immature B-cells</a> in bone marrow and expression of IL6-inducible liver genes, but the <a href="cope.cgi?key=Cytokine%20Inter%2dspecies%20Reactivities">mice</a> appear healthy and can easily be used for breeding. A high incidence of <a href="cope.cgi?key=Lymphoma">lymphomas</a> associated with different tissues is observed only in <a href="cope.cgi?key=Cytokine%20Inter%2dspecies%20Reactivities">mice</a> older than 18 months.</span> </p><p><span style='mso-bidi-font-size:9.0pt; mso-bidi-font-family:"Times New Roman";color:black'>Intracerebral overexpression of IL6 in <a href="cope.cgi?key=transgenic">transgenic</a> <a href="cope.cgi?key=Cytokine%20Inter%2dspecies%20Reactivities">mice</a> has been shown to be associated with neurological syndromes the severity of which correlate with the levels of IL6 expression. These <a href="cope.cgi?key=Cytokine%20Inter%2dspecies%20Reactivities">mice</a> are characterized by runting, tremor, neurodegeneration, astrocytosis, <a href="cope.cgi?key=Angiogenesis">angiogenesis</a>, and induction of <a href="cope.cgi?key=Acute%20phase%20proteins">acute phase proteins</a> production, suggesting a direct pathogenic role of IL6 in <a href="cope.cgi?key=inflammation">inflammatory</a>, infectious, and neurodegenerative CNS diseases.</span> </p><p><span style='mso-bidi-font-size:9.0pt; mso-bidi-font-family:"Times New Roman";color:black'>Brett et al (1995) have used a <a href="cope.cgi?key=transgenic">transgenic</a> <a href="cope.cgi?key=Cytokine%20Inter%2dspecies%20Reactivities">mouse</a> model to express IL6 in brain <a href="cope.cgi?key=astrocytes">astrocytes</a>. They demonstrate an extensive break down of the blood brain barrier. Depending upon expression levels and age the animals show a leptomeningeal <a href="cope.cgi?key=inflammation">inflammatory</a> infiltrate, vacuolated <a href="cope.cgi?key=astrocytes">astrocytic</a> foot processes and endothelial abnormalities, parenchymal <a href="cope.cgi?key=inflammation">inflammation</a>, gliosis, spongiform change, axonal degeneration and <a href="cope.cgi?key=macrophages">macrophage</a> accumulation.</span> </p><p><span style='mso-bidi-font-size:9.0pt; mso-bidi-font-family:"Times New Roman";color:black'>Kitamura et al (1995) have produced <a href="cope.cgi?key=transgenic">transgenic</a> <a href="cope.cgi?key=Cytokine%20Inter%2dspecies%20Reactivities">mice</a> expressing <a href="cope.cgi?key=Cytokine%20Inter%2dspecies%20Reactivities">human</a> IL6. The animals showed histologically evident neutrophilia in the bone marrow. A <a href="cope.cgi?key=Colony%20formation%20assay">Colony formation assay</a> of <a href="cope.cgi?key=bone%20marrow%20cells">bone marrow cells</a> for <a href="cope.cgi?key=CFU%2dC">CFU-C</a> revealed increases in precursors of <a href="cope.cgi?key=granulocytes">granulocytes</a> and <a href="cope.cgi?key=monocytes">monocytes</a> (see also: <a href="cope.cgi?key=Hematopoiesis">hematopoiesis</a>). A decrease in <a href="cope.cgi?key=osteoblasts">osteoblast</a> <a href="cope.cgi?key=precursor%20cells">precursor cells</a> was observed in 15 week old <a href="cope.cgi?key=Cytokine%20Inter%2dspecies%20Reactivities">mice</a>. <a href="cope.cgi?key=osteoclasts">Osteoclast</a> numbers and bone resorption were also decreased.</span> </p><p><span style='mso-bidi-font-size:9.0pt; mso-bidi-font-family:"Times New Roman";color:black'>The biological activities of IL6 have been studied also in IL6 deficient <a href="cope.cgi?key=Cytokine%20Inter%2dspecies%20Reactivities">mice</a> generated by <a href="cope.cgi?key=Targeted%20disruption">targeted disruption</a> of the IL6 gene in <a href="cope.cgi?key=embryonic%20stem%20cells">embryonic stem cells</a> (see: <a href="cope.cgi?key=ES%20cells">ES cells</a>). IL6 deficient <a href="cope.cgi?key=Cytokine%20Inter%2dspecies%20Reactivities">mice</a> of both sexes are viable and fertile and do not present any evident phenotypic abnormality. However, analysis of bone metabolism in females demonstrates that these animals have higher rates of bone turnover than control litter mates. In these <a href="cope.cgi?key=Cytokine%20Inter%2dspecies%20Reactivities">mice</a>, ovariectomy, which is known to result in increased bone turnover with bone resorption exceeding bone formation in normal animals, does not induce any change in either bone mass or bone remodeling rates. These results suggest that IL6 plays an important role in the local regulation of bone turnover and appears to be essential for bone loss caused by estrogen deficiency.</span> </p><p><span style='mso-bidi-font-size:9.0pt; mso-bidi-font-family:"Times New Roman";color:black'>The biological consequences of an IL6 <a href="cope.cgi?key=Knock%2dout">gene disruption</a> have been studied in <a href="cope.cgi?key=Cytokine%20Inter%2dspecies%20Reactivities">mice</a> generated from <a href="cope.cgi?key=ES%20cells">ES cells</a> carrying a <a href="cope.cgi?key=Targeted%20deletion">targeted deletion</a> of the gene. <a href="cope.cgi?key=Cytokine%20Inter%2dspecies%20Reactivities">Mice</a> homozygous for a <a href="cope.cgi?key=Targeted%20disruption">targeted disruption</a> of the IL6 gene develop normally. The development of bone marrow and spleen <a href="cope.cgi?key=B%2dcells">B-cells</a> in IL6 deficient <a href="cope.cgi?key=Cytokine%20Inter%2dspecies%20Reactivities">mice</a> appears to be normal. Numbers of <a href="cope.cgi?key=thymocytes">thymocytes</a> and peripheral <a href="cope.cgi?key=T%2dcells">T-cells</a> are consistently reduced by 20-40 % as compared to controls, suggesting that IL6 is involved in <a href="cope.cgi?key=T%2dcells">T-cell</a> proliferation. <a href="cope.cgi?key=thymocytes">Thymocytes</a> and <a href="cope.cgi?key=T%2dcells">T-cells</a> show a normal expression pattern of <a href="cope.cgi?key=T%2dcells">T-cell</a> receptor alpha, beta, gamma, and <a href="cope.cgi?key=Delta">delta</a> chains, <a href="cope.cgi?key=CD4">CD4</a>, <a href="cope.cgi?key=CD8">CD8</a>, and some other markers.</span> </p><p><span style='mso-bidi-font-size:9.0pt; mso-bidi-font-family:"Times New Roman";color:black'>IL6 deficient <a href="cope.cgi?key=Cytokine%20Inter%2dspecies%20Reactivities">mice</a> fail to control efficiently vaccinia virus and infection with Listeria monocytogenes. The <a href="cope.cgi?key=T%2dcells">T-cell</a> dependent antibody response against vesicular stomatitis virus is impaired. IL6 deficient <a href="cope.cgi?key=Cytokine%20Inter%2dspecies%20Reactivities">mice</a> also show gross abnormalities with respect to the <a href="cope.cgi?key=Acute%20phase%20reaction">acute phase reaction</a> in response to tissue damage or infection (see also: <a href="cope.cgi?key=inflammation">inflammation</a>, <a href="cope.cgi?key=Wound%20healing">wound healing</a>). This response, however, is only moderately affected after challenge with <a href="cope.cgi?key=endotoxins">bacterial lipopolysaccharides</a>.</span> </p><p><span style='mso-bidi-font-size:9.0pt; mso-bidi-font-family:"Times New Roman";color:black'><br/> <b style="mso-bidi-font-weight:normal">DETECTION AND ASSAY METHODS</b></span> </p><p><span style='mso-bidi-font-size:9.0pt; mso-bidi-font-family:"Times New Roman";color:black'>IL6 can be detected in <a href="cope.cgi?key=bioassays">bioassays</a> employing IL6 responsive <a href="cope.cgi?key=Cell%20lines%20in%20Cytokine%20Research">cell lines</a> (see: <a href="cope.cgi?key=7TD1">7TD1</a>; <a href="cope.cgi?key=B9">B9</a>; <a href="cope.cgi?key=CESS">CESS</a>, <a href="cope.cgi?key=KPMM2">KPMM2</a>, <a href="cope.cgi?key=KT%2d3">KT-3</a>; <a href="cope.cgi?key=M1">M1</a>, <a href="cope.cgi?key=MH60%2dBSF%2d2">MH60-BSF-2</a>, <a href="cope.cgi?key=MO7E">MO7E</a>; <a href="cope.cgi?key=Mono%20Mac%206">Mono Mac 6</a>; <a href="cope.cgi?key=NFS%2d60">NFS-60</a>; <a href="cope.cgi?key=PIL%2d6">PIL-6</a>; <a href="cope.cgi?key=SKW6%2dCl4">SKW6-Cl4</a>;<b style="mso-bidi-font-weight:normal"> </b><a href="cope.cgi?key=T1165">T1165</a>; <a href="cope.cgi?key=XG%2d1">XG-1</a>). IL6 can be assayed also by its activity as a <a href="cope.cgi?key=Hybridoma%20growth%20factor">hybridoma growth factor</a> (see: <a href="cope.cgi?key=HGF">HGF</a>).</span> </p><p><span style='mso-bidi-font-size:9.0pt; mso-bidi-font-family:"Times New Roman";color:black'>Sensitive <a href="cope.cgi?key=Immunoassays">immunoassays</a> and colorimetric tests are also available. An alternative and entirely different detection method is <a href="cope.cgi?key=RT%2dPCR%20quantitation%20of%20cytokines">RT-PCR quantitation of cytokines</a>. An <a href="cope.cgi?key=ELISA">ELISA</a> assay exists for detecting the receptor-associated <a href="cope.cgi?key=gp130">gp130</a> protein. For further information see also subentry "Assays" in the reference section. For further information on assays for <a href="cope.cgi?key=cytokines">cytokines</a> see also: <a href="cope.cgi?key=bioassays">bioassays</a>, <a href="cope.cgi?key=Cytokine%20assays">cytokine assays</a>.</span> </p><p><span style='mso-bidi-font-size:9.0pt; mso-bidi-font-family:"Times New Roman";color:black'><br/> <b style="mso-bidi-font-weight:normal">CLINICAL USE AND SIGNIFICANCE</b></span> </p><p><span style='mso-bidi-font-size:9.0pt; mso-bidi-font-family:"Times New Roman";color:black'>The determination of IL6 <a href="cope.cgi?key=Cytokine%20Concentrations%20in%20Biological%20Fluids">serum</a> levels may be useful to monitor the activity of myelomas and to calculate tumor cell masses. Low IL6 <a href="cope.cgi?key=Cytokine%20Concentrations%20in%20Biological%20Fluids">serum</a> levels are observed in monoclonal gammopathies and in smouldering myelomas while IL6 <a href="cope.cgi?key=Cytokine%20Concentrations%20in%20Biological%20Fluids">serum</a> levels are markedly increased in patients with progressive disease and also in patients with <a href="cope.cgi?key=plasma%20cells">plasma cell</a> <a href="cope.cgi?key=leukemia">leukemia</a>. A blockade of the IL6 receptor or the inhibition of IL6 by monoclonal antibodies may be a way to delay or prevent the maturation of <a href="cope.cgi?key=B%2dcells">B-cells</a> into <a href="cope.cgi?key=plasma%20cells">plasma cells</a>, suggesting also a new therapeutical concept involving cytostatic drugs coupled to monoclonal antibodies.</span> </p><p><span style='mso-bidi-font-size:9.0pt; mso-bidi-font-family:"Times New Roman";color:black'>The deregulated expression of IL6 is probably one of the major factor involved in the pathogenesis of a number of diseases. The excessive overproduction of IL6 (and other <a href="cope.cgi?key=B%2dcell%20differentiation%20factors">B-cell differentiation factors</a>; see also: <a href="cope.cgi?key=BCDF">BCDF</a>) has been observed in various pathological conditions such as rheumatoid arthritis, <a href="cope.cgi?key=multiple%20myeloma%20cells">multiple myeloma</a>, Lennert syndrome (<a href="cope.cgi?key=histiocytes">histiocytic</a> <a href="cope.cgi?key=Lymphoma">lymphoma</a>), Castleman's disease (lymphadenopathy with massive infiltration of <a href="cope.cgi?key=plasma%20cells">plasma cells</a>, hyper gamma-globulinemia, anemia, and enhanced <a href="cope.cgi?key=Cytokine%20Concentrations%20in%20Biological%20Fluids">concentrations</a> of <a href="cope.cgi?key=Acute%20phase%20proteins">acute phase proteins</a>), cardiac myxomas and liver cirrhosis. The constitutive synthesis of IL6 by glioblastomas and the secretion of IL6 into the cerebrospinal fluid may explain the elevated levels of <a href="cope.cgi?key=Acute%20phase%20proteins">acute phase proteins</a> and immune complexes in the <a href="cope.cgi?key=Cytokine%20Concentrations%20in%20Biological%20Fluids">serum</a>.</span> </p><p><span style='mso-bidi-font-size:9.0pt; mso-bidi-font-family:"Times New Roman";color:black'>IL6 probably also plays a role in the pathogenesis of chronic polyarthritis (together with <a href="cope.cgi?key=IL1">IL1</a> and <a href="cope.cgi?key=IL8">IL8</a>) since excessive <a href="cope.cgi?key=Cytokine%20Concentrations%20in%20Biological%20Fluids">concentrations</a> of IL6 are found in the synovial fluid.</span> </p><p><span style='mso-bidi-font-size:9.0pt; mso-bidi-font-family:"Times New Roman";color:black'>It has been suggested that IL6, due to its effects on <a href="cope.cgi?key=hematopoietic%20cells">hematopoietic cells</a>, may be suitable for the treatment of certain types of anemia and thrombocytopenia. Pretreatment with <a href="cope.cgi?key=IL3">IL3</a> and subsequent administration of IL6 has been shown to increase <a href="cope.cgi?key=platelets">platelet</a> counts considerable. A combination of these two factors could therefore be valuable for the effective control of thromocytopenias and the very severe complications (excessive bleeding) usually associated with this condition. In combination with other <a href="cope.cgi?key=cytokines">cytokines</a> (for example, <a href="cope.cgi?key=IL2">IL2</a>) IL6 may be useful in the treatment of some tumor types.</span> </p><p><span style='mso-bidi-font-size:9.0pt; mso-bidi-font-family:"Times New Roman";color:black'>Very high levels of IL6 in the cerebrospinal fluid are observed frequently in bacterial (up to 500 ng/mL) and viral meningitis (10 - 1000 ng/mL). The detection of elevated <a href="cope.cgi?key=Cytokine%20Concentrations%20in%20Biological%20Fluids">concentrations</a> of IL6 in the <a href="cope.cgi?key=Cytokine%20Concentrations%20in%20Biological%20Fluids">urine</a> of transplanted patients may be an early indicator of a graft-versus-host reaction. The detection of IL6 in the amniotic fluid may be an indication of intra-amniotic infections. In <a href="cope.cgi?key=inflammation">inflammatory</a> intestinal diseases elevated <a href="cope.cgi?key=Cytokine%20Concentrations%20in%20Biological%20Fluids">plasma</a> levels of IL6 may be an indicator of disease status. In patients with mesangioproliferative glomerulonephritis elevated <a href="cope.cgi?key=Cytokine%20Concentrations%20in%20Biological%20Fluids">urine</a> levels of IL6 are also an indicator of disease status.</span> </p><p><span style='mso-bidi-font-size:9.0pt; mso-bidi-font-family:"Times New Roman";color:black'>Monitoring of postoperative <a href="cope.cgi?key=Cytokine%20Concentrations%20in%20Biological%20Fluids">serum</a> IL6 levels may be more helpful than monitoring of <a href="cope.cgi?key=C%2dreactive%20protein">C-reactive protein</a> levels for estimation of <a href="cope.cgi?key=inflammation">inflammatory</a> status and early detection of an <a href="cope.cgi?key=Acute%20phase%20reaction">acute phase reaction</a>.</span> </p><p><span style='mso-bidi-font-size:9.0pt; mso-bidi-font-family:"Times New Roman";color:black'>The transduction of <a href="cope.cgi?key=Cytokine%20Inter%2dspecies%20Reactivities">murine</a> tumor <a href="cope.cgi?key=cell%20types">cells</a> with a functional IL6 gene has been shown to lead to the rejection of the genetically modified <a href="cope.cgi?key=cell%20types">cells</a> by syngeneic hosts. Altered tumor <a href="cope.cgi?key=cell%20types">cells</a> expressing <a href="cope.cgi?key=IL4">IL4</a> also increase systemic immunity. <a href="cope.cgi?key=Cytokine%20Inter%2dspecies%20Reactivities">Mice</a> vaccinated with transduced <a href="cope.cgi?key=cell%20types">cells</a> reject a subsequent challenge of non-transduced <a href="cope.cgi?key=cell%20types">cells</a>, and, in some cases, a pre-existing tumor (for <a href="cope.cgi?key=Vaccination%20against%20cancer">cancer vaccines</a> see also: <a href="cope.cgi?key=Cytokine%20gene%20transfer">Cytokine gene transfer</a>).</span> </p><p><span style='mso-bidi-font-size:9.0pt; mso-bidi-font-family:"Times New Roman";color:black'><a href="cope.cgi?key=Cytokine%20Concentrations%20in%20Biological%20Fluids">Serum</a> and urinary IL6 levels have been shown to be predicting factors of Kawasaki disease activity.</span> </p><p><br/></p>

<h2>IL8</h2><p><span style='mso-bidi-font-size:9.0pt; mso-bidi-font-family:"Times New Roman";color:black'><a href="cope.cgi?key=Interleukin%2d8">Interleukin-8</a>.</span> </p><p><span style='mso-bidi-font-size:9.0pt; mso-bidi-font-family:"Times New Roman";color:black'><br/> <b style="mso-bidi-font-weight:normal">ALTERNATIVE NAMES</b></span> </p><p><b style="mso-bidi-font-weight:normal"><span style='mso-bidi-font-size:9.0pt;mso-bidi-font-family:"Times New Roman"; color:black'><a href="cope.cgi?key=3%2d10C">3-10C</a></span></b><span style='mso-bidi-font-size:9.0pt;mso-bidi-font-family: "Times New Roman";color:black'>;<br/> <b style="mso-bidi-font-weight:normal"><a href="cope.cgi?key=9E3">9E3</a></b><br/> <b style="mso-bidi-font-weight:normal"><a href="cope.cgi?key=AIF">AIF</a> </b>[<a href="cope.cgi?key=HL%2d60%2dderived%20apoptosis%20inducing%20factor">HL-60-derived apoptosis inducing factor</a>]<br/> <b style="mso-bidi-font-weight:normal"><a href="cope.cgi?key=AMCF%2d1">AMCF-1</a></b> [<a href="cope.cgi?key=alveolar%20macrophage%20chemotactic%20factor%2d1">Alveolar macrophage chemotactic factor-1</a>]<br/> <b style="mso-bidi-font-weight:normal"><a href="cope.cgi?key=ANAP">ANAP</a></b> (<a href="cope.cgi?key=anionic%20neutrophil%2dactivating%20peptide">anionic neutrophil-activating peptide</a>);<br/> <b style="mso-bidi-font-weight:normal"><a href="cope.cgi?key=chemotaxin">Chemotaxin</a></b><br/> <b style="mso-bidi-font-weight:normal"><a href="cope.cgi?key=CEF%2d4">CEF-4</a></b><br/> <b style="mso-bidi-font-weight:normal"><a href="cope.cgi?key=CT%2fIL8">CT/IL8</a></b><br/> <b style="mso-bidi-font-weight:normal"><a href="cope.cgi?key=CXCL8">CXCL8</a></b><br/> <b style="mso-bidi-font-weight:normal"><a href="cope.cgi?key=EDNAP">EDNAP</a></b> (<a href="cope.cgi?key=Endothelial%2dderived%20neutrophil%2dactivating%20peptide">endothelial-derived neutrophil-activating peptide</a>);<br/> <b style="mso-bidi-font-weight:normal"><a href="cope.cgi?key=EMF%2d1">EMF-1</a></b> [<a href="cope.cgi?key=embryo%20fibroblast%20protein%201">embryo fibroblast protein 1</a>]<br/> <b style="mso-bidi-font-weight:normal"><a href="cope.cgi?key=Emoctakin">Emoctakin</a></b><br/> <b style="mso-bidi-font-weight:normal"><a href="cope.cgi?key=ENAP">ENAP</a></b> (<a href="cope.cgi?key=Endothelial%20cell%20neutrophil%2dactivating%20peptide">Endothelial cell neutrophil-activating peptide</a>);<br/> <b style="mso-bidi-font-weight:normal"><a href="cope.cgi?key=FDNAP">FDNAP</a></b> (<a href="cope.cgi?key=Fibroblast%2dderived%20neutrophil%2dactivating%20peptide">Fibroblast-derived neutrophil-activating peptide</a>);<br/> <b style="mso-bidi-font-weight:normal"><a href="cope.cgi?key=FINAP">FINAP</a></b> (<a href="cope.cgi?key=Fibroblast%2dderived%20neutrophil%2dactivating%20protein">fibroblast-derived neutrophil-activating protein</a>);<br/> <b style="mso-bidi-font-weight:normal"><a href="cope.cgi?key=GCF">GCF</a></b> (<a href="cope.cgi?key=Granulocyte%20chemotactic%20factor">granulocyte chemotactic factor</a>);<br/> <b style="mso-bidi-font-weight:normal"><a href="cope.cgi?key=GCP">GCP</a></b> (<a href="cope.cgi?key=Granulocyte%20chemotactic%20peptide">granulocyte chemotactic peptide</a>);<br/> <b style="mso-bidi-font-weight:normal"><a href="cope.cgi?key=LAI">LAI</a></b> (<a href="cope.cgi?key=Leukocyte%20adhesion%20inhibitor">leukocyte adhesion inhibitor</a>);<br/> <b style="mso-bidi-font-weight:normal"><a href="cope.cgi?key=LCF">LCF</a></b> (<a href="cope.cgi?key=Lymphocyte%20chemotactic%20factors">lymphocyte chemotactic factors</a>);<br/> <b style="mso-bidi-font-weight:normal"><a href="cope.cgi?key=LDNAP">LDNAP</a></b> (<a href="cope.cgi?key=Leukocyte%2dderived%20neutrophil%2dactivating%20peptide">leukocyte-derived neutrophil-activating peptide</a>);<br/> <b style="mso-bidi-font-weight:normal"><a href="cope.cgi?key=LIF">LIF</a></b> (<a href="cope.cgi?key=Leukocyte%20inhibitory%20factor">leukocyte inhibitory factor</a>);<br/> <b style="mso-bidi-font-weight:normal"><a href="cope.cgi?key=LUCT">LUCT</a></b> [<a href="cope.cgi?key=Lung%20carcinoma%2dderived%20chemotaxin">lung carcinoma-derived chemotaxin</a>]<br/> <b style="mso-bidi-font-weight:normal"><a href="cope.cgi?key=LYNAP">LYNAP</a></b> (<a href="cope.cgi?key=Lymphocyte%2dderived%20neutrophil%2dactivating%20peptide">lymphocyte-derived neutrophil-activating peptide</a>);<br/> <b style="mso-bidi-font-weight:normal"><a href="cope.cgi?key=MDNAP">MDNAP</a></b> (<a href="cope.cgi?key=Monocyte%2dderived%20neutrophil%2dactivating%20peptide">monocyte-derived neutrophil-activating peptide</a>);<br/> <b style="mso-bidi-font-weight:normal"><a href="cope.cgi?key=MDNCF">MDNCF</a></b> (<a href="cope.cgi?key=Monocyte%2dderived%20neutrophil%20chemotactic%20factor">monocyte-derived neutrophil chemotactic factor</a>);<br/> <b style="mso-bidi-font-weight:normal"><a href="cope.cgi?key=MOC">MOC</a></b> (<a href="cope.cgi?key=Monocyte%2dderived%20chemotaxin">monocyte-derived chemotaxin</a>);<br/> <b style="mso-bidi-font-weight:normal"><a href="cope.cgi?key=MONAP">MONAP</a></b> (<a href="cope.cgi?key=Monocyte%2dderived%20neutrophil%2dactivating%20peptide">monocyte-derived neutrophil-activating peptide</a>);<br/> <b style="mso-bidi-font-weight:normal"><a href="cope.cgi?key=NAF">NAF</a></b> (<a href="cope.cgi?key=Neutrophil%2dactivating%20factor">neutrophil-activating factor</a>);<br/> <b style="mso-bidi-font-weight:normal"><a href="cope.cgi?key=NAP%2d1">NAP-1</a></b> (<a href="cope.cgi?key=Neutrophil%2dactivating%20protein%2d1">neutrophil-activating protein-1</a>);<br/> <b style="mso-bidi-font-weight:normal"><a href="cope.cgi?key=NCF">NCF</a></b> (<a href="cope.cgi?key=Neutrophil%20chemotactic%20factor">neutrophil chemotactic factor</a>);<br/> <b style="mso-bidi-font-weight:normal"><a href="cope.cgi?key=NCP">NCP</a></b> (<a href="cope.cgi?key=Neutrophil%20chemotactic%20protein">neutrophil chemotactic protein</a>);<br/> <b style="mso-bidi-font-weight:normal"><a href="cope.cgi?key=PLF">PLF</a></b> (<a href="cope.cgi?key=Psoriatic%20leukotactic%20factor">psoriatic leukotactic factor</a>);<br/> <b style="mso-bidi-font-weight:normal"><a href="cope.cgi?key=TCF">TCF</a></b> (<a href="cope.cgi?key=T%2dcell%20chemotactic%20factor">T-cell chemotactic factor</a>);<br/> <b style="mso-bidi-font-weight:normal"><a href="cope.cgi?key=TSG%2d1">TSG-1</a></b> (<a href="cope.cgi?key=Tumor%20necrosis%20factor%2dstimulated%20gene%20sequences">Tumor necrosis factor-stimulated gene sequences</a>; see: <a href="cope.cgi?key=TSG%20genes">TSG genes</a>).<br/> See also: individual entries for further information.</span> </p><p><span style='mso-bidi-font-size:9.0pt; mso-bidi-font-family:"Times New Roman";color:black'><br/> <b style="mso-bidi-font-weight:normal">SOURCES</b></span> </p><p><span style='mso-bidi-font-size:9.0pt; mso-bidi-font-family:"Times New Roman";color:black'>IL8 is produced by stimulated <a href="cope.cgi?key=monocytes">monocytes</a> but not by <a href="cope.cgi?key=tissue%20macrophages">tissue macrophages</a> and <a href="cope.cgi?key=T%2dlymphocytes">T-lymphocytes</a>. IL8 is produced also by <a href="cope.cgi?key=macrophages">macrophages</a>, <a href="cope.cgi?key=fibroblasts">fibroblasts</a>, <a href="cope.cgi?key=endothelial%20cells">endothelial cells</a>, <a href="cope.cgi?key=keratinocytes">keratinocytes</a>, <a href="cope.cgi?key=melanocytes">melanocytes</a>, <a href="cope.cgi?key=hepatocytes">hepatocytes</a>, <a href="cope.cgi?key=chondrocytes">chondrocytes</a>, and a number of tumor <a href="cope.cgi?key=Cell%20lines%20in%20Cytokine%20Research">cell lines</a>.</span> </p><p><span style='mso-bidi-font-size:9.0pt; mso-bidi-font-family:"Times New Roman";color:black'>In many <a href="cope.cgi?key=cell%20types">cell types</a> the synthesis of IL8 is strongly stimulated by <a href="cope.cgi?key=IL1">IL1</a> and <a href="cope.cgi?key=TNF%2dalpha">TNF-alpha</a>. In <a href="cope.cgi?key=Cytokine%20Inter%2dspecies%20Reactivities">human</a> skin <a href="cope.cgi?key=fibroblasts">fibroblasts</a> the expression of IL8 is enhanced by <a href="cope.cgi?key=Leukoregulin">Leukoregulin</a>. The <a href="cope.cgi?key=Interferons">interferon</a> <a href="cope.cgi?key=IFN%2dgamma">IFN-gamma</a> can function as a <a href="cope.cgi?key=Costimulator">costimulator</a>. The synthesis of IL8 is induced also by phytohemagglutinins, concanavalin A, double-stranded RNA, <a href="cope.cgi?key=Phorbol%20esters">Phorbol esters</a>, sodium urate crystals, viruses, and <a href="cope.cgi?key=endotoxins">bacterial lipopolysaccharides</a>. The expression of IL8 from resting and stimulated <a href="cope.cgi?key=Cytokine%20Inter%2dspecies%20Reactivities">human</a> blood <a href="cope.cgi?key=monocytes">monocytes</a> is upregulated by <a href="cope.cgi?key=IL7">IL7</a>. In <a href="cope.cgi?key=chondrocytes">chondrocytes</a> the synthesis of IL8 is stimulated by <a href="cope.cgi?key=IL1%2dbeta">IL1-beta</a> (see: <a href="cope.cgi?key=IL1">IL1</a>), <a href="cope.cgi?key=TNF%2dalpha">TNF-alpha</a> and <a href="cope.cgi?key=endotoxins">bacterial lipopolysaccharides</a>. In <a href="cope.cgi?key=Cytokine%20Inter%2dspecies%20Reactivities">human</a> <a href="cope.cgi?key=astrocytes">astrocytes</a> the synthesis and secretion of IL8 is induced by <a href="cope.cgi?key=IL1">IL1</a> and <a href="cope.cgi?key=TNF%2dalpha">TNF-alpha</a>. Glucocorticoids, <a href="cope.cgi?key=IL4">IL4</a>, <a href="cope.cgi?key=TGF%2dbeta">TGF-beta</a>, inhibitors of 5' lipoxygenase, and 1,25(OH)<sub>2</sub> vitamin D<sub>3</sub> inhibit the synthesis of IL8. IL8 is constitutively and commonly produced by various carcinoma <a href="cope.cgi?key=Cell%20lines%20in%20Cytokine%20Research">cell lines</a> and this synthesis may be related to the elevation of <a href="cope.cgi?key=Cytokine%20Concentrations%20in%20Biological%20Fluids">serum</a> IL8 in patients with <a href="cope.cgi?key=hepatocellular%20carcinoma">hepatocellular carcinoma</a>. In epithelial, endothelial, and <a href="cope.cgi?key=fibroblastic%20cells">fibroblastic cells</a> secretion of IL8 is induced by <a href="cope.cgi?key=IL17">IL17</a>.</span> </p><p><span style='mso-bidi-font-size:9.0pt; mso-bidi-font-family:"Times New Roman";color:black'><br/> <b style="mso-bidi-font-weight:normal">PROTEIN CHARACTERISTICS</b></span> </p><p><span style='mso-bidi-font-size:9.0pt; mso-bidi-font-family:"Times New Roman";color:black'>IL8 is a non-glycosylated protein of 8 kDa (72 amino acids). It is produced by processing of a precursor protein of 99 amino acids. Processing of this precursor by specific proteases yields N-terminal variants of IL8. One of the enzymes converting the 77 amino acid form to the 72 amino acid form has been identified as <a href="cope.cgi?key=cathepsin%20L">cathepsin L</a> (see: <a href="cope.cgi?key=IL8%20converting%20enzyme">IL8 converting enzyme</a>).</span> </p><p><b style="mso-bidi-font-weight:normal"><span style='mso-bidi-font-size:9.0pt;mso-bidi-font-family:"Times New Roman"; color:black'><a href="cope.cgi?key=AVLPR%2dIL8">AVLPR-IL8</a></span></b><span style='mso-bidi-font-size:9.0pt; mso-bidi-font-family:"Times New Roman";color:black'> is a truncated IL8 variant lacking the first five amino acids. This shortened protein is identical with <a href="cope.cgi?key=FDNCF">FDNCF</a> (<a href="cope.cgi?key=Fibroblast%2dderived%20neutrophil%20chemotactic%20factor">fibroblast-derived neutrophil chemotactic factor</a>).</span> </p><p><span style='mso-bidi-font-size:9.0pt; mso-bidi-font-family:"Times New Roman";color:black'>Longer forms of IL8 (79 and 77 amino acids) and shorter forms (69 amino acids) have been isolated also from <a href="cope.cgi?key=conditioned%20medium">conditioned medium</a> of <a href="cope.cgi?key=lymphocytes">lymphocytes</a> stimulated with <a href="cope.cgi?key=endotoxins">bacterial lipopolysaccharides</a> (see: <a href="cope.cgi?key=MDNCF">MDNCF</a>, <a href="cope.cgi?key=monocytes">monocyte-derived</a> <a href="cope.cgi?key=neutrophils">neutrophil</a> <a href="cope.cgi?key=chemotaxis">chemotactic</a> factors and <a href="cope.cgi?key=FINAP">FINAP</a>, <a href="cope.cgi?key=Fibroblast%2dderived%20neutrophil%2dactivating%20protein">Fibroblast-derived neutrophil-activating protein</a>), <a href="cope.cgi?key=fibroblasts">Fibroblasts</a> stimulated by <a href="cope.cgi?key=IL1">IL1</a> or <a href="cope.cgi?key=TNF">TNF</a> (see: <a href="cope.cgi?key=NAP%2d1">NAP-1</a>, neutrophil-activating protein), and polyI: C-stimulated <a href="cope.cgi?key=endothelial%20cells">endothelial cells</a> (see: <a href="cope.cgi?key=LAI">LAI</a>, <a href="cope.cgi?key=Leukocyte%20adhesion%20inhibitor">leukocyte adhesion inhibitor</a>). The predominant form of IL8 produced by <a href="cope.cgi?key=endothelial%20cells">endothelial cells</a> (and also by <a href="cope.cgi?key=Anchorage%2ddependent%20cells">anchorage-dependent cells</a> and <a href="cope.cgi?key=Cytokine%20Inter%2dspecies%20Reactivities">human</a> glioblastoma <a href="cope.cgi?key=cell%20types">cells</a>) is the 77 amino acid variant. For an <a href="cope.cgi?key=endothelial%20cells">endothelial cell-derived</a> IL8 variant ([(Ala)-IL8](77)) serving as an <a href="cope.cgi?key=Apoptosis%20inducing%20factor">apoptosis inducing factor</a> see also: <a href="cope.cgi?key=HL%2d60">HL-60</a> <a href="cope.cgi?key=Cell%20lines%20in%20Cytokine%20Research">cell line</a>.</span> </p><p><span style='mso-bidi-font-size:9.0pt; mso-bidi-font-family:"Times New Roman";color:black'>The IL8 protein contains four cysteine residues participating in disulfide bridges (Cys-7/Cys-34; Cys-9/Cys-50).</span> </p><p><span style='mso-bidi-font-size:9.0pt; mso-bidi-font-family:"Times New Roman";color:black'>A Leu25Tyr mutation of IL8, which introduces the conserved tyrosine residue present in <a href="cope.cgi?key=CC%2dChemokines">CC-Chemokines</a> has been shown to create a factor that bestows upon IL8 the property to act as a <a href="cope.cgi?key=chemoattractants">chemoattractant</a> for <a href="cope.cgi?key=monocytes">monocytes</a> and the ability to bind to the <a href="cope.cgi?key=CCR1">CCR1</a> <a href="cope.cgi?key=Chemokines">chemokine</a> receptor. A Leu25Cys mutation of IL8 introduces <a href="cope.cgi?key=chemoattractants">chemoattractant</a> activity for <a href="cope.cgi?key=monocytes">monocytes</a> and the ability to displace <a href="cope.cgi?key=MIP%2d1%2dalpha">MIP-1-alpha</a> from the <a href="cope.cgi?key=CCR1">CCR1</a> receptor.</span> </p><p><span style='mso-bidi-font-size:9.0pt; mso-bidi-font-family:"Times New Roman";color:black'><br/> <b style="mso-bidi-font-weight:normal">GENE STRUCTURE</b></span> </p><p><span style='mso-bidi-font-size:9.0pt; mso-bidi-font-family:"Times New Roman";color:black'>The <a href="cope.cgi?key=Cytokine%20Inter%2dspecies%20Reactivities">human</a> IL8 gene (<a href="cope.cgi?key=SCYB8">SCYB8</a>) has a length of 5.1 kb and contains four exons. It maps to <a href="cope.cgi?key=Cytokine%20Inter%2dspecies%20Reactivities">human</a> chromosome 4q12-q21. The mRNA consists of a 101 base 5' untranslated region, an <a href="cope.cgi?key=orf">open reading frame</a> of 297 bases, and a long 3' untranslated region of 1.2 kb. The 5' flanking region of the IL8 gene contains potential binding sites for several <a href="cope.cgi?key=Nuclear%20factors">nuclear factors</a> including activation <a href="cope.cgi?key=Factor%2d1">factor-1</a>, activation <a href="cope.cgi?key=Factor%2d2">factor-2</a>, <a href="cope.cgi?key=IFN">IFN</a> regulatory <a href="cope.cgi?key=Factor%2d1">factor-1</a>, <a href="cope.cgi?key=hepatocytes">hepatocyte</a> nuclear <a href="cope.cgi?key=Factor%2d1">factor-1</a>, a glucocorticoid <a href="cope.cgi?key=response%20elements">responsive element</a>, and a heat <a href="cope.cgi?key=shock">shock</a> element.</span> </p><p><span style='mso-bidi-font-size:9.0pt; mso-bidi-font-family:"Times New Roman";color:black'><br/> <b style="mso-bidi-font-weight:normal">RELATED FACTORS</b></span> </p><p><span style='mso-bidi-font-size:9.0pt; mso-bidi-font-family:"Times New Roman";color:black'>The proteins <a href="cope.cgi?key=mig">mig</a> (<a href="cope.cgi?key=Monokine%20induced%20by%20gamma%2dInterferon">monokine induced by gamma-Interferon</a>) (see also: <a href="cope.cgi?key=Monokines">Monokines</a>), <a href="cope.cgi?key=PF4">PF4</a> (<a href="cope.cgi?key=Platelet%20factor%2d4">platelet factor-4</a>), <a href="cope.cgi?key=MGSA">MGSA</a> (<a href="cope.cgi?key=Melanoma%20growth%20stimulatory%20activity">melanoma growth stimulatory activity</a>), and a number of several other factors belonging to the family of <a href="cope.cgi?key=chemotactic%20cytokines">chemotactic cytokines</a> known as <a href="cope.cgi?key=Chemokines">Chemokines</a> are related to IL8.</span> </p><p><span style='mso-bidi-font-size:9.0pt; mso-bidi-font-family:"Times New Roman";color:black'><br/> <b style="mso-bidi-font-weight:normal">RECEPTORS</b></span> </p><p><span style='mso-bidi-font-size:9.0pt; mso-bidi-font-family:"Times New Roman";color:black'>The IL8 receptor is a dimeric glycoprotein consisting of a 59 kDa and a 67 kDa subunit. It has been given the <a href="cope.cgi?key=nomenclature">name</a> <b style="mso-bidi-font-weight:normal"><a href="cope.cgi?key=CD128">CD128</a></b>. It is expressed in many different <a href="cope.cgi?key=cell%20types">cell types</a> including those not responding to IL8. The receptor density is approximately 20000/cell in <a href="cope.cgi?key=neutrophils">neutrophils</a> and approximately 300/cell in <a href="cope.cgi?key=T%2dlymphocytes">T-lymphocytes</a>.</span> </p><p><span style='mso-bidi-font-size:9.0pt; mso-bidi-font-family:"Times New Roman";color:black'>The IL8 receptor is a member of a <a href="cope.cgi?key=G%2dprotein%2dcoupled%20receptors">G-protein-coupled receptor</a> <a href="cope.cgi?key=protein%20family">protein family</a> (see also: <a href="cope.cgi?key=GPR9">GPR9</a>). There are at least two different IL8 receptor types. The type 1 receptor specifically binds IL8 (Kd = 0.8-4 nM). The type 2 receptor (Kd for IL8 = 0.3-2 nM) also binds the IL8-related factors <a href="cope.cgi?key=MGSA">MGSA</a> (<a href="cope.cgi?key=Melanoma%20growth%20stimulatory%20activity">Melanoma growth stimulatory activity</a>), <a href="cope.cgi?key=GRO">GRO</a> (see: <a href="cope.cgi?key=MGSA">MGSA</a>), <a href="cope.cgi?key=MIP%2d2">MIP-2</a> (see: <a href="cope.cgi?key=MIP">MIP</a>, <a href="cope.cgi?key=Macrophage%20inflammatory%20protein">macrophage inflammatory protein</a>), and <a href="cope.cgi?key=NAP%2d2">NAP-2</a> (<a href="cope.cgi?key=Neutrophil%2dactivating%20protein%2d2">neutrophil-activating protein-2</a>). Both receptor genes <a href="cope.cgi?key=Map">map</a> to <a href="cope.cgi?key=Cytokine%20Inter%2dspecies%20Reactivities">human</a> chromosome 2q35. For a protein highly <a href="cope.cgi?key=homolog">homologous</a> to the IL8 receptors see: <a href="cope.cgi?key=EBI%2d1">EBI-1</a> (<a href="cope.cgi?key=EBV%20induced%20gene%2d1">EBV induced gene-1</a>) and <a href="cope.cgi?key=ECRF%2d3">ECRF-3</a>. The MGSA/GRO/IL8/MIP receptor has been identified as <a href="cope.cgi?key=CKR1">CKR1</a>, which is identical with the <a href="cope.cgi?key=Duffy%20blood%20group%20antigens">Duffy blood group antigen</a> that appears to be a receptor for the malarial parasite Plasmodium vivax.</span> </p><p><span style='mso-bidi-font-size:9.0pt; mso-bidi-font-family:"Times New Roman";color:black'><a href="cope.cgi?key=orf74">orf74</a> encoded by the <a href="cope.cgi?key=Kaposi%20sarcoma%2dassociated%20herpesvirus">Kaposi sarcoma-associated herpesvirus</a> <a href="cope.cgi?key=KSHV">KSHV</a> has been shown to encode a protein with significant sequence homology to the high-affinity IL8 receptor (see also: <a href="cope.cgi?key=Viroceptor">Viroceptor</a>). IL8 has been shown to bind to the virus-encoded <a href="cope.cgi?key=Viroceptor">viroceptor</a> <a href="cope.cgi?key=M3">M3</a>.</span> </p><p><span style='mso-bidi-font-size:9.0pt; mso-bidi-font-family:"Times New Roman";color:black'><br/> <b style="mso-bidi-font-weight:normal">BIOLOGICAL ACTIVITIES</b></span> </p><p><span style='mso-bidi-font-size:9.0pt; mso-bidi-font-family:"Times New Roman";color:black'>The activities of IL8 are not <a href="cope.cgi?key=Cytokine%20Inter%2dspecies%20Reactivities">species-specific</a>. <a href="cope.cgi?key=Cytokine%20Inter%2dspecies%20Reactivities">Human</a> IL8 is also active in <a href="cope.cgi?key=Cytokine%20Inter%2dspecies%20Reactivities">rodent</a> and <a href="cope.cgi?key=Cytokine%20Inter%2dspecies%20Reactivities">rabbit</a> <a href="cope.cgi?key=cell%20types">cells</a>. The biological activities of IL8 resemble those of a related protein, <a href="cope.cgi?key=NAP%2d2">NAP-2</a> (<a href="cope.cgi?key=Neutrophil%2dactivating%20protein%2d2">neutrophil-activating protein-2</a>).</span> </p><p><span style='mso-bidi-font-size:9.0pt; mso-bidi-font-family:"Times New Roman";color:black'>IL8 differs from all other <a href="cope.cgi?key=cytokines">cytokines</a> in its ability to specifically activate <a href="cope.cgi?key=neutrophils">neutrophil</a> <a href="cope.cgi?key=granulocytes">granulocytes</a>. In <a href="cope.cgi?key=neutrophils">neutrophils</a> IL8 causes a transient increase in cytosolic calcium levels (see also: <a href="cope.cgi?key=Calcium%20ionophore">Calcium ionophore</a>) and the release of enzymes from granules. IL8 also enhances the metabolism of reactive oxygen <a href="cope.cgi?key=Cytokine%20Inter%2dspecies%20Reactivities">species</a> and increases <a href="cope.cgi?key=chemotaxis">Chemotaxis</a> and the enhanced expression of adhesion molecules. A pre-activation by <a href="cope.cgi?key=IL3">IL3</a> is required to render <a href="cope.cgi?key=basophils">basophils</a> and <a href="cope.cgi?key=neutrophils">neutrophils</a> susceptible to further activation by IL8. IL8 alone does not release histamines. IL8 actually inhibits histamine release from <a href="cope.cgi?key=Cytokine%20Inter%2dspecies%20Reactivities">human</a> <a href="cope.cgi?key=basophils">basophils</a> induced by <a href="cope.cgi?key=Histamine%20releasing%20factors">histamine releasing factors</a> (see also: <a href="cope.cgi?key=HRF">HRF</a>), <a href="cope.cgi?key=CTAP%2d3">CTAP-3</a> (<a href="cope.cgi?key=Connective%20tissue%20activating%20protein%2d3">connective tissue activating protein-3</a>), and <a href="cope.cgi?key=IL3">IL3</a>. IL8 is involved also in mediating pain.</span> </p><p><span style='mso-bidi-font-size:9.0pt; mso-bidi-font-family:"Times New Roman";color:black'>IL8 antagonizes IgE production by <a href="cope.cgi?key=Cytokine%20Inter%2dspecies%20Reactivities">human</a> <a href="cope.cgi?key=B%2dcells">B-cells</a> without induced by <a href="cope.cgi?key=IL4">IL4</a>, affecting IgM, IgG1, IgG2, IgG3, IgG4, or IgA production. IL8 directly affects <a href="cope.cgi?key=B%2dcells">B-cells</a> through a specific mechanism that is different from <a href="cope.cgi?key=IFN%2dgamma">IFN-gamma</a>, <a href="cope.cgi?key=IFN%2dalpha">IFN-alpha</a>, or prostaglandin <a href="cope.cgi?key=E2">E2</a></span> </p><p><span style='mso-bidi-font-size:9.0pt; mso-bidi-font-family:"Times New Roman";color:black'>The intravenous administration of IL8 in baboons causes a severe, albeit transient, granulocytopenia, followed by a granulocytosis, which persists as long as sufficient IL8 levels are maintained.</span> </p><p><span style='mso-bidi-font-size:9.0pt; mso-bidi-font-family:"Times New Roman";color:black'>IL8 is <a href="cope.cgi?key=chemotaxis">chemotactic</a> for all known types of migratory <a href="cope.cgi?key=immune%20cells">immune cells</a> (see also: <a href="cope.cgi?key=chemotaxis">Chemotaxis</a>). IL8 inhibits the adhesion of <a href="cope.cgi?key=leukocytes">leukocytes</a> to activated <a href="cope.cgi?key=endothelial%20cells">endothelial cells</a> (see also: <a href="cope.cgi?key=Cell%20activation">cell activation</a>) and therefore possesses <a href="cope.cgi?key=inflammation">anti-inflammatory</a> activities (see also: <a href="cope.cgi?key=LAI">LAI</a>, <a href="cope.cgi?key=Leukocyte%20adhesion%20inhibitor">leukocyte adhesion inhibitor</a>). The 72 amino acid form of IL8 is approximately ten-fold more potent in inhibiting adhesion of <a href="cope.cgi?key=neutrophils">neutrophils</a> than the 77 amino acid variant. IL8 is a <a href="cope.cgi?key=Cell%20cycle">mitogen</a> for epidermal <a href="cope.cgi?key=cell%20types">cells</a>. In vivo IL8 strongly binds to <a href="cope.cgi?key=erythrocytes">erythrocytes</a>. This absorption may be of physiological importance in the regulation of <a href="cope.cgi?key=inflammation">inflammatory reactions</a> since IL8 bound to <a href="cope.cgi?key=erythrocytes">erythrocytes</a> no longer activates <a href="cope.cgi?key=neutrophils">neutrophils</a>. <a href="cope.cgi?key=macrophages">Macrophage-derived</a> IL8 supports <a href="cope.cgi?key=Angiogenesis">angiogenesis</a> and may play a role in disorders such as rheumatoid arthritis, tumor growth, and <a href="cope.cgi?key=Wound%20healing">wound healing</a> that critically depend on <a href="cope.cgi?key=Angiogenesis">angiogenesis</a>.</span> </p><p><span style='mso-bidi-font-size:9.0pt; mso-bidi-font-family:"Times New Roman";color:black'>Binding of IL8 to its receptor and bioactivities of IL8 are inhibited by a synthetic peptide, <a href="cope.cgi?key=Antileukinate">antileukinate</a>.</span> </p><p><span style='mso-bidi-font-size:9.0pt; mso-bidi-font-family:"Times New Roman";color:black'><br/> <b style="mso-bidi-font-weight:normal">TRANSGENIC ANIMALS, KNOCK-OUT, AND ANTISENSE STUDIES</b></span> </p><p><span style='mso-bidi-font-size:9.0pt; mso-bidi-font-family:"Times New Roman";color:black'>Blockade of IL8 expression in some <a href="cope.cgi?key=Cytokine%20Inter%2dspecies%20Reactivities">human</a> <a href="cope.cgi?key=melanoma%20cells">melanoma cell</a> lines by <a href="cope.cgi?key=Antisense">antisense RNA</a> has shown that IL8 functions as an <a href="cope.cgi?key=Autocrine">autocrine</a> growth modulator for these <a href="cope.cgi?key=cell%20types">cells</a>. A participation of IL8 in <a href="cope.cgi?key=macrophages">macrophage</a> mediated <a href="cope.cgi?key=Angiogenesis">angiogenesis</a> is suggested by the observation that IL8 <a href="cope.cgi?key=Antisense">antisense RNA</a> blocks <a href="cope.cgi?key=angiogenesis%20factors">angiogenic activity</a> induced by <a href="cope.cgi?key=monocytes">monocytes</a>.</span> </p><p><span style='mso-bidi-font-size:9.0pt; mso-bidi-font-family:"Times New Roman";color:black'>Simonet et al (1994) have studied <a href="cope.cgi?key=transgenic">transgenic</a> <a href="cope.cgi?key=Cytokine%20Inter%2dspecies%20Reactivities">mice</a> overexpressing IL8. Elevated <a href="cope.cgi?key=Cytokine%20Concentrations%20in%20Biological%20Fluids">serum</a> IL8 levels were found to correlate with increases in circulating <a href="cope.cgi?key=neutrophils">neutrophils</a> and decreases in <a href="cope.cgi?key=L%2dselectin">L-selectin</a> expression on the surface of blood <a href="cope.cgi?key=neutrophils">neutrophils</a>. Changes in the expression of the <a href="cope.cgi?key=integrin%2dbeta%2d2">integrin-beta-2</a> integrins <a href="cope.cgi?key=Mac%2d1">Mac-1</a> (<a href="cope.cgi?key=CD11b">CD11b</a>) and <a href="cope.cgi?key=LFA%2d1">LFA-1</a> (<a href="cope.cgi?key=CD11a">CD11a</a>) on peripheral blood neutrophilswere not observed. Expression of <a href="cope.cgi?key=L%2dselectin">L-selectin</a> on bone marrow <a href="cope.cgi?key=neutrophils">neutrophils</a> and their precursors was normal. The accumulation of <a href="cope.cgi?key=neutrophils">neutrophils</a> was observed in the microcirculation of the lung, liver and spleen. <a href="cope.cgi?key=neutrophils">Neutrophil</a> extravasation, <a href="cope.cgi?key=Cytokine%20Concentrations%20in%20Biological%20Fluids">plasma</a> exudation or tissue damage were absent. Migration of <a href="cope.cgi?key=neutrophils">neutrophils</a> into the inflamed peritoneal cavity was severely inhibited.</span> </p><p><span style='mso-bidi-font-size:9.0pt; mso-bidi-font-family:"Times New Roman";color:black'><br/> <b style="mso-bidi-font-weight:normal">DETECTION AND ASSAY METHODS</b></span> </p><p><span style='mso-bidi-font-size:9.0pt; mso-bidi-font-family:"Times New Roman";color:black'>IL8 can be detected in assays measuring the migration of <a href="cope.cgi?key=buffy">buffy</a> coat <a href="cope.cgi?key=leukocytes">leukocytes</a> from agarose blocks. Sensitive <a href="cope.cgi?key=Immunoassays">immunoassays</a> are also available. For further information see also subentry "Assays" in the reference section. For further information on assays for <a href="cope.cgi?key=cytokines">cytokines</a> see also: <a href="cope.cgi?key=bioassays">bioassays</a>, <a href="cope.cgi?key=Cytokine%20assays">cytokine assays</a>.</span> </p><p><span style='mso-bidi-font-size:9.0pt; mso-bidi-font-family:"Times New Roman";color:black'><br/> <b style="mso-bidi-font-weight:normal">CLINICAL USE AND SIGNIFICANCE</b></span> </p><p><span style='mso-bidi-font-size:9.0pt; mso-bidi-font-family:"Times New Roman";color:black'>IL8 may be of clinical relevance in psoriasis and rheumatoid arthritis. Elevated <a href="cope.cgi?key=Cytokine%20Concentrations%20in%20Biological%20Fluids">concentrations</a> are observed in psoriatic scales and this may explain the high proliferation rate observed in these <a href="cope.cgi?key=cell%20types">cells</a>. IL8 may be also a marker of different <a href="cope.cgi?key=inflammation">inflammatory</a> processes.</span> </p><p><span style='mso-bidi-font-size:9.0pt; mso-bidi-font-family:"Times New Roman";color:black'>IL8 (and also <a href="cope.cgi?key=IL1">IL1</a> and <a href="cope.cgi?key=IL6">IL6</a>) probably plays a role in the pathogenesis of chronic polyarthritis since excessive amounts of this factor are found in synovial fluids. The activation of <a href="cope.cgi?key=neutrophils">neutrophils</a> may enhance the migration of <a href="cope.cgi?key=cell%20types">cells</a> into the capillaries of the joints. These <a href="cope.cgi?key=cell%20types">cells</a> are thought to pass through the capillaries and enter the surrounding tissues thus causing a constant stream of <a href="cope.cgi?key=inflammatory%20cells">inflammatory cells</a> through the joints.</span> </p><p><span style='mso-bidi-font-size:9.0pt; mso-bidi-font-family:"Times New Roman";color:black'><a href="cope.cgi?key=Cytokine%20Inter%2dspecies%20Reactivities">Human</a> recombinant IL8 (see also: <a href="cope.cgi?key=recombinant%20cytokines">Recombinant cytokines</a>) has been shown that the lesion responsible for defective functions of <a href="cope.cgi?key=neutrophils">neutrophils</a> in patients with myelodysplastic syndrome can be restored without stimulating <a href="cope.cgi?key=myeloid%20progenitor%20cells">myeloid progenitor cells</a>. IL8 may be able, therefore, to reduce the risks of lethal infections in these patients without the potential risk of stimulating leukemic clones.</span> </p><p><br/></p>

<h2>MIF</h2><p><span style='mso-bidi-font-size:9.0pt; mso-bidi-font-family:"Times New Roman";color:black'>This term has multiple meanings:</span> </p><p><b style="mso-bidi-font-weight:normal"><span style='mso-bidi-font-size:9.0pt;mso-bidi-font-family:"Times New Roman"; color:#993300'><br/> </span></b><b style="mso-bidi-font-weight:normal"><span style='mso-bidi-font-size: 9.0pt;mso-bidi-font-family:"Times New Roman";color:black'>(-1-) <a href="cope.cgi?key=Mesoderm%20inducing%20factor">mesoderm inducing factor</a></span></b><span style='mso-bidi-font-size:9.0pt;mso-bidi-font-family: "Times New Roman";color:black'>. See: <a href="cope.cgi?key=XTC%2dMIF">XTC-MIF</a>.</span> </p><p><span style='mso-bidi-font-size:9.0pt; mso-bidi-font-family:"Times New Roman";color:red'><br/> </span><b style="mso-bidi-font-weight:normal"><span style="color:red"><a href="cope.cgi?key=Copyright">Copyright</a> &#169; 2012 by H IBELGAUFTS. All rights reserved.</span></b><b style="mso-bidi-font-weight: normal"><span style='font-size:10.0pt;font-family:Times;mso-fareast-font-family: "Times New Roman"'><br/> </span><span style="color:red">ENTRY COMPLETED.</span></b> </p><p><span style='mso-bidi-font-size:9.0pt; mso-bidi-font-family:"Times New Roman";color:black'><br/> </span><b style="mso-bidi-font-weight:normal"><span style='mso-bidi-font-size: 9.0pt;mso-bidi-font-family:"Times New Roman";color:#993300'>_____________________________________________________________________________</span></b><span style='mso-bidi-font-size:9.0pt;mso-bidi-font-family:"Times New Roman"; color:black'><br/> <br/> <b style="mso-bidi-font-weight:normal">(-2-) <a href="cope.cgi?key=mesoderm%20inducing%20factors">mesoderm inducing factors</a></b></span> </p><p><span style='mso-bidi-font-size:9.0pt; mso-bidi-font-family:"Times New Roman";color:red'><br/> </span><b style="mso-bidi-font-weight:normal"><span style="color:red"><a href="cope.cgi?key=Copyright">Copyright</a> &#169; 2012 by H IBELGAUFTS. All rights reserved.</span></b><b style="mso-bidi-font-weight: normal"><span style='font-size:10.0pt;font-family:Times;mso-fareast-font-family: "Times New Roman"'><br/> </span><span style="color:red">ENTRY COMPLETED.</span></b> </p><p><span style='mso-bidi-font-size:9.0pt; mso-bidi-font-family:"Times New Roman";color:black'><br/> </span><b style="mso-bidi-font-weight:normal"><span style='mso-bidi-font-size: 9.0pt;mso-bidi-font-family:"Times New Roman";color:#993300'>_____________________________________________________________________________</span></b><span style='mso-bidi-font-size:9.0pt;mso-bidi-font-family:"Times New Roman"; color:black'><br/> <br/> <b style="mso-bidi-font-weight:normal">(-3-) <a href="cope.cgi?key=M%9fllerian%20inhibiting%20factor">M&#159;llerian inhibiting factor</a></b>. See: <a href="cope.cgi?key=MIS">MIS</a> (<a href="cope.cgi?key=M%9fllerian%20inhibiting%20substance">M&#159;llerian inhibiting substance</a>).</span> </p><p><span style='mso-bidi-font-size:9.0pt; mso-bidi-font-family:"Times New Roman";color:red'><br/> </span><b style="mso-bidi-font-weight:normal"><span style="color:red"><a href="cope.cgi?key=Copyright">Copyright</a> &#169; 2012 by H IBELGAUFTS. All rights reserved.</span></b><b style="mso-bidi-font-weight: normal"><span style='font-size:10.0pt;font-family:Times;mso-fareast-font-family: "Times New Roman"'><br/> </span><span style="color:red">ENTRY COMPLETED.</span></b> </p><p><span style='mso-bidi-font-size:9.0pt; mso-bidi-font-family:"Times New Roman";color:black'><br/> </span><b style="mso-bidi-font-weight:normal"><span style='mso-bidi-font-size: 9.0pt;mso-bidi-font-family:"Times New Roman";color:#993300'>_____________________________________________________________________________</span></b><span style='mso-bidi-font-size:9.0pt;mso-bidi-font-family:"Times New Roman"; color:black'><br/> <br/> <b style="mso-bidi-font-weight:normal">(-4-) <a href="cope.cgi?key=Migration%20inhibition%20factor">migration inhibition factor</a></b>, <b style="mso-bidi-font-weight:normal"><a href="cope.cgi?key=Migration%20inhibitory%20factor">migration inhibitory factor</a></b>, <b style="mso-bidi-font-weight:normal"><a href="cope.cgi?key=Macrophage%20inhibition%20factor">macrophage inhibition factor</a></b>, <b style="mso-bidi-font-weight:normal"><a href="cope.cgi?key=Macrophage%20migration%20inhibitory%20factor">macrophage migration inhibitory factor</a></b> (<b style="mso-bidi-font-weight:normal"><a href="cope.cgi?key=MMIF">MMIF</a></b>)</span> </p><p><span style='mso-bidi-font-size:9.0pt; mso-bidi-font-family:"Times New Roman";color:black'>An operational definition for factors that inhibit in vitro the migration of <a href="cope.cgi?key=macrophages">macrophages</a> out of capillary tubes or small pieces of tissue (see also: <a href="cope.cgi?key=motogenic%20cytokines">Motogenic cytokines</a>). Many proteins have been described to possess MIF activity, including <a href="cope.cgi?key=TNF">TNF</a>, <a href="cope.cgi?key=IFN%2dgamma">IFN-gamma</a>, <a href="cope.cgi?key=IL1">IL1</a>, <a href="cope.cgi?key=IL2">IL2</a>, <a href="cope.cgi?key=GM%2dCSF">GM-CSF</a> (see also: <a href="cope.cgi?key=LIF">LIF</a> (<a href="cope.cgi?key=Leukocyte%20migration%20inhibitory%20factor">leukocyte migration inhibitory factor</a>). The proteins known as <b style="mso-bidi-font-weight:normal"><a href="cope.cgi?key=MRP%2d8">MRP-8</a> </b>and <b style="mso-bidi-font-weight:normal"><a href="cope.cgi?key=MRP%2d14">MRP-14</a></b> (MIF-related protein) are MIF-related proteins that are recognized by some monoclonal antibodies directed against MIF activities. They are related to <a href="cope.cgi?key=Calgranulins">Calgranulins</a>.</span> </p><p><span style='mso-bidi-font-size:9.0pt; mso-bidi-font-family:"Times New Roman";color:black'>Another protein, called <b style="mso-bidi-font-weight:normal"><a href="cope.cgi?key=MIF%2d1">MIF-1</a></b>, with MIF activity is secreted by a <a href="cope.cgi?key=T%2dcells">T-cell</a> hybridoma. Another <a href="cope.cgi?key=Uncharacterized%20factors">biochemically uncharacterized</a> <a href="cope.cgi?key=Migration%20inhibitory%20factor">migration inhibitory factor</a> is <b style="mso-bidi-font-weight:normal"><a href="cope.cgi?key=F5MIF%2d2">F5MIF-2</a></b>. Another factor influencing the <a href="cope.cgi?key=chemotaxis">chemotactic</a> behavior of <a href="cope.cgi?key=neutrophils">neutrophilic</a> <a href="cope.cgi?key=macrophages">macrophages</a> (see also: <a href="cope.cgi?key=chemotaxis">Chemotaxis</a>) is <a href="cope.cgi?key=HDLF">HDLF</a> (<a href="cope.cgi?key=Hodgkin%2dderived%20leukocyte%20factor">Hodgkin-derived leukocyte factor</a>). In addition there are many other <a href="cope.cgi?key=Uncharacterized%20factors">biochemically uncharacterized</a> factors with MIF activity that cannot be blocked by antibodies against known <a href="cope.cgi?key=cytokines">cytokines</a> and that are therefore probably distinct factors.</span> </p><p><b style="mso-bidi-font-weight:normal"><span style='mso-bidi-font-size:9.0pt;mso-bidi-font-family:"Times New Roman"; color:black'><a href="cope.cgi?key=MMIF">MMIF</a></span></b><span style='mso-bidi-font-size:9.0pt;mso-bidi-font-family: "Times New Roman";color:black'> has been <a href="cope.cgi?key=Gene%20library">cloned</a> and has been shown to be a major secreted protein released by anterior pituitary <a href="cope.cgi?key=cell%20types">cells</a> in response to <a href="cope.cgi?key=endotoxins">bacterial lipopolysaccharides</a>. It is identical with <b style="mso-bidi-font-weight: normal"><a href="cope.cgi?key=Sarcolectin%20binding%20protein">Sarcolectin binding protein</a></b>. Pituitary-derived MIF contributes to circulating MIF present in the post-acute phase of endotoxinemia (see also: <a href="cope.cgi?key=Systemic%20inflammatory%20response%20syndrome">Systemic inflammatory response syndrome</a>). Recombinant <a href="cope.cgi?key=Cytokine%20Inter%2dspecies%20Reactivities">murine</a> MIF (see also: <a href="cope.cgi?key=recombinant%20cytokines">Recombinant cytokines</a>) greatly enhances lethality when co-injected with <a href="cope.cgi?key=endotoxins">bacterial lipopolysaccharides</a> and anti-MIF antibodies confer protection against lethal endotoxinemia. One particular factor with MIF activity is found also in <a href="cope.cgi?key=Cytokine%20Inter%2dspecies%20Reactivities">chicken</a> <a href="cope.cgi?key=Cytokine%20Inter%2dspecies%20Reactivities">murine</a> and <a href="cope.cgi?key=Cytokine%20Inter%2dspecies%20Reactivities">human</a> embryonic eye lenses (see: <b style="mso-bidi-font-weight: normal"><a href="cope.cgi?key=10K%20protein">10K protein</a></b>). The <a href="cope.cgi?key=Cytokine%20Inter%2dspecies%20Reactivities">human</a> gene for this factor has been mapped by Budarf et al (1997) to chromosome 22q11.2.</span> </p><p><span style='mso-bidi-font-size:9.0pt; mso-bidi-font-family:"Times New Roman";color:black'>A 12 kDa factor of 115 amino acids that also inhibits the migration of <a href="cope.cgi?key=macrophages">macrophages</a> is produced by antigen-stimulated <a href="cope.cgi?key=T%2dcells">T-cells</a>. These proteins show extensive sequence homology with each other and with a <a href="cope.cgi?key=Cytokine%20Inter%2dspecies%20Reactivities">rat</a> liver protein, <a href="cope.cgi?key=nomenclature">designated</a> <b style="mso-bidi-font-weight: normal"><a href="cope.cgi?key=TRANSMIF">TRANSMIF</a></b>, a <a href="cope.cgi?key=Cytokine%20Inter%2dspecies%20Reactivities">murine</a> protein <a href="cope.cgi?key=nomenclature">designated</a> <b style="mso-bidi-font-weight: normal"><a href="cope.cgi?key=GIF">GIF</a></b> (<a href="cope.cgi?key=Glycosylation%20inhibiting%20factor">glycosylation inhibiting factor</a>), and a <a href="cope.cgi?key=Cytokine%20Inter%2dspecies%20Reactivities">mouse</a> <a href="cope.cgi?key=Early%20response%20gene">delayed-early response gene</a>, <a href="cope.cgi?key=nomenclature">designated</a> <b style="mso-bidi-font-weight:normal"><a href="cope.cgi?key=DER6">DER6</a> </b></span>[<a href="cope.cgi?key=delayed%20early%20response%20gene%206">delayed early response gene 6</a>]<span style='mso-bidi-font-size:9.0pt;mso-bidi-font-family: "Times New Roman";color:black'>. These highly <a href="cope.cgi?key=homolog">homologous</a> proteins, sharing sequence homologies of up to 98 %, are structurally related to the theta-class of <b style="mso-bidi-font-weight:normal"><a href="cope.cgi?key=Glutathione%2dS%2dtransferase">Glutathione-S-transferase</a></b> (<a href="cope.cgi?key=GST">GST</a>), a subclass of GSTs thought to be the most ancient evolutionary <a href="cope.cgi?key=GST">GST</a> class. All proteins have retained a glutathione binding <a href="cope.cgi?key=domain">domain</a> and demonstrate transferase activity. GSTs protect against xenobiotic chemicals by catalyzing the conjugation of glutathione, which renders them non-toxic. <a href="cope.cgi?key=Cytokine%20Inter%2dspecies%20Reactivities">Mouse</a>, <a href="cope.cgi?key=Cytokine%20Inter%2dspecies%20Reactivities">human</a> and <a href="cope.cgi?key=Cytokine%20Inter%2dspecies%20Reactivities">chicken</a> <a href="cope.cgi?key=Macrophage%20migration%20inhibitory%20factor">macrophage migration inhibitory factor</a> has been found to be highly <a href="cope.cgi?key=homolog">homologous</a> to <a href="cope.cgi?key=rat%20liver%2013k%20protein">rat liver 13k protein</a>.</span> </p><p><span style='mso-bidi-font-size:9.0pt; mso-bidi-font-family:"Times New Roman";color:black'><br/> The receptor for MIF has been shown to be <a href="cope.cgi?key=CD74">CD74</a> (Leng et al, 2003). The receptor complex uses <a href="cope.cgi?key=CD44">CD44</a> as a signaling <a href="cope.cgi?key=coreceptor">coreceptor</a> (Shi et al, 2006).</span> </p><p><span style='mso-bidi-font-size:9.0pt; mso-bidi-font-family:"Times New Roman";color:black'><br/> MIF is known as a mediator of cellular immunity with specific effects on the <a href="cope.cgi?key=differentiation">differentiation</a> of <a href="cope.cgi?key=mononuclear%20phagocytes">mononuclear phagocytes</a>. The expression of MIF activity correlates well with delayed hypersensitivity and cellular immunity in <a href="cope.cgi?key=Cytokine%20Inter%2dspecies%20Reactivities">humans</a> and MIF is now recognized as a principal <a href="cope.cgi?key=cytokines">cytokine</a> modulating <a href="cope.cgi?key=T%2dcells">T-cell</a> / <a href="cope.cgi?key=macrophages">macrophage</a> interactions in the expression of delayed hypersensitivity and acquired cellular immunity. Recombinant <a href="cope.cgi?key=Cytokine%20Inter%2dspecies%20Reactivities">human</a> MIF is responsible for the specific activation of <a href="cope.cgi?key=macrophages">macrophages</a> to kill intracellular parasites such as Mycobacterium avium and Leishmania donovani.</span> </p><p><span style='mso-bidi-font-size:9.0pt; mso-bidi-font-family:"Times New Roman";color:black'>Recombinant <a href="cope.cgi?key=Cytokine%20Inter%2dspecies%20Reactivities">human</a> MIF has been shown to activate <a href="cope.cgi?key=macrophages">macrophage</a> expression of NO, a potent antimicrobial agent that is produced by the NO synthase mediated oxidation of terminal L-arginine guanidine nitrogen atoms.</span> </p><p><span style='mso-bidi-font-size:9.0pt; mso-bidi-font-family:"Times New Roman";color:black'>Recombinant <a href="cope.cgi?key=Cytokine%20Inter%2dspecies%20Reactivities">human</a> MIF upregulates expression of genes encoding HLA-DR and <a href="cope.cgi?key=IL1%2dbeta">IL1-beta</a> (see: <a href="cope.cgi?key=IL1">IL1</a>) and elaboration of <a href="cope.cgi?key=IL1%2dbeta">IL1-beta</a> by <a href="cope.cgi?key=Cytokine%20Inter%2dspecies%20Reactivities">human</a> <a href="cope.cgi?key=monocyte%2dderived%20macrophages">monocyte-derived macrophages</a>. <a href="cope.cgi?key=Cytokine%20Inter%2dspecies%20Reactivities">Human</a> recombinant MIF can also activate cultured <a href="cope.cgi?key=Cytokine%20Inter%2dspecies%20Reactivities">human</a> peripheral blood <a href="cope.cgi?key=monocytes">monocytes</a> and <a href="cope.cgi?key=monocyte%2dderived%20macrophages">monocyte-derived macrophages</a> to become cytotoxic for tumor <a href="cope.cgi?key=cell%20types">cells</a> in vitro. MIF also induces <a href="cope.cgi?key=macrophages">macrophages</a> to produce <a href="cope.cgi?key=TNF%2dalpha">TNF-alpha</a> and <a href="cope.cgi?key=IL1%2dbeta">IL1-beta</a> (see: <a href="cope.cgi?key=IL1">IL1</a>). MIF also stimulates nitric oxide production by <a href="cope.cgi?key=macrophages">macrophages</a> primed with <a href="cope.cgi?key=IFN%2dgamma">IFN-gamma</a>.</span> </p><p><span style='mso-bidi-font-size:9.0pt; mso-bidi-font-family:"Times New Roman";color:black'>Administration of soluble <a href="cope.cgi?key=Cytokine%20Inter%2dspecies%20Reactivities">bovine</a> <a href="cope.cgi?key=serum%20albumin">serum albumin</a> or <a href="cope.cgi?key=Cytokine%20Inter%2dspecies%20Reactivities">human</a> immunodeficiency virus 120 kDa glycoprotein to <a href="cope.cgi?key=Cytokine%20Inter%2dspecies%20Reactivities">mice</a> in the presence of recombinant MIF together with incomplete Freund's adjuvant induces a strong <a href="cope.cgi?key=T%2dcells">T-cell</a> proliferative response comparable to that of complete Freund's adjuvant. Recombinant MIF also increases antibody production, especially of IgG1 and IgM, in <a href="cope.cgi?key=Cytokine%20Inter%2dspecies%20Reactivities">mice</a>. MIF may be useful, therefore, as an adjuvant in the development of vaccines.</span> </p><p><span style='mso-bidi-font-size:9.0pt; mso-bidi-font-family:"Times New Roman";color:black'>MIF activity can be detected in the synovia of patients with rheumatoid arthritis. The expression of MIF at sites of <a href="cope.cgi?key=inflammation">inflammation</a> also suggests a role for the mediator in regulating the function of <a href="cope.cgi?key=macrophages">macrophages</a> in host defense.</span> </p><p><span style='mso-bidi-font-size:9.0pt; mso-bidi-font-family:"Times New Roman";color:black'>For a <a href="cope.cgi?key=homolog">homolog</a> of MIF encoded by a parasite see also: <a href="cope.cgi?key=Bm%2dMIF">Bm-MIF</a>.</span> </p><p><b style="mso-bidi-font-weight:normal"><span style='mso-bidi-font-size:9.0pt;mso-bidi-font-family:"Times New Roman"; color:black'>TRANSGENIC ANIMALS, KNOCK-OUT, AND ANTISENSE STUDIES</span></b> </p><p><span style='mso-bidi-font-size:9.0pt; mso-bidi-font-family:"Times New Roman";color:black'>Takahashi et al (1998) have investigated the expression of MIF in a colon cancer <a href="cope.cgi?key=Cell%20lines%20in%20Cytokine%20Research">cell line</a> (colon 26 <a href="cope.cgi?key=cell%20types">cells</a>) and its correlation with <a href="cope.cgi?key=Cell%20cycle">cell proliferation</a>. Sublines from tumors obtained by serial transplantation in <a href="cope.cgi?key=Cytokine%20Inter%2dspecies%20Reactivities">mice</a> showed a significantly higher in vitro <a href="cope.cgi?key=Cell%20cycle">cell proliferation</a> rate than the parent <a href="cope.cgi?key=Cell%20lines%20in%20Cytokine%20Research">cell line</a> and also showed higher levels of expression of MIF protein and mRNA. Transfection of <a href="cope.cgi?key=Antisense">antisense RNA</a> against MIF into the parent <a href="cope.cgi?key=Cell%20lines%20in%20Cytokine%20Research">cell line</a> suppressed cell growth significantly. The authors point out that MIF may work as a <a href="cope.cgi?key=Growth%20factors">growth factor</a> for tumor cell growth and may be involved in the mechanism of metastasis.</span> </p><p><span style='mso-bidi-font-size:9.0pt; mso-bidi-font-family:"Times New Roman";color:red'><br/> </span><b style="mso-bidi-font-weight:normal"><span style="color:red"><a href="cope.cgi?key=Copyright">Copyright</a> &#169; 2012 by H IBELGAUFTS. All rights reserved.</span></b><b style="mso-bidi-font-weight: normal"><span style='font-size:10.0pt;font-family:Times;mso-fareast-font-family: "Times New Roman"'><br/> </span></b><span style='mso-bidi-font-size:9.0pt;mso-bidi-font-family:"Times New Roman"; color:red'>ENTRY LAST MODIFIED: April 2004</span> </p><p><br/></p>

<h2>PDGFB</h2>

<h2>SCF</h2><p><span style='mso-bidi-font-size:9.0pt; mso-bidi-font-family:"Times New Roman";color:black'>This term has multiple meanings:</span> </p><p><b style="mso-bidi-font-weight:normal"><span style='mso-bidi-font-size:9.0pt;mso-bidi-font-family:"Times New Roman"; color:black'>(-1-)</span></b><span style='mso-bidi-font-size:9.0pt;mso-bidi-font-family: "Times New Roman";color:black'> see: <b style="mso-bidi-font-weight:normal"><a href="cope.cgi?key=Sertoli%20cell%20factor">Sertoli cell factor</a></b></span> </p><p><span style='mso-bidi-font-size:9.0pt; mso-bidi-font-family:"Times New Roman";color:red'><br/> </span><b style="mso-bidi-font-weight:normal"><span style="color:red"><a href="cope.cgi?key=Copyright">Copyright</a> &#169; 2012 by H IBELGAUFTS. All rights reserved.</span></b><b style="mso-bidi-font-weight: normal"><span style='font-size:10.0pt;font-family:Times;mso-fareast-font-family: "Times New Roman"'><br/> </span><span style="color:red">ENTRY COMPLETED.</span></b> </p><p><span style='mso-bidi-font-size:9.0pt; mso-bidi-font-family:"Times New Roman";color:black'><br/> </span><b style="mso-bidi-font-weight:normal"><span style='mso-bidi-font-size: 9.0pt;mso-bidi-font-family:"Times New Roman";color:#993300'>_____________________________________________________________________________</span></b><span style='mso-bidi-font-size:9.0pt;mso-bidi-font-family:"Times New Roman"; color:black'><br/> <br/> <b style="mso-bidi-font-weight:normal">(-2-)</b> see: <b style="mso-bidi-font-weight: normal"><a href="cope.cgi?key=Stem%20cell%20factor">stem cell factor</a></b></span> </p><p><b style="mso-bidi-font-weight:normal"><span style='mso-bidi-font-size:9.0pt;mso-bidi-font-family:"Times New Roman"; color:black'>Note: </span></b><span style='mso-bidi-font-size:9.0pt;mso-bidi-font-family: "Times New Roman";color:black'>the abbreviation SCF commonly refers to <a href="cope.cgi?key=Stem%20cell%20factor">stem cell factor</a>.</span> </p><p><span style='mso-bidi-font-size:9.0pt; mso-bidi-font-family:"Times New Roman";color:red'><br/> </span><b style="mso-bidi-font-weight:normal"><span style="color:red"><a href="cope.cgi?key=Copyright">Copyright</a> &#169; 2012 by H IBELGAUFTS. All rights reserved.</span></b><b style="mso-bidi-font-weight: normal"><span style='font-size:10.0pt;font-family:Times;mso-fareast-font-family: "Times New Roman"'><br/> </span><span style="color:red">ENTRY COMPLETED.</span></b></p><p><br/></p>

<h2>TNFSF10</h2><p><span style='mso-bidi-font-size:9.0pt; mso-bidi-font-family:"Times New Roman";color:black'>[<a href="cope.cgi?key=TNF%20ligand%20superfamily%20member%2010">TNF ligand superfamily member 10</a>] This designation is based on homology with other members of the <a href="cope.cgi?key=TNF%20ligand%20superfamily">TNF ligand superfamily</a> of proteins. The protein in question is <a href="cope.cgi?key=TRAIL">TRAIL</a>, which is known also as <a href="cope.cgi?key=APO%2d2%20ligand">APO-2 ligand</a> or <a href="cope.cgi?key=TL2">TL2</a>. The <a href="cope.cgi?key=Cytokine%20Inter%2dspecies%20Reactivities">murine</a> antigen is <a href="cope.cgi?key=Ly81">Ly81</a>. In the <a href="cope.cgi?key=nomenclature">nomenclature</a> of <a href="cope.cgi?key=CD%20antigens">CD antigens</a> this protein has been given the designation <a href="cope.cgi?key=CD253">CD253</a>.</span> </p><p><span style='mso-bidi-font-size:9.0pt; mso-bidi-font-family:"Times New Roman";color:red'><br/> </span><b style="mso-bidi-font-weight:normal"><span style="color:red"><a href="cope.cgi?key=Copyright">Copyright</a> &#169; 2012 by H IBELGAUFTS. All rights reserved.</span></b><b style="mso-bidi-font-weight: normal"><span style='font-size:10.0pt;font-family:Times;mso-fareast-font-family: "Times New Roman"'><br/> </span></b><span style='mso-bidi-font-size:9.0pt;mso-bidi-font-family:"Times New Roman"; color:red'>ENTRY LAST MODIFIED: September 2004</span></p><p><br/></p>

<h2>VCAM1</h2>

<h2>VEGFA</h2>

</body>
</html>